PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

EHA2024 Hybrid Congress

June, 13-16 Madrid

N. Poster

Poster title

Applicant name

Status


P-0340	SELECTIVE INHIBITION OF HDAC CLASS IIA AS THERAPEUTIC INTERVENTION FOR KMT2A-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA	Tamara C.A.I. Verbeek	Received

P-0342	ACTIVINA PROMOTES CHEMORESISTANCE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)	Rita Starace	Received

P-0343	ASPARAGINASE-INDUCED AMINO ACID DEPRIVATION AND GCN2 INHIBITION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Maaike Van Trimpont	Received

P-0347	TRANSCRIPTION FACTOR NKX2-1 PROTECTS T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS FROM DNA DAMAGE	David Cabrerizo Granados	Received

P-348	T-ALL MUTATIONAL PROFILING IDENTIFIES PROGNOSTIC AND PREDICTIVE MARKERS IN PHENOTYPIC AND GENOMIC SUBGROUPS	Valentina Bardelli	Received

P-0350	A DESIGNER PEPTIDE FOR THE TREATMENT OF DUX4-R+ ACUTE LYMPHOBLASTIC LEUKEMIA	Mara Salomè	Received

P-0351	LEF1 INTRAGENIC DELETION INDUCES DOMINANT-NEGATIVE ISOFORM EXPRESSION AND UNVEILS WNT-B CATENIN VULNERABILITY IN T ACUTE LYMPHOBLASTIC LEUKEMIA	Manon DELAFOY	Received

P-0352	CHARACTERIZATION OF THE ONCOGENIC ACTIVITY OF TLX1 AND TLX3 TRANSCRIPTION COMPLEXES IN T-ALL	Alexandra Bacquelaine Veloso	Received

P-0353	RECURRENT SOMATIC VARIANTS IN THE NON-CODING GENOME ALTER THE CIS-REGULATORY MECHANISMS OF GENES ASSOCIATED WITH PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA	Efe Aydin	Received

P-0354	TARGETING CD38 FOR T-CELL LYMPHOID NEOPLASMS	Ruonan Li	Received

P-0355	CONVERGING CHAOS: UNVEILING DOUBLE-HIT EVENTS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA THROUGH INTEGRATED OPTICAL GENOME MAPPING AND SOMATIC WES ANALYSIS.	Elena García Sánchez	Received

P-0356	TMAPS: NOVEL SURFACE MARKERS EVALUATION FOR MINIMAL RESIDUAL DISEASE MONITORING OF PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS	Adela Vavrova	Received

P-0357	THE DISEASE-DEFINING TRANSCRIPTIONAL PROGRAM OF PH+ B-ALL LEUKAEMIA CELLS IS ORCHESTRATED BY GENE-ENHANCER INTERACTIONS AND SIGNAL-INDUCED TRANSCRIPTION FACTORS	Niklas Feldhahn	Received

P-0358	DRUG RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA IS ASSOCIATED WITH INCREASED WNT-SIGNALING ACTIVITY AND CAN BE OVERCOME BY CO-TARGETING BCL-2	Qian Sun	Received

P-0359	CONTRIBUTION OF COPY NUMBER VARIATIONS TO RISK STRATIFICATION OF ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) PATIENTS ENROLLED IN MEASURABLE RESIDUAL DISEASE-ORIENTED TRIALS	Celia González Gil	Received

P-0360	DUAL TARGETING OF EZH2 AND HISTONE DEACETYLASES IN HEMATOLOGICAL MALIGNANCIES PROMOTES TRANSCRIPTIONAL AND METABOLIC DEREGULATION LEADING TO FERROPTOSIS.	Marlies Vanden Bempt	Received

P-0361	LOSS OF DNTT EXPRESSION CONFERS RESISTANCE TO INOTUZUMAB OZOGAMICIN IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY ALTERING DNA DAMAGE SIGNALING	Carolin Escherich	Received

P-0362	OPTICAL GENOME MAPPING (OGM) AS A NEW GENETIC DIAGNOSTIC TOOL FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL)	Idoia Vázquez	Received

P-0364	ENHANCED PROLIFERATION IN B-CELL ACUTE LYMPHOID LEUKEMIA ASSOCIATED WITH EPIGENETIC REGULATION OF SETD6 EXPRESSION	Yoana Veselinova Kalaydzhieva	Received

P-0365	TARGETING THE INTERLEUKIN-4 PATHWAY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Wouter Sleeckx	Received

P-0367	EXPLOITING THE THERAPEUTIC POTENTIAL OF SPHINGOSINE KINASE ACTIVITY IN IL7R-DEPENDENT ACUTE LYMPHOBLASTIC LEUKEMIA	Marta Fernandes	Received

P-0368	THE GENOMIC LANDSCAPE OF RELAPSED INFANT AND CHILDHOOD KMT2A-REARRANGED ACUTE LEUKEMIA	Louise Ahlgren	Received

P-0369	A DUAL ROLE FOR PSIP1/LEDGF IN T-ALL	Lisa Demoen	Received

P-0370	A NEW AKR1C3-ACTIVATED PRODRUG, ACHM-025, ERADICATES DISEASE IN PRECLINICAL MODELS OF AGGRESSIVE T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Charles De Bock	Received

P-0371	THE ROLE OF THE BONE MARROW IMMUNE NICHE IN PREVENTING RELAPSE IN B-ALL FOLLOWING REDUCED INTENSITY CONDITIONING ALLO-HSCT	Hermione Allen	Received

P-0372	DECIPHERING B-ALL AND MSC INTERACTION: PATHWAYS TO CHEMORESISTANCE AND CELL CONTACT DYNAMICS	Emily Cutler	Received

P-0373	SINGLE-CELL ANALYSIS OF PAX5-DRIVEN BCP-ALL EVOLUTION REVEALS A ROLE OF MYC AT EARLY STAGES OF MALIGNANT TRANSFORMATION	Franziska Auer	Received

P-0374	ETV6::ACSL6 TRANSLOCATION-DRIVEN SUPER-ENHANCER ACTIVATION LEADS TO EOSINOPHILIA IN ACUTE LYMPHOBLASTIC LEUKEMIA THROUGH IL-3 OVEREXPRESSION	Wenqian Xu	Received

P-0375	INDISULAM AS A NOVEL THERAPEUTIC STRATEGY IN T-ALL: TARGETING RBM39 FOR IMPROVED OUTCOMES	Tongting Ji	Received

P-0377	HIGH FLT3 GENE EXPRESSION OFFERS NOVEL THERAPEUTIC OPPORTUNITIES IN PEDIATRIC IAMP21 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Gábor Bedics	Received

P-0379	A NOVEL ETV6::RUNX1+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA MODEL REVEALS FERROPTOSIS AS A POTENTIAL THERAPEUTIC VULNERABILITY	Ersen Kameri	Received

P-0380	SYNERGISTIC EFFECT OF CHIDAMIDE AND VENETOCLAX IN IKZF1 DELETION ACUTE B LYMPHOBLASTIC LEUKEMIA CELLS AND ITS MECHANISM	Jiawang Ou	Received

P-0381	DECODING THE GENOMIC SYMPHONY: UNRAVELING THE INTERPLAY BETWEEN GERMLINE DNA REPAIR VARIANTS AND SOMATIC STRUCTURAL ALTERATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA	Jorge Garcia Martinez	Received

P-0382	FUNCTIONAL CHARACTERISATION OF KDM6B IN IMMATURE LEUKEMIA	Cristina Borin	Received

P-0383	MIR-181A QUANTIFICATION IN THE CEREBROSPINAL FLUID IMPROVES PATIENT STRATIFICATION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA	Borbála Péterffy	Received

P-0384	INSIGHT INTO HEMATOPOIETIC STEM AND PROGENITOR CELLS AND THE NICHE OF DONOR CELL LEUKEMIA AT SINGLE-CELL RESOLUTION	Yan Liu	Received

P-0385	VALIDATION OF WGS AND WTS AS DIAGNOSTIC TOOLS FOR ACUTE LYMPHOBLASTIC LEUKEMIA – A NATIONWIDE INITIATIVE BY GENOMIC MEDICINE SWEDEN	Gisela Barbany	Received

P-0386	GERMINAL AND SOMATIC INTEGRATED WES ANALYSIS REVEALS DUAL GENETIC PREDISPOSITION: DECIPHERING IMMUNODEFICIENCY AND PREDISPOSITION TO ACUTE LYMPHOBLASTIC LEUKEMIA IN A REVEALING CASE	Jaanam Lalchandani	Received

P-0387	TARGETING PATIENT-SPECIFIC VULNERABILITIES IN ANTI-APOPTOTIC PATHWAY COMBINED WITH CXCR4 EXPRESSING CAR-T CELLS ELIMINATES HIGH-RISK LEUKEMIA.	Ryo Nakagawa	Received

P-0388	CD133 POSITIVE BLASTS IN MLL::AF4 LEUKAEMIA ARE MORE AGRESSIVE AND STEM-CELL LIKE	Joe Cross	Received

P-0389	GENOMIC CHARACTERIZATION OF PH- B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS ENROLLED IN THE GIMEMA LAL2317 TRIAL	Deborah Cardinali	Received

P-0390	GUICAOBAIDU DECOCTION TARGETING M5C RNA METHYLATION IMPROVES BNIP3 ASSOCIATED MITOPHAGY IN DOXORUBICIN-INDUCED MYOCARDIAL CARDIOTOXICITY	Xing Cui	Received

P-0391	SINGLE-CELL RNA-SEQUENCING REVEALS THE ACTION MECHANISM OF BLINATUMOMAB IN PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Ruidong Zhang	Received

P-0392	ASSESSING THE EFFECTIVENESS OF INTEGRATING OPTICAL GENOME MAPPING INTO THE DIAGNOSTIC APPROACH FOR PEDIATRIC AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	Gayane Avetisyan	Received

P-0393	METHOTREXATE PHARMACOGENOMICS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: DESIGN OF A PANEL FOR PREEMPTIVE PHARMACOGENOMICS TESTING	Branka Zukic	Received

P-0394	SUPER ENHANCER REGULATORY GENE SH2D1A PROMOTES THE PROGRESSION OF T CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY ACTIVATING CHI3L2	Wanyan Jiao	Received

P-0395	SUBSEQUENT ALLOTRANSPLANT IN ADULTS WITH ADVANCED ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CD19 CAR-T-CELL THERAPY: A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL	Jia Chen	Received

P-0396	CAMPUS ALL MULTICENTER STUDY ON OUTCOME OF 421 ADULT PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED IN REAL-LIFE WITH AN INTENSIVE PROGRAM INSPIRED TO THE GIMEMA LAL1913 CLINICAL TRIAL	Davide Lazzarotto	Received

P-0397	AUGMENTED USE OF L-ASPARAGINASE MARKEDLY IMPROVES THE TREATMENT RESULT OF AYA ALL PATIENTS: RESULT OF PROSPECTIVE MRD 2014 STUDY CONDUCTED BY FUKUOKA BLOOD AND MARROW TRANSPLANTATION GROUP (FBMTG)	Koji Nagafuji	Received

P-0398	PONATINIB, CHEMOTHERAPY AND TRANSPLANTATION FOR NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL). FINAL RESULTS OF THE PHASE 2 PONALFIL TRIAL	Josep Maria Ribera	Received

P-0399	OUTCOME PREDICTORS FOR PATIENTS AGED 55 YEARS AND OLDER WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE STUDY FROM THE HARMONY BIG DATA PLATFORM	Amin Turki	Received

P-0400	BUSULFAN PLUS CYCLOPHOSPHAMIDE VS. TOTAL BODY IRRADIATION PLUS CYCLOPHOSPHAMIDE FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE T LYMPHOBLASTIC LEUKEMIA	Yifan Shen	Received

P-0401	EFFICACY AND SAFETY ANALYSIS OF HYPER-CVAD AND SEQUENTIAL BLINATUMOMAB FOR ACUTE LYMPHOCYTIC LEUKEMIA AND CHRONIC MYELOID LEUKEMIA BLAST CRISIS PATIENTS	Qiuling Wu	Received

P-0402	EFFICACY AND TOLERANCE OF MODIFIED HYPERCVAD, BLINATUMOMAB, AND TKI COMBINATION AS A TREATMENT FOR RELAPSED OR REFRACTORY PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Gaétan BASILE	Received

P-0404	RISK ASSESSMENT OF CANCER THERAPY-RELATED CARDIOVASCULAR TOXICITY: A PROGNOSTIC FACTOR IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.	Laura Elena Valdovinos-Elizalde	Received

P-0405	ACUTE LYMPHOBLASTIC LEUKAEMIA IN PATIENTS TREATED WITH LENALIDOMIDE IN MULTIPLE MYELOMA: A SAFETY META-ANALYSIS COMBINED WITH A RETROSPECTIVE STUDY OF THE WHO´S PHARMACOVIGILANCE DATABASE	PIERRE MARIE MORICE	Received

P-0406	OCCULT CENTRAL NERVOUS SYSTEM LOCALIZATION IN ADULT PATIENTS AFFECTED WITH ACUTE LYMPHOBLASTIC LEUKEMIA. A CAMPUS ALL PROSPECTIVE STUDY.	Maria Ilaria DEL PRINCIPE	Received

P-0407	RECOMBINANT ERWINIA ASPARAGINASE (JZP458) IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (ALL/LBL): POST HOC ANALYSIS OF ADVERSE EVENTS OF INTERESTS FROM AALL1931	Luke Maese	Received

P-0408	PRELIMINARY EFFECT OF ENHANCED LYMPHODEPLETION (ELD) ON WU-CART-007 IN TALL/LBL	Ibrahim Aldoss	Received

P-0410	ASCIMINIB FOR RELAPSED OR REFRACTORY PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) AND LYMPHOID BLAST CRISIS CHRONIC MYELOGENOUS LEUKEMIA (LBC-CML).	Mathilde CHANUT	Received

P-0411	A FULL PEDIATRIC REGIMEN FOR ADULT PATIENTS WITH PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA ACHIEVES EXCELLENT OUTCOME WITH ACCEPTABLE TOXICITY.	Michela Frello	Received

P-0412	PROFILE AND PROGNOSTIC SIGNIFICANCE OF RAS PATHWAY ALTERATIONS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA	Jiawang Ou	Received

P-0414	PROGNOSTIC FACTORS IMPACTING POST-TRANSPLANT OUTCOMES IN ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A REGISTRY-BASED STUDY BY THE EBMT ACUTE LEUKEMIA WORKING PARTY	Jean El Cheikh	Received

P-0415	ALLOGENEIC STEM CELL TRANSPLANTATION DOES NOT SUGGEST IMPROVING OVERALL SURVIVAL IN ADOLESCENT AND YOUNG ADULT WITH PHILADELPHIA CHROMOSOME ACUTE LYMPHOBLASTIC LEUKEMIA WITH UNDETECTABLE BCR::ABL1.	Talha Badar	Received

P-0416	BLINATUMOMAB ALTERNATING WITH LOW-INTENSITY CHEMOTHERAPY (LIC) IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): SAFETY RUN-IN FOLLOW-UP FOR THE PHASE 3 GOLDEN GATE STUDY	Elias Jabbour	Received

P-0417	TREATMENT AND OUTCOMES OF OLDER PATIENTS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA. A NATIONWIDE CAMPUS ALL REAL-LIFE STUDY ON 302 PATIENTS	Marco Cerrano	Received

P-0418	OBECABTAGENE AUTOLEUCEL (OBE-CEL, AUTO1) FOR RELAPSED/REFRACTORY ADULT B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): THE IMPACT OF INOTUZUMAB-CONTAINING BRIDGING THERAPY ON TREATMENT OUTCOMES	Jae H. Park	Received

P-0420	AUTOLOGOUS CD19-DIRECTED CAR T CELLS PRODUCED BY NOVEL BEDSIDE-MANUFACTURE PLATFORM EXHIBIT SAFETY AND EFFICACY IN R/R B-ALL	Shiqi Li	Received

P-0421	FLOW-CYTOMETRIC MRD DETECTION IN PEDIATRIC T-ALL: A CONSENSUS-BASED STANDARDIZED APPROACH	Michaela Reiterová	Received

P-0422	IMPACT OF PROPHYLACTIC CRANIAL IRRADIATION ON OUTCOMES OF ADULTS ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PEDIATRIC INSPIRED PROTOCOL	Mohammad Alwadi	Received

P-0423	SHORT-TERM BLINATUMOMAB BRIDGING ALLO-HSCT IN HR B-ALL	Huizhu Kang	Received

P-0424	REAL-WORLD UTILIZATION OF BLINATUMOMAB IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FRANCE: RESULTS FROM THE ATHENA STUDY	Thomas Cluzeau	Received

P-0426	DE-INTENSIFYING POST-INDUCTION THERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA, GOOD RISK GENETICS AND INTERMEDIATE MRD AT THE END OF INDUCTION.	Anthony Moorman	Received

P-0427	COMBINATION OF THIRD GENERATION TKI OLVEREMBATINIB AND CHEMOTHERAPY OR BLINATUMOMAB FOR NEW DIAGNOSED ADULT PH+ ALL PATIENTS	Hongsheng Zhou	Received

P-0428	HEM-ISMART: AN INTERNATIONAL PROOF OF CONCEPT THERAPEUTIC STRATIFICATION TRIAL OF MOLECULAR ANOMALIES IN RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES IN CHILDREN	Andrej Lissat	Received

P-0431	PATHOPHYSIOLOGY OF DIFFERENTIATION SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA	Giulia Falconi	Received

P-0432	RUNX1 STOP-LOSS MUTATIONS DEFINE A DISTINCT PROGNOSTIC SUBSET WITHIN RUNX1-MUTATED ACUTE MYELOID LEUKAEMIA	Radha Ramanan	Received

P-0433	CD34+CD38- LEUKEMIA STEM CELLS ARE ASSOCIATED WITH PROGNOSIS IN NON-INTENSIVELY TREATED ACUTE MYELOID LEUKEMIA	Tom Reuvekamp	Received

P-0435	FLT3-ITD INDUCES IMMUNE ESCAPE IN AML VIA UP-REGULATING CD47 EXPRESSION AND DECREASED PHAGOCYTIC ABILITY OF MACROPHAGES	Liang Yang	Received

P-0436	THE NOVEL TYROSINE KINASE INHIBITOR AD80 EXHIBITS POTENT ANTINEOPLASTIC EFFECTS ON AML MODELS WITH FLT3-ITD MUTATIONS	Lívia Bassani Lins de Miranda	Received

P-0437	ERR? ROLE AS THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA	wonhyoung Seo	Received

P-0438	A CLL1 AND CD38 DUAL TARGETING FASTCAR T THERAPY FOR ACUTE MYELOID LEUKEMIA	Jiaxing Tang	Received

P-0439	TARGETING THE LEUKAEMIC BONE MARROW PROTECTIVE NICHE MAY INCREASE THE SENSITIVITY OF ACUTE MYELOID LEUKAEMIA (AML) TO STANDARD CHEMOTHERAPY.	Ahmed Elmarghany	Received

P-0441	PROGNOSTIC RELEVANCE OF MEASURABLE RESIDUAL MUTATED IDH2 AFTER INTENSIVE INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Lena Cimbalnik	Received

P-442	SEX DISPARITIES IN GENETIC LANDSCAPE OF ACUTE MYELOID LEUKEMIA: A COMPREHENSIVE ANALYSIS USING THE HARMONY CONSORTIUM DATASET	Jesse Tettero	Received

P-0443	THE PROGNOSTIC LNCRNA FAM30A REGULATES THE MUSASHI2-RUNX1 AXIS AND CONFERS STEMNESS, CHEMORESISTANCE AND ENGRAFTMENT TO AML CELLS	Jaime Calvo Sánchez	Received

P-0444	TARGETING MYC BY DEGRADATION REWIRES METABOLOMICS AND INDUCES CELL KILL IN TP53 MUTANT ACUTE MYELOID LEUKEMIAS	Michael Andreeff	Received

P-0445	KK2845, A PBD DIMER-CONTAINING ANTIBODY-DRUG CONJUGATE TARGETING TIM-3-EXPRESSING LEUKEMIA STEM CELLS OF AML	Jian Zou	Received

P-0446	ABERRANT EXPRESSION OF SLAMF6 CONSTITUTES A NOVEL AND TARGETABLE IMMUNE ESCAPE MECHANISM IN ACUTE MYELOID LEUKEMIA	Carl Sandén	Received

P-0447	RUNX1-ETO AND CBFB-MYH11 CONVERGE ON ABERRANT ACTIVATION OF BCAT1 TO CONFER A THERAPEUTIC VULNERABILITY IN CORE BINDING FACTOR-ACUTE MYELOID LEUKEMIA	Siyang Wang	Received

P-0449	TARGETED RNA SEQUENCING FREQUENTLY IDENTIFIES HIGH-RISK FUSION GENES IN YOUNGER ADULTS WITH OTHERWISE INTERMEDIATE-RISK AML AND ISOLATED FLT3-ITD	Nicola Potter	Received

P-0450	VENETOCLAX INDUCES MITOCHONDRIAL ROS-MEDIATED APOPTOSIS VIA STAT3/ BCL2/ BECLIN-1 AXES TO OVERCOME ARSENIC RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA	Deepshikha Dutta	Received

P-0452	TRMT5 METHYLATES DISTINCT MITOCHONDRIAL TRNAS TO SUSTAIN THE DYNAMIC UPREGULATION OF OXPHOS FOR SURVIVAL AND DRUG TOLERANCE IN AML	Michael Kienhöfer	Received

P-0453	CCTX-001, A FIRST IN CLASS AUTOLOGOUS ANTI-IL-1RAP CAR T-CELL THERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY AML	Nicolas Boissel	Received

P-0454	BIOMARKER RESULTS OF THE PHASE 1 DOSE ESCALATION TRIAL OF THE HLA-A2-WT1 CD3 T-CELL BISPECIFIC (TCB) ANTIBODY RO7283420 (RG6007) IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)	Marion Subklewe	Received

P-0455	SINGLE CELL SEQUENCING REVEALED THE SIGNIFICANT ROLE OF HOPX IN CONTRIBUTING TO CHEMO-RESISTANCE IN ACUTE MYELOID LEUKEMIA	Gelan Zhu	Received

P-0456	OVERCOMING AGGRESSIVE EMT-ASSOCIATED PHENOTYPES IN ACUTE MYELOID LEUKEMIA CELLS WITH KMT2A-MLLT3 REARRANGEMENTS THROUGH THE MODULATION OF MICRORNA-204	Liam MacPhee	Received

P-0458	IDENTIFICATION OF PREDICTIVE BIOMARKERS AND COMBINATORIAL TREATMENTS FOR AML USING AN ADVANCED CRISPR/CAS9 SCREENING PLATFORM	Johannes Schmoellerl	Received

P-0459	ABSENCE OF STAT3? CONTRIBUTES TO ADVERSE OUTCOME IN ACUTE MYELOID LEUKEMIA BY ENHANCING THE INTERFERON RESPONSE	Sophie Edtmayer	Received

P-0460	MULTICENTER RETROSPECTIVE OBSERVATORY OF ACUTE MYELOID LEUKEMIA PATIENTS WITH NUP98 REARRANGEMENT. A STUDY FROM THE ALFA-FILO FRENCH AML INTERGROUP.	Benoît Ducourneau	Received

P-0461	MLLT1/3 TARGETED AGENTS AS NOVEL INHIBITORS OF THE SUPER-ELONGATION COMPLEX (SEC) TO TREAT MOLECULARLY DEFINED ACUTE LEUKEMIA INCLUDING MENIN-INHIBITOR RESISTANT AND REFRACTORY DISEASE.	Alison Maloney	Received

P-0463	BRD4 DEGRADATION AS A NOVEL STRATEGY TO OVERCOME INTRINSIC, ACQUIRED, NICHE-INDUCED AND CHECKPOINT-MEDIATED RESISTANCE IN AML AND ALL	Karin Bauer	Received

P-0464	INVESTIGATION OF THE REGULATORS OF NUP98 FUSION ONCOPROTEIN HOMEOSTASIS	Ecem Kirkiz	Received

P-0465	IDENTIFICATION OF ZFP91 AS THE MASTER TRANSCRIPTION FACTOR FOR EVI1 GENE EXPRESSION IN MYELOID LEUKEMIA	Hiroki Hayashida	Received

P-0466	(R)-WAC-224, A NOVEL ANTICANCER QUINOLONE AND VENETOCLAX PLUS AZACITIDINE OVERCOME VENETOCLAX-RESISTANT AML VIA DOWNREGULATION OF MCL-1	Hiroshi Ureshino	Received

P-0467	PROTEOMIC ANALYSIS BY OLINK INFLAMMATION PLATFORM PREDICTED THE CHEMORESITANCE IN AML UNDER 7+3	Ling-Chiao Teng	Received

P-0468	SINGLE-CELL COMPUTER VISION UNVEILS DISCRIMINATIVE FEATURES OF LATENT CELLULAR MORPHOLOGY IN MYELOID CLONAL HEMATOPOIESIS	Helong Zhao	Received

P-0469	INTERPLAY BETWEEN MACROPHAGES AND AML BLASTS IN PEDIATRIC ACUTE MYELOID LEUKEMIA	Alicia Perzolli	Received

P-0470	ENHANCING THE EFFICACY OF P53-Y220C REACTIVATOR PC14586 BY COMBINATION WITH MDM2 OR BCL-2 INHIBITORS IN TP53-Y220C AML	Bing Carter	Received

P-0473	CD37 IS A RELEVANT TARGET FOR AML AND MDS TREATMENT BY DEBIO 1562M ANTIBODY DRUG CONJUGATE (ADC)	Lisa Ivanschitz	Received

P-0474	MUTANT U2AF1-INDUCED MIS-SPLICING OF MRNA TRANSLATION GENES CONFERS RESISTANCE TO CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA	Peng Jin	Received

P-0475	EXPLORING DOSE-RESPONSE RELATIONSHIP OF A NOVEL CD123 NK CELL ENGAGER SAR443579 IN ACUTE MYELOID LEUKEMIA (AML) MODELS	Angela Virone-Oddos	Received

P-0476	THE DIFFERENTIAL ROLE OF STAT3 AND STAT5 FACTORS IN LEUKEMIC TRANSFORMATION FROM MDS TO AML	Eirini Sofia Fasouli	Received

P-0477	IDENTIFICATION OF FUNCTIONALLY ACTIVE AND ESSENTIAL ENHANCERS IN ACUTE MYELOID LEUKAEMIA	Bettina Wingelhofer	Received

P-0479	SINGLE-CELL GUIDED IMMUNE DECONVOLUTION IDENTIFIES CHEMOTHERAPY-ASSOCIATED ALTERATIONS OF THE BONE MARROW IMMUNE MICROENVIRONMENT IN PEDIATRIC AML	Joost Koedijk	Received

P-0480	TRANSCRIPTION FACTOR MYBL2 ACTS AS A MOLECULAR SWITCH BETWEEN PROLIFERATION AND SENESCENCE IN ACUTE MYELOID LEUKEMIA	Sandra Schuster	Received

P-0482	MOLECULAR BACKTRACKING OF LEUKEMIC CELLS IN CRYOPRESERVED OVARIAN TISSUE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Augustin Boudry	Received

P-0483	CEBPA MUTATIONAL SPECTRUM AND ITS CLINICAL IMPLICATIONS IN AML VERSUS MDS – RETROSPECTIVE REAL WORLD STUDY OF CEBPA-MUTATED PATIENTS	Katrin Schweneker	Received

P-0484	INDUCTION OF AML CELL DEATH AND DIFFERENTIATION USING HOXA9/DNA BINDING INHIBITORS DB818 AND DB1055 AS A POTENTIAL THERAPEUTIC OPTION FOR AML PATIENTS.	Marie-Helene DAVID-CORDONNIER	Received

P-0485	M6A RNA MODIFICATION INITIATED BY METTL3 PROMOTES FOXO3 EXPRESSION TO INDUCE ANTHRACYCLINE RESISTANCE IN ACUTE MYELOID LEUKEMIA CELLS	Xiawei Zhang	Received

P-0486	INHIBITION OF PINK1-MEDIATED MITOPHAGY POTENTIATES VENETOCLAX ACTIVITY IN ACUTE MYELOID LEUKEMIA.	Romain Vazquez	Received

P-0487	UBE2Q1 IMPAIRS ANTIGEN PRESENTATION IN AML	Xiaoxuan Yu	Received

P-0488	CLINICAL SIGNIFICANCE OF NPM1 SUBGROUPS IN THE DIAGNOSIS OF AML PATIENTS	Wencke Walter	Received

P-0489	CSF1R MARKS A SUBSET OF FETAL LMPP WITH ACUTE MYELOID LEUKEMIA PROPAGATION PROPERTIES IN A MLL-AF9 MOUSE MODEL	Giuseppina Camiolo	Received

P-0490	UNRAVELING CLONAL EVOLUTION AND MECHANISMS OF TREATMENT RESISTANCE IN MURINE KMT2A-REARRANGED LEUKEMIA WITH SUBCLONAL FLT3N676K	Ton Falqués-Costa	Received

P-0491	NOVEL VHH-BASED CAR-T CELLS AGAINST CD33 WITH DIFFERENT AFFINITIES PRESENT IMPROVED EFFICACY FOR THE TREATMENT OF AML	Franco Bernasconi Bisio	Received

P-0492	THE TGF? SIGNALING PARADOX IN AML: A SYSTEMATIC CRISPRI-BASED SCREENING APPROACH TO OVERCOME DRUG RESISTANCE	Elahe Rahimian	Received

P-0493	CCRL2 PROMOTES MALIGNANT CELL GROWTH AND INDUCES STAT1 SIGNALING IN ERYTHROLEUKEMIA	Nour Naji	Received

P-0494	SELECTIVE ABLATION OF CXCR4+ AML PATIENT CELLS IN VITRO AND INHIBITION OF LEUKEMIA DISSEMINATION IN VIVO BY A MULTIVALENT MMAE-BASED HUMANIZED NANOCONJUGATE	Annabel Garcia León	Received

P-0495	PP2A- BASED THERAPEUTIC STRATEGIES FOR KMT2A-REARRANGED LEUKAEMIA	Maria Teresa Esposito	Received

P-0496	TRANSFERRIN IN COMBINATION WITH INDUCTION CHEMOTHERAPY IMPROVES OUTCOMES IN AN IMMUNOCOMPETENT MOUSE MODEL OF ACUTE MYELOID LEUKEMIA	Marta Lopes	Received

P-497	NOVEL EPIGENETIC BASED DIFFERENTIATION THERAPY FOR ACUTE MYELOID LEUKEMIA	Edurne San Jose-Eneriz	Received

P-0498	SYNERGISTIC ROLE OF ALDEHYDE DEHYDROGENASE INHIBITION AND HYPOMETHYLATING AGENTS IN RELAPSE/REFRACTORY AML	Mehak Shaikh	Received

P-0499	PI3K ACTIVATION REGULATES LEUKAEMIA ASSOCIATED MACROPHAGE POLARISATION IN THE AML TUMOUR MICROENVIRONMENT	George Bell	Received

P-0500	ESTABLISHING A GENETICALLY-DEFINED IN VIVO MODEL FOR PRECISELY INVESTIGATING PEDIATRIC ACUTE MYELOID LEUKEMIA	Hasan Issa	Received

P-0501	A LEUKEMIC STEM CELL-SPECIFIC CRISPRI SCREEN DEMONSTRATES FUNCTIONAL DIVERSITY OF LONG NON-CODING RNAS IN ACUTE MYELOID LEUKEMIA	Silvia Schäfer	Received

P-0502	CHARACTERIZATION OF IMMUNOPHENOTYPIC CHANGES FOLLOWING MENIN INHIBITION IN ACUTE MYELOID LEUKEMIA	Sanam Loghavi	Received

P-0503	EVALUATING THE EFFICACY OF PATIENT-ORIENTED COMBINATION THERAPIES FOR AML VIA EX VIVO AND IN VIVO MODELS	elham gholizadeh	Received

P-0504	THE POTENTIAL OF CIRCFN IN MODULATING PML-RAR? STABILITY AND PROGRESSION IN ACUTE PROMYELOCYTIC LEUKEMIA	Jiacheng Lou	Received

P-0505	GENOME ENGINEERED TET2 LOSS-OF-FUNCTION MUTATIONS INCREASE SELF-RENEWAL AND COMPETITIVE POTENTIAL IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS	Erdem Özkaya	Received

P-506	TUMORAL AND NON-TUMORAL INFLUENCE ON NATURAL KILLER CELL IMMUNOSURVEILLANCE DURING MDS PROGRESSION TO SAML	Berenice Schell	Received

P-0507	EXPLORING NOVEL CHARACTERISTICS OF LEUKEMIA STEM CELLS: INSIGHTS INTO MITOCHONDRIAL DEPENDENCE.	Maddalena Benetton	Received

P-0508	DECIPHERING THE MOLECULAR MECHANISM OF MESENCHYMAL STROMAL CELL MEDIATED DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA	sayantanee Dutta	Received

P-0510	TARGETING O-GLCNAC TRANSFERASE (OGT) AS A NOVEL THERAPEUTIC STRATEGY FOR EVI1+ ACUTE MYELOID LEUKEMIA: ENHANCING MITOCHONDRIAL PRIMING FOR IMPROVED OUTCOMES	Junbum Im	Received

P-0511	IDENTIFICATION AND CHARACTERISATION OF PU.1-DRIVEN GENE REGULATORY COMPLEXES AND NETWORKS IN ACUTE MYELOID LEUKAEMIA.	Jaana Bagri	Received

P-0512	THE COMBINATION CHLOROQUINE WITH FLT3 INHIBITORS OVERCOMES DRUG RESISTANCE IN FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA	Manuela Melo	Received

P-0513	BIALLELIC MUTATION OF DNMT3A DRIVES METHYLATION DAMAGE AND POOR SURVIVAL IN ACUTE MYELOID LEUKEMIA	Sanne Massaar	Received

P-0514	MIR-210 MEDIATED REGULATION OF PD-L1 EXPRESSION VIA THE JAK-STAT PATHWAY IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA	Leo Escano	Received

P-0515	SIMULTANEOUS EVALUATION OF TIM-3+LSC AND LAIP-BASED MRD ENHANCES RELAPSE PREDICTION: A SINGLE-TUBE APPROACH	teppei sakoda	Received

P-0516	ANTILEUKEMIC THERAPY WITH DOT1L INHIBITOR DEPENDS ON NORMAL ACTIVITY OF TRANSCRIPTION FACTORS PU.1 AND C/EBP?	Monica Cusan	Received

P-0517	STING ACTIVATION INDUCES PHAGOCYTIC CLEARANCE OF AML BY MACROPHAGES THROUGH AN ICAM/LFA1-DEPENDENT MECHANISM	Matthew Markham	Received

P-0518	HIGH IASPP (PPP1R13L) EXPRESSION IS AN INDEPENDENT PREDICTOR OF CLINICAL OUTCOME IN ACUTE MYELOID LEUKEMIA (AML)	Kerstin Kampa-Schittenhelm	Received

P-0519	DUAL TARGETING OF FLT3-ITD AND CLK BY SCREENED DONATED CHEMICAL PROBES IN ACUTE MYELOID LEUKEMIA	Stephanie Laszig	Received

P-0520	AZD9829 DEMONSTRATES COMBINATION BENEFIT WITH HMA AND VENETOCLAX IN AML CELL LINES, PATIENT SAMPLES AND PDX MODELS.	Dipannita Dutta	Received

P-0522	COMPARISON OF TWO HIERARCHICAL DIRICHLET MIXTURE MODELS FOR THE GENOMIC STRATIFICATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA	Amin Turki	Received

P-0524	IDENTIFICATION OF THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR, PAROXETINE, AS A NOVEL THERAPEUTIC AGENT IN MLL-REARRANGED ACUTE MYELOID LEUKAEMIA	Cheuk Yin Yuen	Received

P-0525	SYNERGISTIC POTENTIAL OF RVU120, A FIRST-IN-CLASS CDK8/CDK19 INHIBITOR, WITH VENETOCLAX IN AML: PRECLINICAL AND INITIAL CLINICAL INSIGHTS	Urszula Pakulska	Received

P-0526	AML LACKING PSAT1 EXPRESSION IS VULNERABLE TO SERINE-DEPLETION STRATEGIES	Ilias Sinanidis	Received

P-0527	CELLULAR CONTEXT DETERMINES SENSITIVITY TO ASCORBIC ACID IN AN IDH1-MUTANT ACUTE MYELOID LEUKEMIA MODEL.	Sarah Grasedieck	Received

P-0528	GENOME-WIDE ANALYSES IN OVER 363,000 INDIVIDUALS IDENTIFIES NEW MULTI-OMIC DETERMINANTS OF CLONAL HAEMATOPOIESIS AND HEMATOPOIETIC MOSAIC CHROMOSOMAL ALTERATIONS	Jonathan Bowles	Received

P-0529	FETAL MLL-ENL INITIATION INDUCES HERITABLE PROTECTIVE TRANSCRIPTIONAL PROGRAMS AGAINST TRANSFORMATION THAT DEPEND ON MLL3	Jonny Mendoza-Castrejon	Received

P-0531	REM-422, A POTENT, SELECTIVE, ORAL SMALL MOLECULE MRNA DEGRADER OF THE MYB ONCOGENE, DEMONSTRATES ANTI-TUMOR ACTIVITY IN MOUSE XENOGRAFT MODELS OF AML	Charles Kung	Received

P-0532	HMPL-306 IN PATIENTS WITH RELAPSED OR REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR IDH2 MUTATIONS: FINAL RESULT OF DOSE EXPANSION IN PHASE 1 STUDY	Xiaojun Huang	Received

P-0533	CLINICAL CHARACTERISTICS, GENETIC HETEROGENEITY, AND OUTCOMES OF KMT2A-REARRANGED AML IN ADULTS: A RETROSPECTIVE COHORT STUDY	Li Chen	Received

P-0534	COUPLING FUNCTIONAL RESISTANCE MARKERS AND COMPUTATIONAL ANALYSIS TO IMPROVE AND SIMPLIFY FLOW CYTOMETRIC MRD DETECTION IN AML	Nicholas McCarthy	Received

P-0535	A PROSPECTIVE, CROSSOVER DESIGN STUDY FOR THE SECONDARY PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA IN ACUTE MYELOID LEUKEMIA PATIENTS POST-CYTARABINE CONSOLIDATION CHEMOTHERAPY	Wenlan Chen	Received

P-0539	THE ROLE OF INTENSIVE CHEMOTHERAPY IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM	Philip Haddad	Received

P-0540	SAFETY AND ACTIVITY OF REVUMENIB IN COMBINATION WITH FLUDARABINE/CYTARABINE (FLA) IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS	Neerav Shukla	Received

P-0541	OVERALL SURVIVAL IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS WITH MIDH1 OR MIDH2 IN THE US, FROM AN INTERNATIONAL REAL-WORLD DATABASE (REAL-IDH)	Joshua Zeidner	Received

P-0542	EARLY RESPONSE ASSESSMENT AFTER CPX-351 INDUCTION THERAPY FOR ACUTE MYELOID LEUKEMIA	Julian Ronnacker	Received

P-0543	TOLERABILITY AND EFFICACY OF MAGROLIMAB PLUS MITOXANTRONE, ETOPOSIDE, AND CYTARABINE (MEC) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) REFRACTORY/RELAPSED (R/R) AFTER INDUCTION CHEMOTHERAPY (IC)	Gabriel Mannis	Received

P-0544	VENETOCLAX PLUS AZACITIDINE, CYTARABINE, ACLARUBICIN AND G-CSF (VA-CAG REGIMEN) FOR NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA: UPDATE OF A PROSPECTIVE, MULTICENTER, PHASE 2 CLINICAL TRIAL	Xiaoping Li	Received

P-0545	TREATMENT EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS IN PATIENT SUBGROUPS WITH ACUTE MYELOID LEUKEMIA: EXPERIENCE FROM ROUTINE CLINICAL PRACTICES IN THE UNITED STATES	Pankit Vachhani	Received

P-0546	OPTIMAL DURATION OF CPX-351 TREATMENT AND BEST TIMING FOR CONSOLIDATION WITH ALLOGENEIC STEM CELL TRANSPLANTATION: EVIDENCE FROM A LARGE REAL-WORLD ITALIAN STUDY.	Fabio Guolo	Received

P-0548	DISMAL OUTCOMES FOLLOWING ALLOGENEIC TRANSPLANTATION IN AML PATIENTS WITH T(16;21)(P11.2;Q22.2)/FUS::ERG TRANSLOCATION	Yi-han Yang	Received

P-0549	PHASE 1 STUDY OF HMPL-306 IN PATIENTS WITH ADVANCED ACUTE MYELOID LEUKEMIA WITH ISOCITRATE DEHYDROGENASE (IDH) MUTATIONS: PRELIMINARY RESULTS OF THE DOSE ESCALATION COHORTS	Pau Montesinos	Received

P-0550	BASELINE PREDICTORS OF SURVIVAL IN 263 PATIENTS WITH AML TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX: A MULTICENTER COHORT STUDY.	Stefano Cordella	Received

P-0552	BLEEDING PREDICTORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Nikola Pantic	Received

P-0554	PRELIMINARY EFFICACY AND MOLECULAR CHARACTERIZATION OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS WITH FLT3 MUTATION TREATED WITH SINGLE AGENT EMAVUSERTIB (CA-4948)	Eric Winer	Received

P-0555	DISTINCT CLINICAL AND BIOLOGICAL CHARACTERISTICS OF ACUTE MYELOID LEUKEMIA WITH HIGHER EXPRESSION OF PIWIL4	Sheng-Yu Hung	Received

P-0556	RANDOMIZED PHASE 2 STUDY OF CPX-351 + POMALIDOMIDE VS CPX-351 ALONE IN NEWLY DIAGNOSED AML WITH MDS-RELATED CHANGES: RESULTS OF SAFETY RUN-IN EVALUATION	Daniel Peters	Received

P-0557	SAFETY AND EFFICACY OF TUSPETINIB AS MONOTHERAPY AND COMBINED WITH VENETOCLAX IN A PHASE 1/2 TRIAL OF PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)	Rafael Bejar	Received

P-0558	ADULT AND PEDIATRIC DETERMINANTS OF SURVIVAL IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM	Philip Haddad	Received

P-0559	A MULTI-CENTER, OPEN-LABEL, SINGLE-ARM PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FCN-159 IN ADULTS WITH HISTIOCYTIC NEOPLASMS	Xin-xin Cao	Received

P-560	IMPACT OF TP53 MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DURING ORAL AZACITIDINE MAINTENANCE THERAPY: OUTCOMES FROM THE QUAZAR AML-001 TRIAL	Andrew H. Wei	Received

P-0561	GILTERITINIB PLUS VENETOCLAX, LOW-DOSE CYTARABINE, AND ACTINOMYCIN D AS FIRST SALVAGE THERAPY FOR RELAPSED OR REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA	Andrius Žucenka	Received

P-0563	VENETOCLAX AND HYPOMETHYLATING AGENTS COMPARED TO OTHER STRATEGIES IN OLDER ACUTE MYELOID LEUKAEMIA PATIENTS IN THE REAL LIFE. A RETE EMATOLOGICA LOMBARDA (REL) STUDY	Erika Borlenghi	Received

P-565	FLAG REGIMEN, COMBINED WITH GEMTUZUMAB (FLAG-GO) RESULTS IN BETTER OPTIMAL MOLECULAR RESPONSE AND OUTCOMES, COMPARED TO COMBINATION WITH IDARUBICIN (FLAG-IDA) IN UNTREATED CORE BINDING FACTOR AML	Gautam Borthakur	Received

P-0566	ROLE OF MRD AS A BIOMARKER TO OPTIMIZE OUTCOME IN ELN2017 INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: COMPARISON BETWEEN GIMEMA AML1310 MRD-DRIVEN PROTOCOL AND REAL-LIFE DECISION-MAKING PROCESS.	Raffaele Palmieri	Received

P-0567	VENETOCLAX-AZACITIDINE VERSUS AZACITIDINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN FIRST RELAPSE OR PRIMARY REFRACTORY TO INTENSIVE CHEMOTHERAPY. AN IPC-DATAML-MSKCC STUDY	Sylvain Garciaz	Received

P-0568	OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 70 YEARS WITHIN THE LAST 25 YEARS, A SINGLE CENTER EXPERIENCE	Claudia Roggenbuck	Received

P-0570	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY AS CONSOLIDATION TREATMENT FOR ACUTE MYELOID LEUKEMIA IN FIRST REMISSION: A PETHEMA REGISTRY STUDY.	Ana Alfonso Piérola	Received

P-0571	REAL-WORLD USE OF ORAL-AZACITIDINE AS MAINTENANCE THERAPY FOR ACUTE MYELOID LEUKEMIA IN REMISSION: CHARACTERISTICS AND OUTCOMES OF A FRENCH PATIENT POPULATION	Christian Récher	Received

P-0573	PROGNOSTIC RELEVANCE OF TP53 MUTATIONS WITH OR WITHOUT CONCOMITANT COMPLEX KARYOTYPE IN PATIENTS TREATED WITH CPX-351: EVIDENCE FROM A LARGE REAL-WORLD ITALIAN STUDY.	Elisabetta Todisco	Received

P-0574	NUP98 FUSIONS IN ADULT AML: A COHORT ANALYSIS ON FREQUENCY, CO-MUTATIONS AND GENETIC IDENTIFICATION OF A NOVEL FUSION PARTNER	James Heald	Received

P-0575	RESULTS OF THE PETHEMA PEVOLAM TRIAL: A PHASE III RANDOMIZED OPEN LABEL STUDY COMPARING AZACITIDINE PLUS PEVONEDISTAT VERSUS AZACITIDINE IN UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Rebeca Rodriguez Veiga	Received

P-0576	PROGNOSTIC IMPLICATIONS OF MEASURABLE RESIDUAL DISEASE AND KIT MUTATION IN PEDIATRIC CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA	TINGCHI YEH	Received

P-0577	PRELIMINARY RESULTS OF THE FRIDA STUDY: IADADEMSTAT AND GILTERITINIB IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA.	Amir Fathi	Received

P-0578	MUTATIONAL PATTERNS AND CLONAL HIERARCHY IN 430 PATIENTS WITH IDH1 MUTATED AML INDICATE PRACTICAL IMPLICATIONS FOR MOLECULAR TESTING AND TARGETED TREATMENT	Gregor Hoermann	Received

P-0579	CHARACTERISTICS AND OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA CHARACTERIZED BY ISOLATED TRISOMIES AS COMPARED TO COMPLEX KARYOTYPES ACCORDING TO DIFFERENT TREATMENT STRATEGIES	Sabine Kayser	Received

P-0580	A MULTICENTER REAL-WORLD ANALYSIS OF GEMTUZUMAB OZOGAMICIN IN THE FIRST-LINE TREATMENT OF CBF-AML	Philippe Muller	Received

P-0581	LIPOSOMAL CYTARABINE AND DAUNORUBICIN (CPX-351) VERSUS INTENSIVE INDUCTION CHEMOTHERAPY IN PATIENTS WITH THERAPY-RELATED AML OR AML WITH MDS-RELATED CHANGES: A COMPARATIVE HOVON-SAKK ANALYSIS	Dimitrios Kotsos	Received

P-0582	A PHASE 1, DOSE-ESCALATION STUDY OF QLF32101, A CLL1/CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)	Jianxiang Wang	Received

P-0583	GENETIC PROGNOSTIC SCORING SYSTEM FOR AML WITH MYELODYSPLASIA-RELATEDABNORMALITIES	Yijing Zhao	Received

P-0584	A NON-INTERVENTIONAL COHORT STUDY INVESTIGATING THE CLONAL EVOLUTION OF FMS-LIKE TYROSINE KINASE 3 MUTATIONS DURING DISEASE PROGRESSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: SECOND INTERIM RESULTS	Cristina Papayannidis	Received

P-585	GENOMIC PROFILES AND CLINICAL OUTCOMES IN DE NOVO VERSUS THERAPY-RELATED CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA (AML) AND OUTCOMES PREDICTORS	May Chiu	Received

P-0587	BRAF DELETION IN ADULT PATIENTS WITH LANGERHANS CELL HISTIOCYTOSIS CORRELATES WITH MULTISYSTEM DISEASE AND POOR OUTCOME	Min Lang	Received

P-0588	QUALITY OF LIFE BENEFITS OF ATO VS CHEMOTHERAPY IN PATIENTS WITH APL ARE SUSTAINED OVER TIME: RESULTS FROM THE GIMEMA APL0406	Fabio Efficace	Received

P-0590	REDUCED VENETOCLAX EXPOSURE TO 7 DAYS VS STANDARD VENETOCLAX EXPOSURE WITH HYPOMETHYLATING AGENT IN OLDER/UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COMPARISON.	Christophe Willekens	Received

P-0591	REAL-WORLD EXPERIENCE WITH CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND: UPDATED ANALYSIS OF THE CANCER ANALYSIS SYSTEM DATABASE	Alexandrina Lambova	Received

P-0592	A RANDOMIZED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS): A SUBGROUP ANALYSIS OF UK NCRI AML19	Alex Legg	Received

P-0593	TREATMENT PATTERNS AND CLINICAL OUTCOMES IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WITH AND WITHOUT MIDH1/MIDH2 TREATED WITHOUT INTENSIVE CHEMOTHERAPY: REAL-IDH A STUDY OF REAL WORLD DATABASES	Christian Récher	Received

P-0595	FLAVIDA CHEMOTHERAPY IS AN EFFECTIVE BRIDGE-TO-TRANSPLANT STRATEGY IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS	Rabia Shahswar	Received

P-0596	HIGH RISK MUTATIONS IN CRITICAL GENES DO NOT AFFECT REMISSION RATES AND MRD CLEARANCE IN ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING CPX-351 INDUCTION	Carola Riva	Received

P-0597	PREDICTORS OF EARLY MORTALITY IN 1,073 PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA BASED ON THE 2022 INTERNATIONAL CONSENSUS CLASSIFICATION	Hsin-Yu Lu	Received

P-0598	CLINICAL CHARACTERISTICS OF RARE GENETIC ALTERATIONS ASSOCIATED WITH UPREGULATION OF HOX GENES IN ADULTS WITH ACUTE LEUKEMIA	Aziz Farhat	Received

P-0600	RVU120, A FIRST-IN-CLASS CDK8 INHIBITOR FOR THE TREATMENT OF RELAPSED/REFRACTORY AML AND HIGH-RISK MDS: PRELIMINARY RESULTS FROM TWO ONGOING STUDIES	Dominik Chraniuk	Received

P-0601	INTERIM ANALYSIS OF A RANDOMIZED PHASE 1 TRIAL IN HEALTHY VOLUNTEERS INVESTIGATING THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL FLT3/IRAK4 INHIBITOR, LOMONITINIB (ZE46-0134)	John C. Byrd	Received

P-0602	REAL-WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME REGIMEN FOR ACUTE MYELOID LEUKEMIA: A SHORT-TERM ANALYSIS OF EFFICACY AND SAFETY	Ma Jun	Received

P-0603	PHASE II STUDY OF CLADRIBINE, IDARUBICIN, AND HIGHER DOSE CYTARABINE (CLIA) IN PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)	Tapan Kadia	Received

P-0604	BARRIERS TO AN ALLOGENEIC HSCT IN OLDER AML PATIENTS ACHIEVING REMISSION WITH INTENSIVE CHEMOTHERAPY: INSIGHTS FROM THE UK NCRI AML 18 TRIAL.	Priyanka Mehta	Received

P-0605	OLUTASIDENIB DEMONSTRATES CLINICAL ACTIVITY IN MUTATED IDH1 ACUTE MYELOID LEUKEMIA (AML) SECONDARY TO MYELOPROLIFERATIVE NEOPLASMS (MPN)	Stéphane De Botton	Received

P-0607	LEUKAPHERESIS DOES NOT HAVE AN IMPACT ON EARLY MORTALITY RATE IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS	Mirjana Cvetkovic	Received

P-0609	REAL-WORLD EFFICACY OF VENETOCLAX-AZACITIDINE IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A MULTICENTRIC STUDY FROM THE GRUPO PORTUGUÊS DE LEUCEMIAS AGUDAS (GPLA)	Luis Monteiro	Received

P-0610	NEW COMBINATION REGIMENS VS FLAI IN THE TREATMENT OF INTERMEDIATE OR LOW RISK NPM1-MUTATED AML: A RETROSPECTIVE ANALYSIS FROM 7 ITALIAN CENTERS	Giulia Battaglia	Received

P-0611	SAFETY AND EFFICACY OF OLUTASIDENIB TREATMENT IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY MIDH1 ACUTE MYELOID LEUKEMIA	Stéphane De Botton	Received

P-0613	THE CLINICAL IMPACT OF CONCURRENT GENE MUTATIONS AND CYTOGENETIC ABNORMALITIES ON NPM1-MUTATED AML: A RETROSPECTIVE COHORT STUDY OF 1,520 PATIENTS	Ting-Wei Lyu	Received

P-0614	RESPONSE TO OLUTASIDENIB IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) FOLLOWING VENETOCLAX FAILURE	Jorge Cortes	Received

P-0617	IMPACT OF PREVIOUS CHEMOTHERAPY (CT) EXPOSURE ON MOLECULAR CHARACTERISTICS AND TREATMENT OUTCOMES OF THERAPY RELATED MYELOID NEOPLASMS (T-MN)	Pinkal Desai	Received

P-0618	PRESENCE OF BONE MARROW FIBROSIS AND NECROSIS IS ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA	Elliot Smith	Received

P-0619	COMPARING OUTCOMES BETWEEN CPX-351 AND FLUDARABINE-BASED INDUCTION IN SECONDARY OR THERAPY RELATED ACUTE MYELOID LEUKEMIA: THE PROGNOSTIC ROLE OF MRD	Chiara Vernarecci	Received

P-0622	BURDEN OF ACUTE LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES IN A LARGE OBSERVATIONAL STUDY (ILL-CAR-2018-01) ON LONG-TERM BREAST CANCER SURVIVORS	Jorge Illarramendi Esteban	Received

P-0625	BASELINE GENOMIC TESTING AND OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN THE MODERN ERA: REAL-WORLD DATA FROM A LARGE US COHORT	Xin Wang	Received

P-0626	CLINICAL OUTCOMES OF CONCURRENT FLT3 INHIBITOR AND IDH INHIBITOR THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Catherine Gutierrez Moore	Received

P-0627	CHEMOTHERAPY-FREE CONSOLIDATION IS EQUALLY EFFECTIVE AS CHEMOTHERAPY-INCLUSIVE APPROACHES IN HIGH-RISK APL PATIENTS POST-REMISSION INDUCTION	Fangyi Dong	Received

P-0628	RICHTER SYNDROME DIFFUSE LARGE B-CELL LYMPHOMA TYPE: PHENOTYPIC CHARACTERIZATION AND COMPARATIVE ANALYSIS WITH THE ORIGINAL CLL AND WITH DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS	Fernando Martin Moro	Received

P-0630	ASSOCIATION BETWEEN GENOMIC ALTERATIONS AND SERUM MONOCLONAL PROTEINS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Juan Antonio Pineyroa Gigosos	Received

P-0631	FOXO1-MEDIATED CELL CYCLE ARREST AND APOPTOSIS IS INHIBITED BY USP7 DOWNSTREAM OF BCR LIGATION IN CLL CELLS.	Hassan Almuhanna	Received

P-0632	CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) PATIENT DEMOGRAPHICS AND PATIENT-REPORTED BURDEN IN IBRUTINIB AND NON-IBRUTINIB RECEIVERS IN THE US: A REAL-WORLD STUDY.	Amber Simpson	Received

P-0634	EXPLORING THE RELATIONSHIP BETWEEN KARYOTYPE COMPLEXITY AND DNA METHYLATION IN UNMUTATED IGHV CHRONIC LYMPHOCYTIC LEUKEMIA	Stella Charalampopoulou	Received

P-0635	A CX3CR1 (FRACTALKINE RECEPTOR) SMALL MOLECULE ANTAGONIST (KAND567) SUPPRESSED THE GROWTH-PROMOTING EFFECT OF NURSE-LIKE CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Wen Zhong	Received

P-0636	JAK3-STAT5 SIGNALING IS INVOLVED IN SHAPING THE IMMUNE INHIBITORY PHENOTYPE OF T HELPER CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Shimrit Ringelstein-Harlev	Received

P-0639	GLUTAMINE ADDICTION IN THE CLL MICROENVIRONMENT; TOWARDS IMPROVED DETECTION WITH PET IMAGING	Helga Simon-Molas	Received

P-0640	PREVALENCE AND CLINICAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA	Samir Mouhssine	Received

P-0641	FUNCTIONAL PHENOTYPE MODEL PREDICTS PROGRESSION FREE SURVIVAL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON141/VISION TRIAL	Weikaixin Kong	Received

P-0642	PRELIMINARY ANALYSIS OF THE COMPLEX PROJECT: IMPACT OF GENOMIC COMPLEXITY IN CLL PATIENTS TREATED WITH TARGETED THERAPIES IN A REAL-LIFE SETTING	Silvia Ramos-Campoy	Received

P-0643	IMMUNE CELL EFFECTS OF LONG-TERM ACALABRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Olina Lind	Received

P-0644	?ON-MUTATIONAL MYC ACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA: FROM TRANSCRIPTOMICS TO CLINICOBIOLOGICAL ASSOCIATIONS	Maria Tsagiopoulou	Received

P-0645	SINGLE-CELL SEQUENCING OF IN VITRO 3D CLL MODEL PROVIDE INSIGHT INTO INTERACTIONS WITHIN THE CLL LYMPH NODE NICHE UPON TREATMENT WITH BTK INHIBITORS	Marco Haselager	Received

P-0646	ANALYSIS OF MUTATIONS IN BTK AND BCL2 WITH CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS SUGGESTS DIFFERENT RESISTANCE MECHANISMS AND SUBCLONAL DYNAMICS UNDER TREATMENT WITH BTK OR BCL2 INHIBITORS	Miguel Bastos Boente	Received

P-0647	DIETARY INFLUENCES ON CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION: UNVEILING THE POTENTIAL OF EARLY-STAGE INTERVENTION	Maike Buchner	Received

P-0648	LIVE CLL CELLS INSIDE THE BONE MARROW FIBROBLASTS AND ITS IMPLICATION IN DISEASE PERSISTENCE	Y. Lynn Wang	Received

P-0649	DYNAMIC STIMULATION PROMOTES FUNCTIONAL TISSUE-LIKE ORGANISATION OF A 3D HUMAN LYMPHOID MICROENVIRONMENT MODEL AND ALLOWS TO STUDY CLL CELLS TRAFFICKING IN VITRO	Dafne Barozzi	Received

P-0650	MUTATIONAL STATUS OF KAPPA AND LAMBDA LIGHT CHAIN GENES INDEPENDENTLY PREDICTS TIME TO FIRST TREATMENT IN EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA	Donatella Talotta	Received

P-0651	REAL-WORLD USE AND EFFECTIVENESS OF ACALABRUTINIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA: THE NATIONAL ACALABRUTINIB OBSERVATIONAL STUDY (NAOS)	Anne Quinquenel	Received

P-0652	REAL LIFE EVIDENCE OF THE USE OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A REGISTRY STUDY ON BEHALF OF THE SPANISH CLL GROUP (GELLC)	Alberto Lopez García	Received

P-0653	PRELIMINARY SAFETY AND EFFICACY RESULTS FROM A PHASE 1B STUDY OF ORAL NON-COVALENT BTK INHIBITOR AS-1763 IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES	Nitin Jain	Received

P-0654	REAL-WORLD OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH BTK INHIBITORS (BTKI): A SUBGROUP ANALYSIS OF OVER 1100 PATIENTS ENROLLED INTO THE GIMEMA CLL2121 STUDY	Lydia Scarfò	Received

P-0655	PHASE I TRIAL OF A PERSONALIZED MULTI-PEPTIDE VACCINE COMBINED WITH THE TLR1/2 LIGAND XS15 UNDER BRUTON-TYROSINE-KINASE INHIBITOR (BTKI) TREATMENT IN CLL PATIENTS	Susanne Jung	Received

P-0656	PIRTOBRUTINIB IN RELAPSED/REFRACTORY CLL/SLL: RESULTS FROM BTKI NAÏVE COHORT IN THE PHASE 1/2 BRUIN STUDY	Toby Eyre	Received

P-657	TARGETED THERAPIES ERADICATE THE NEGATIVE PROGNOSTIC IMPACT OF IGHV SUBSET#2 IN CHRONIC LYMPHOCYTIC LEUKEMIA : A RETROSPECTIVE REAL-LIFE MULTICENTER FRENCH STUDY	Lucile Bussot	Received

P-0658	TIME TO NEXT TREATMENT AFTER FIRST-LINE TREATMENT WITH TIME-LIMITED TARGETED AGENTS: A POOLED ANALYSIS OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITHIN CLINICAL TRIALS OF THE GCLLSG	Nadine Kutsch	Received

P-0659	REAL-WORLD CARDIOVASCULAR AND CLINICAL OUTCOMES IN PATIENTS INITIATING COVALENT BTK INHIBITORS (CBTKI) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) IN THE UNITED STATES	Hayden Hyatt	Received

P-0660	A CLINICAL PHASE II STUDY ON INTERMITTENT AND REPEATED DOSING ("ON-OFF-REPEAT") OF IBRUTINIB TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Jeanette Lundin	Received

P-0661	IMPACT OF VENETOCLAX-BASED THERAPIES ON AUTOIMMUNE CYTOPENIAS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER STUDY CONDUCTED BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL	Marta Coscia	Received

P-0665	REAL-WORLD TREATMENT EFFECTIVENESS IN HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING VENETOCLAX-BASED THERAPY: AN INTERNATIONAL STUDY	Catherine C. Coombs	Received

P-0666	EFFICACY OF PEMBROLIZUMAB MONOTHERAPY AND IN COMBINATION WITH BCR INHIBITORS FOR RICHTER TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA	Yucai Wang	Received

P-0667	IBRUTINIB LEAD-IN FOLLOWED BY VENETOCLAX PLUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA	Davide Rossi	Received

P-0668	CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT (CNSI)	Mariia Mikhaleva	Received

P-0669	SAFETY AND EFFICACY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA FROM A PHASE I STUDY	Wei Xu	Received

P-0670	FINAL ANALYSIS OF THE RESONATE-2 STUDY: UP TO 10 YEARS OF FOLLOW-UP OF FIRST-LINE IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA	Jan Burger	Received

P-0671	REAL-WORLD TREATMENT EFFECTIVENESS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING VENETOCLAX-BASED THERAPY AFTER BRUTON TYROSINE KINASE INHIBITORS: AN INTERNATIONAL STUDY	Nilanjan Ghosh	Received

P-0672	A PHASE 2 STUDY OF MINIMAL RESIDUAL DISEASE (MRD)-ADAPTED, TIME-LIMITED ACALABRUTINIB AND OBINUTUZUMAB FOR THE INITIAL TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): MRD OUTCOMES	Lindsey Roeker	Received

P-0673	CLINICAL IMPACT OF CLONAL RELATIONSHIP IN RICHTER TRANSFORMATION: AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC	Riccardo Moia	Received

P-0674	OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA THAT FAILED BTK INHIBITOR AND VENETOCLAX-BASED TREATMENTS, AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC	Thomas Chatzikonstantinou	Received

P-0675	OUTCOMES IN HIGH-RISK SUBGROUPS AFTER FIXED-DURATION IBRUTINIB + VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: UP TO 5.5 YEARS OF FOLLOW-UP IN THE PHASE 2 CAPTIVATE STUDY	Ryan Jacobs	Received

P-0676	HOW WELL ARE OUR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA?	Claire Hutchinson	Received

P-0677	UPTAKE OF THE FIRST TO FIFTH DOSES OF COVID-19 VACCINE IN INDIVIDUALS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: A NATIONWIDE COHORT STUDY IN SWEDEN	Lisa Blixt	Received

P-678	A PATIENT PERSPECTIVE ON BEING TOLD THEY HAVE A NEW DIAGNOSIS OF CLL: RESULTS OF AN ONLINE SURVEY IN THE UK	Renata Walewska	Received

P-0679	CENTRAL NERVOUS SYSTEM INVOLVEMENT IN CLL. AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL	Maya Koren-Michowitz	Received

P-0680	ORELABRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (OFCG) FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER, INVESTIGATOR-INITIATED STUDY (CWCLL-001 STUDY)	Huayuan Zhu	Received

P-0681	LONG TERM FOLLOW-UP OF HAIRY CELL LEUKEMIA TREATMENT: 30-YEAR EXPERIENCE AT SINGLE UNIVERSITY CENTER	Jelena Ivanovic	Received

P-0682	RETREATMENT WITH VENETOCLAX AND RITUXIMAB COMBINATION FOLLOWING DISEASE PROGRESSION WHILE OFF THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Danielle M. Brander	Received

P-0683	SF3B1 MUTATION PREDICTS SHORTENED SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB	Anna Petrácková	Received

P-0684	INTERIM RESULTS FROM ASSURE: A PHASE 3B SAFETY STUDY OF ACALABRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Stephen Opat	Received

P-0686	ANALYSIS OF CLINICAL OUTCOMES OF THE CONSERVATIVE APPROACH IN TREATMENT INDICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHTS FROM THE BRAZILIAN REGISTRY OF CLL	Celso Arrais-Rodrigues	Received

P-0687	ALLOGENIC TRANSPLANTATION IN CHRONIC LYMPHOCYTIC LEUKEMIA IN A SINGLE CENTER: 10 YEARS FOLLOW-UP AND FOCUS ON BTKI/BCL2I DOUBLE EXPOSED CLL	Thérèse Aurran	Received

P-0688	PROGNOSTIC RELEVANCE OF THE IMMUNOGLOBULIN LIGHT CHAIN REARRANGEMENT IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA	Mischa Vervoordeldonk	Received

P-0689	THE ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) INDEPENDENTLY PREDICTS TIME TO FIRST TREATMENT IN CLL, WHILE ITS IMPACT ON PFS SEEMS TO DEPEND ON THE TREATMENT STRATEGY	Pablo Mozas	Received

P-0690	PROGRESSION ON COVALENT BRUTON TYROSINE KINASE INHIBITORS PREDICTS POOR OUTCOMES IN CBTKI-EXPOSED AND CBTKI-VENETOCLAX DOUBLE-EXPOSED POPULATIONS: A RETROSPECTIVE FILO STUDY IN 154 R/R CLL PATIENTS	Loïc Ysebaert	Received

P-0691	IMPACT OF FIRST-YEAR DOSE MODIFICATIONS OF ACALABRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Alessandra Tedeschi	Received

P-0692	SCOPING OUT CARDIOVASCULAR ASSESSMENT ON INITIATION AND SUBSEQUENT MONITORING DURING BTKI THERAPY, AN ERIC INITIATIVE	Thomas Chatzikonstantinou	Received

P-0693	INCIDENTAL LYMPHADENOPATHY AND SPLENOMEGALY ON IMAGING STUDIES CAN PREDICT TIME TO FIRST CLL THERAPY AND OVERALL SURVIVAL IN PATIENTS WITH CLL-LIKE HIGH COUNT MONOCLONAL B-CELL LYMPHOCYTOSIS	Samuel Kosydar	Received

P-0694	COMPARATIVE EFFECTIVENESS OF IBRUTINIB FLEXIBLE DOSING TREATMENT STRATEGIES ON TIME TO NEXT TREATMENT IN A LARGELY COMMUNITY-BASED CLAIMS DATABASE: A TARGET TRIAL EMULATION STUDY	Nilanjan Ghosh	Received

P-0695	POT1 MUTATIONS IDENTIFY INFERIOR OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA AND DISRUPTED TELOMERE BIOLOGY FUNCTION	Bihui Pan	Received

P-0696	COMPARISON OF TIME TO NEXT TREATMENT BETWEEN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA INITIATING FIRST-LINE IBRUTINIB OR ACALABRUTINIB OVERALL AND IN A SUBGROUP WITH HIGH-RISK CHARACTERISTICS	Ryan Jacobs	Received

P-0699	6-YEAR TIME TO NEXT TREATMENT (TTNT) EXTRAPOLATION CURVE FOR GLOW STUDY: FIRST-LINE IBRUTINIB + VENETOCLAX (I+V) OFFERS LONG TREATMENT-FREE PERIOD FOR ELDERLY/UNFIT CLL PATIENTS	Santiago Ossorio Prendes	Received

P-0703	IMPACT OF ACALABRUTINIB TREATMENT BY LINE OF THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: POOLED ANALYSIS FROM ELEVATE-TN, ELEVATE-RR, AND ASCEND	Paolo Ghia	Received

P-0705	C3G DEFICIENCY DELAYS CHRONIC MYELOID LEUKEMIA DEVELOPMENT IN A P210 BCR-ABL1 TRANSGENIC MODEL	Pablo Berrocal	Received

P-0706	DESIGN AND VALIDATION OF A MASS CYTOMETRY APOPTOTIC PANEL FOR PREDICTING SENSITIVITY OF CHRONIC MYELOID BLAST CELLS CROSS-RESISTANT TO TYROSINE KINASE INHIBITORS TO THE BCL2 INHIBITOR VENETOCLAX	Adam Laznicka	Received

P-0707	MAKING TKI DISCONTINUATION MORE EFFICIENT IN CHRONIC MYELOID LEUKEMIA: THE ROLE OF CIRCULATING CYTOKINES AND RESIDUAL PRIMITIVE LEUKEMIC CELLS.	Michele Bianchini	Received

P-0709	MODELING SRSF2/TET2 MUTATIONAL COOPERATIVITY IN CMML DEVELOPMENT	Dina Alihodzic	Received

P-0710	KF-1601, A DUAL INHIBITOR BCR::ABL1 AND FLT3 , OVERCOMES DRUG RESISTANCE IN FLT3+ BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA	Sung-Min Ahn	Received

P-0713	EUROPEAN LEUKEMIANET MILESTONES AND THEIR PROGNOSTIC RELEVANCE FOR ACHIEVING DEEP MOLECULAR RESPONSE AND TREATMENT-FREE REMISSION IN ROUTINE CARE: RESULTS OF THE GERMAN CML REGISTRY	Katharina Kohlbrenner	Received

P-0714	TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 657 ITALIAN PATIENTS	Valentina Bonuomo	Received

P-0715	DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA. ELIGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI: THE LABNET CML NATIONAL NETWORK	Massimo Breccia	Received

P-0716	IMPROVEMENT OF TREATMENT-FREE REMISSION RATE FOLLOWING DISCONTINUATION OF BCR::ABL1 TKI WITH A FASTER INITIAL DECLINE OF BCR::ABL1 TRANSCRIPT AND LONGER TREATMENT DURATION IN CHRONIC MYELOID LEUKEMIA	SEWON LEE	Received

P-0717	ONE YEAR ANALYSIS OF GROWTH DATA IN NEWLY-DIAGNOSED PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB: RESULTS FROM TRIAL ITCC-054/COG-AAML1921	Edoardo Pennesi	Received

P-0718	RESULTS OF PONATINIB AS FRONTLINE THERAPY FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE	Fadi Haddad	Received

P-0719	LOWER-DOSE INITIATING BOSUTINIB IS SAFE AND EFFECTIVE FOR RESISTANT OR INTOLERANT TO PRIOR THERAPY CHRONIC MYELOID LEUKEMIA PATIENTS (BOGI TRIAL): A SINGLE-ARM, MULTICENTER, PHASE II TRIAL	Shinya Kimura	Received

P-0720	ASC4REAL: EFFICACY AND TOLERABILITY COMPARISON BETWEEN ASCEMBL STUDY, A PHASE 3 RANDOMIZED CLINICAL TRIAL (RCT), AND REAL-WORLD (RW) EXPERIENCE WITH ASCIMINIB IN CML PATIENTS BEYOND 2 TKIS	Anchit Khanna	Received

P-0721	CLINICAL EFFICACY OF FIRST-LINE NILOTINIB OR IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA – NATIONWIDE REAL LIFE DATA	Daniela Žácková	Received

P-0722	OLVEREMBATINIB OVERCOMES PONATINIB AND ASCIMINIB RESISTANCE IN PATIENTS (PTS) WITH HEAVILY PRETREATED CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH? ALL)	Elias Jabbour	Received

P-0723	BCR::ABL1 KINETICS IN CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) PATIENTS AFTER PONATINIB VERSUS NILOTINIB TREATMENT FRONT-LINE	Franck Emmanuel Nicolini	Received

P-0724	TREATMENT PATTERNS AND REAL-WORLD CLINICAL OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE TREATED WITH ASCIMINIB IN ONCOLOGY PRACTICES IN THE UNITED STATES	Ehab Atallah	Received

P-0725	PROPENSITY SCORE MATCHING ANALYSIS COMPARING ASCIMINIB VERSUS PONATINIB FOR ITS TREATMENT OUTOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS	Maria Agustina Perusini	Received

P-0726	IL10 AND IL15 SIGNIFICANTLY PLUMMETED IN PATIENTS PRESENTING WITH TYROSINE KINASE INHIBITOR WITHDRAWAL SYNDROME (TWS). PRELIMINARY RESULTS FROM THE « KIWIS » STUDY DESIGNED FOR TWS.	Hyacinthe Atchroue Johnson Ansah	Received

P-0728	ANALYSIS OF FACTORS AFFECTING THE ACQUISITION OF MR4.5 UNDER FIRST-LINE IMATINIB TREATMENT	Jian Huang	Received

P-0729	KRAS MUTATION PREDICTS POOR OUTCOME IN PATIENTS WITH MYELOID BLAST PHASE CHRONIC MYELOID LEUKEMIA RECEIVING THIRD GENERATION TYROSINE KINASE INHIBITORS COMBINED WITH AZACITIDINE	Mei Bao	Received

P-0730	ASCIMINIB AS INITIAL THERAPY FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (ALERTCML)	Ehab Atallah	Received

P-0731	DECIPHERING TELOMERES VARIANTS IN MYELOID NEOPLASMS: INSIGHTS INTO TERT VARIANTS OF UNCERTAIN SIGNIFICANCE.	Ludovica Marando	Received

P-0732	CHARACTERIZATION OF THE MOLECULAR SIGNATURE OF HUMAN MONOCYTES IN MYELODYSPLASTIC SYNDROME AND AGING.	Ioannis Kotsianidis	Received

P-0733	GENETIC CHARACTERIZATION OF CHIP IN CARDIOVASCULAR DISEASES IN COMPARISON TO MYELOID MALIGNANCIES	Manja Meggendorfer	Received

P-0734	GENOTYPE/PHENOTYPE ASSOCIATIONS IN MDS - HOW GENETICS IMPACT CYTOPENIA	Sandra Huber	Received

P-0735	MOLECULAR LANDSCAPE OF A MDS/MPN COHORT	Diana Margarita Trejos Carvajal	Received

P-0736	PATHOGENESIS OF MYELOID NEOPLASMS WITH DER(1;7)(Q10;P10)	Rurika Okuda	Received

P-0737	MORPHOLOGY-INSPIRED GENETIC GROUPS FOR STRATIFICATION OF MDS PATIENTS WITH INCREASED BLASTS	Maki Sakuma	Received

P-0738	CLASSIFICATION AND PROGNOSTIC STRATIFICATION BASED ON GENOMIC FEATURES IN MYELOID DYSPLASTIC NEOPLASMS, MYELOPROLIFERATIVE NEOPLASMS AND THEIR OVERLAPPING CONDITIONS.	Jungjun Lee	Received

P-0740	MDS-PB13 SCORE - A NEW SCREENING METHOD FOR MDS ASSOCIATED ABERRANCIES BY FLOW CYTOMETRY IN BLOOD: IMPLICATIONS FOR DIAGNOSIS AND PROGNOSIS	Uta Oelschlaegel	Received

P-0741	SENECTUS IPSA MORBUS EST? HOW TO DISTINGUISH INFLAMMAGING FROM INFLAMMATION OF MYELODYSPLASTIC SYNDROMES BY AN ARTIFICIAL INTELLIGENCE APPROACH.	elena tofacchi	Received

P-0742	SOMATIC MUTATIONS AND DNA METHYLATION IDENTIFY A SUBGROUP OF POOR PROGNOSIS WITHIN LOWER RISK MYELODYSPLASTIC SYNDROMES	Michaela Fontenay	Received

P-0743	PARALLEL MONITORING OF MEASURABLE RESIDUAL DISEASE AND CHIMERISM BY NGS IN MYELODYSPLASTIC SYNDROME AFTER ALLOGENIC STEM CELL TRANSPLANT	Irene Zamanillo	Received

P-0744	TARGETING DYSREGULATION OF IRON HOMEOSTASIS IN MDS MICE WITH AN OPTIMISED GALNAC-CONJUGATED TMPRSS6 SIRNA	Jim Vadolas	Received

P-0745	CD56 EXPRESSION IN MYELODYSPLASTIC SYNDROMES: REVIEWING OLD DATA WITH FRESH EYES.	Valérie Bardet	Received

P-0746	CLONAL HIERARCHY OF SOMATIC MUTATIONS IN MYELODYSPLASTIC NEOPLASMS	Claudia Haferlach	Received

P-0747	NAMPT INHIBITORS TARGET MYELOBLASTS FROM HIGH-RISK MDS PATIENTS WITH MONOSOMY 7 OR DELETION 7Q	Nemo Ikonen	Received

P-0748	NHEJ DNA-REPAIR PATHWAY GERMLINE VARIANTS IN EARLY-ONSET ADULT MYELODYSPLASTIC SYNDROMES: HOMOLOGOUS RECOMBINATION DEFICIENCY SCORE AND CLINICAL IMPACT	Andres Jerez	Received

P-0749	COMPARATIVE ANALYSIS OF CLINICAL BENEFIT BY GENOMIC LANDSCAPE AND MUTATIONAL BURDEN OF LUSPATERCEPT VERSUS EPOETIN ALFA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) IN THE PHASE 3 COMMANDS STUDY	Rami S. Komrokji	Received

P-0750	ELTROMBOPAG RESTORES PROLIFERATIVE CAPACITY AND ADIPOSE-OSTEOGENIC BALANCE OF MESENCHYMAL STROMAL CELLS IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES	Minghua Hong	Received

P-0752	CLONAL HIERARCHY OF PPM1D MUTATION IMPACTS RISK OF TRANSFORMATION TOWARDS THERAPY-RELATED MYELOID NEOPLASMS	David Fandrei	Received

P-0753	SINGLE CELL PROFILING OF DEL(5Q) MDS UNVEILS ITS TRANSCRIPTIONAL LANDSCAPE AND THE IMPACT OF LENALIDOMIDE	Nerea Berastegui Zufiaurre	Received

P-0754	DNA METHYLATION PROFILING OF MYELODYSPLASTIC SYNDROMES AND CLINICAL RESPONSE TO AZACITIDINE: A MULTICENTER RETROSPECTIVE STUDY	Ignacio Campillo-Marcos	Received

P-0755	IDENTIFICATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES	Aintzane Díaz-Mazkiaran	Received

P-0756	HIGH PROPORTION OF CD95+/CD45RA- REGULATORY T CELLS IN THE BONE MARROW OF MDS PATIENTS IS A BIOMARKER OF IMMUNE SUPPRESSION AND A HIGHER RISK OF PROGRESSION.	Nicolas Chapuis	Received

P-0757	MYELODYSPLASTIC SYNDROMES BENEFIT OF IRON-RESTRICTED BONE MARROW TRANSPLANTATION IN PRECLINICAL STUDIES	Francesca Vinchi	Received

P-0758	PRIMARY U2AF1(S34F) MUTATED HEMATOPOIETIC CELLS ARE SENSITIVE TO NONSENSE-MEDIATED RNA DECAY DISRUPTION IN VIVO	Claudia Cabrera	Received

P-0759	DEVELOPMENT OF PATIENT DERIVED XENOGRAFT (PDX) MODELS OF MYELODYSPLASTIC SYNDROMES	Ângela Mesquita	Received

P-0760	ACTIVIN A INHIBITION BY ELRITERCEPT (KER-050) IS ASSOCIATED WITH EVIDENCE OF CARDIOVASCULAR BENEFIT: TRANSLATION OF PRECLINICAL OBSERVATIONS TO HUMANS WITH MDS	Shuhying Tan	Received

P-0761	TELOMERE BIOLOGY DRIVES AND SHAPES THE LANDSCAPE OF CLONAL MYELOID DISORDERS IN OLD AGE	Matthew McLoughlin	Received

P-0762	PATHOGENIC ROLES OF DDX41 MUTATIONS IN THE DEVELOPMENT OF MYELOID MALIGNANCIES	Ayana Kon	Received

P-0763	LUSPATERCEPT IMPROVES HEMATOPOIESIS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): COMPARATIVE BIOMARKER ANALYSIS OF RING SIDEROBLAST-POSITIVE AND -NEGATIVE SUBGROUPS FROM THE PHASE 3 COMMANDS STUDY	Uwe Platzbecker	Received

P-0764	UNRAVELING PATHOPHYSIOLOGY AND HEMATOPOIESIS OF VEXAS SYNDROME BY MULTI-OMICS ANALYSES AND TARGETED GENE EDITING	Samuele Ferrari	Received

P-0765	MOLECULAR AND CLINICAL CHARACTERIZATION OF ETNK1-MUTATED MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE AND FUTURE DIRECTIONS	Steven Tessier	Received

P-0766	EXPLORING SEX-DIVERSITY OF GENE MUTATIONS AND RESPONSE TO ESA TREATMENT IN LOW-RISK MYELODYSPLASTIC NEOPLASMS	Marco Raddi	Received

P-0767	IMPACT OF COMPLETE CYTOGENETIC RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Samuel Urrutia	Received

P-0768	REAL-WORLD DOSE ESCALATION AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN CLINICAL PRACTICE	Kashyap Patel	Received

P-0769	THE HUMANISTIC AND ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES ON PATIENTS IN NORTH AMERICA AND EUROPE	María Díez Campelo	Received

P-0770	ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX VERSUS ORAL DECITABINE/CEDAZURIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROME: A PROPENSITY SCORE MATCHED ANALYSIS	Alex Bataller	Received

P-0771	ASSESSMENT OF CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO WERE TREATED WITH ORAL DECITABINE/CEDAZURIDINE (DEC-C) USING THE INTERNATIONAL WORKING GROUP (IWG) 2023 CRITERIA	Amer M. Zeidan	Received

P-0772	CLINICAL IMPLICATIONS OF SPLICING FACTOR MUTATIONS IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS TREATED WITH HYPOMETHYLATING AGENTS (HMA)- A MULTICENTER, RETROSPECTIVE ANALYSIS	Tariq Kewan	Received

P-0773	PHASE 1B STUDY OF SL-172154, A BI-FUNCTIONAL FUSION PROTEIN TARGETING CD47 AND CD40, WITH AZACITIDINE IN PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES	Kazu Kato	Received

P-0774	RELATIONSHIP BETWEEN HAEMOGLOBIN AND QUALITY OF LIFE IN TRANSFUSION-DEPENDENT PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME RECEIVING LUSPATERCEPT OR EPOETIN ALFA	Esther Oliva	Received

P-0775	CLINICAL IMPLICATIONS OF IDH MUTATIONS (IDH MT) IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS (MDS) TREATED WITH HYPOMETHYLATING AGENTS (HMA)	Tariq Kewan	Received

P-0776	CPH DEEP NEURAL NETWORK DEMONSTRATES THAT IWG-2023-PROPOSED LOWERING OF HB THRESHOLD TO =10G/DL FOR RESPONSE ASSESSMENT DOES NOT RESULT IN WORSE OUTCOME PREDICTION THAN =11G/DL AS ASSESSED BY PB-CR	Lisa Pleyer	Received

P-0777	PREVALENCE AND CLINICAL SIGNIFICANCE OF GERMLINE VARIANTS IN CEBPA, DDX41, ETV6, GATA2 AND RUNX1 AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Anna Tranberg	Received

P-0778	REAL-LIFE ANEMIA TREATMENT IN LOW-RISK MYELODYSPLATIC SYNDROME (MDS) PATIENTS: A RETROSPECTIVE MULTICENTER STUDY BY THE GROUPE FRANCOPHONE DES MYÉLODYSPLASIES (GFM) ON 194 PATIENTS	abdessamia gandoul	Received

P-0780	MULTILINEAGE AND SAFETY RESULTS FROM THE COMMANDS TRIAL IN TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH VERY LOW-, LOW-, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES	Guillermo Garcia-Manero	Received

P-0781	PERIPHERAL BLOOD COMPLETE REMISSION (PB-CR) IS ASSOCIATED WITH SIMILAR SURVIVAL AS CR PER IWG 2023 CRITERIA IN PATIENTS WITH HIGHER-RISK MDS – AN INTERNATIONAL STUDY FROM THE VALIDATE CONSORTIUM	Jan Bewersdorf	Received

P-0782	QUANTIFYING THE RELATIONSHIP BETWEEN TRANSFUSION INDEPENDENCE AND OVERALL SURVIVAL IN LOWER-RISK MYELODYSPLASTIC SYNDROMES	Luca Malcovati	Received

P-0783	SPECTRUM AND CLINICAL IMPLICATIONS OF EXTRAMEDULLARY MANIFESTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA	Guillermo Montalban-Bravo	Received

P-0784	CHARACTERISATION AND PROGNOSTIC IMPACT OF ZRSR2 MUTATIONS IN MYELOID NEOPLASMS	Mahmoud Yacout	Received

P-0785	CLINICAL BENEFIT OF LUSPATERCEPT IN TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH VERY LOW-, LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES IN THE COMMANDS TRIAL	Valeria Santini	Received

P-0786	VALIDATION OF IWG-2023 RESPONSE CRITERIA, EXPANSION TO INCLUDE ALL MDS/CMML/AML PATIENTS TREATED WITH AZACITIDINE, AND COMPARISON WITH IWG-2006 AND ELN-2022 CRITERIA USING A CPH DEEP NEURAL NETWORK	Lisa Pleyer	Received

P-0787	PROGNOSTIC FACTORS IN UNTREATED PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH ISOLATED 5Q DELETION	Maria Julia Montoro	Received

P-0788	PHASE I/II STUDY OF SECLIDEMSTAT, AN LSD1 INHIBITOR, IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA	Guillermo Montalban-Bravo	Received

P-0789	VALUE OF EARLY LUSPATERCEPT USE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)	David Valcárcel	Received

P-0792	TARGETING LILRB4 (ILT3) USING IO-202 IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): INTERIM EFFICACY, SAFETY, AND MECHANISM OF ACTION DATA FROM THE PHASE 1B EXPANSION COHORT	Yasuhiro Tabata	Received

P-0793	RECLASSIFICATION MDS PATIENTS AND FURTHER EVALUATION THE IMPACT OF BONE MARROW FIBROSIS ACCORDING TO 5TH (2022) EDITIONS OF THE WHO CLASSIFICATION OF MYELODYSPLASTIC NEOPLASMS	Gaixiang Xu	Received

P-0794	RISK STRATIFICATION IN HYPOMETHYLATING AGENT-TREATED PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A MULTIVARIATE MODEL	Kelly Chien	Received

P-0795	THE DYNAMIC CHANGES OF GENETIC MUTATIONS DURING THE DISEASE COURSE OF MYELODYSPLASTIC NEOPLASMS	Zheng Ge	Received

P-0797	MYELODYSPLASTIC SYNDROMES WITH CONCOMITANT SF3B1 MUTATION AND DELETION OF THE LONG ARM OF CHROMOSOME 5	Zaker Schwabkey	Received

P-0798	ES-3000, A WNT/ ? CATENIN/INFLAMMASOME PATHWAY INHIBITOR COMBINED WITH ORAL DECITABINE/CEDAZURIDINE(ASTX727) FOR PATIENTS WITH MYELODYSPLASIA	Anoop Enjeti	Received

P-0799	QUESTIONABLE BENEFIT OF PRIOR THERAPY IN MDS PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF THE EBMT CHRONIC MALIGNANCIES WORKING PARTY	Christoph Scheid	Received

P-0800	A PHASE I STUDY OF ANTI-TIM-3 ANTIBODY TQB2618 ADDED TO HYPOMETHYLATING AGENTS (HMAS) IN ADULT PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)	Yu Wu	Received

P-0801	AN IMMUNE DYSFUNCTION SIGNATURE ROBUSTLY ILLUMINATES DISEASE DYNAMICS AND PREDICTS SURVIVAL IN MDS/CMML PATIENTS: INSIGHTS FROM A LONGITUDINAL, MULTICENTER STUDY	Yu-Hung Wang	Received

P-0803	MOLECULAR EVENTS CONTRIBUTING TO THE IMMUNE-MEDIATED BONE MARROW FAILURE IN IDIOPATHIC APLASTIC ANEMIA	Zuzana Lenertova	Received

P-0804	SPLICING ALTERATIONS CAUSED BY U2AF1MT-S34 MODIFY THE TRANSCRIPTOME OF POT1 IN PATIENTS WITH TELOMERE BIOLOGY DISORDERS	Alejandro Ferrer	Received

P-0805	ZMAT3 PREVENTS HEMATOPOIETIC STEM CELL EXHAUSTION AND CONTRIBUTES TO CELL TRANSFORMATION BY MODULATING SPHINGOLIPID METABOLISM IN FANCONI ANEMIA DISEASE.	Maeva Loock	Received

P-0806	METABOLOMICS AND OXIDATIVE DAMAGE IN DIAMOND-BLACKFAN ANEMIA	Ondrej Jahoda	Received

P-0807	LONG-READ HLA SEQUENCING UNCOVERS SPECIFIC RISK ALLELES AND CLINICAL ASSOCIATIONS IN APLASTIC ANEMIA	Sunisa Kongkiatkamon	Received

P-0808	SPECTRUM OF GENETIC VARIANTS IN AN ARGENTINE PEDIATRIC COHORT WITH SUSPECTED INHERITED BONE MARROW FAILURE SYNDROMES	Agustina Albero	Received

P-0811	GENETIC VARIANTS AND INBORN ERRORS OF IMMUNITY IN BONE MARROW FAILURE: NOVEL POTENTIAL DRUG TARGETS FOR PRECISION MEDICINE	Vanessa Desantis	Received

P-0812	EFFICACY AND SAFETY OF INTENSIVE PEGCETACOPLAN DOSING FOR THE TREATMENT OF ACUTE HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Morag Griffin	Received

P-0814	LATE ONSET AND LONG LASTING NEUTROPENIA IN CHILDREN AND CHRONIC IDIOPATHIC NEUTROPENIA IN ADULTS: DESCRIPTION OF CLINICAL/ IMMUNOLOGICAL PHENOTYPE AND PRELIMINARY WES RESULTS.	Francesca Fioredda	Received

P-0816	LONG-TERM OUTCOMES OF PEGCETACOPLAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND BASELINE HEMOGLOBIN LEVELS GREATER THAN 10 GRAMS PER DECILITER	Jens Panse	Received

P-0817	OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES.	Celso Arrais-Rodrigues	Received

P-0818	MUTATIONAL LANDSCAPE IN PATIENTS WITH SEVERE APLASTIC ANEMIA IN TAIWAN AND THE CLINICAL SIGNIFICANCE	Kuojui Sun	Received

P-0819	CHARACTERIZATION OF CLINICALLY SIGNIFICANT BREAKTHROUGH HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN	Régis Peffault de Latour	Received

P-0820	LONGITUDINAL ASSESSMENT OF CLONAL HEMATOPOIESIS DYNAMICS IN CHRONIC IDIOPATHIC NEUTROPENIA (CIN)	Grigorios Tsaknakis	Received

P-0821	CLINICAL HETEROGENEITY AND OUTCOME OF PURE RED CELL APLASIA (PRCA): A MULTICENTER INTERNATIONAL STUDY	Francesco Versino	Received

P-0822	EFFECTS OF ORAL IPTACOPAN MONOTHERAPY, INCLUDING INCREASED PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RED BLOOD CELL CLONE SIZE, ARE MAINTAINED IN COMPLEMENT INHIBITOR-NAÏVE PATIENTS: FINAL APPOINT-PNH DATA	Antonio Maria Risitano	Received

P-0823	PURE RED CELL APLASIA ASSOCIATED WITH THYMIC TUMOURS: A NATIONWIDE COHORT	Mylène Hemmer	Received

P-0826	BREAKTHROUGH HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH COMPLEMENT INHIBITORS: A MULTICENTER INTERNATIONAL STUDY	Bruno Fattizzo	Received

P-0827	PREDICTIVE FACTORS FOR THE RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IST-REFRACTORY APLASTIC ANEMIA: DATA FROM TWO CLINICAL TRIALS	Jun-Ho Jang	Received

P-0828	RESULTS FROM THE OPEN-LABEL EXTENSION PERIOD OF A PHASE 2 TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN COMBINATION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	Rodrigo Pavani	Received

P-0829	EFFECTS OF ORAL IPTACOPAN MONOTHERAPY, INCLUDING INCREASED PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RED BLOOD CELL CLONE SIZE, ARE SUSTAINED IN ANTI-C5-TREATED PATIENTS WITH ANEMIA: FINAL APPLY-PNH DATA	Régis Peffault de Latour	Received

P-0830	TREATMENT PATTERNS AND OUTCOMES OF PATIENTS (PTS) WITH ACQUIRED APLASTIC ANEMIA (AA) IN THE UNITED STATES (US): RESULTS FROM A LARGE AND UNIQUE NATIONAL CLAIMS DATABASE	Jessica M. Stempel	Received

P-0832	ACCESS TO EXPENSIVE DRUGS IN EU COUNTRIES FOR VERY RARE HEMATOLOGICAL BLOOD DISORDERS: THE EXAMPLE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. A SURVEY BY ERN-EUROBLOODNET	Mariangela Pellegrini	Received

P-0833	REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH ECULIZUMAB OR RAVULIZUMAB IN THE US - A RETROSPECTIVE CLAIMS DATABASE ANALYSIS	Srinivas Tantravahi	Received

P-0835	EFFICACY AND SAFETY OF POZELIMAB PLUS CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA WHO ARE NAÏVE TO COMPLEMENT INHIBITION	Morag Griffin	Received

P-0836	CLINICAL FEATURES AND OUTCOMES IN LARGE GRANULAR LYMPHOCYTE LEUKEMIAA^ ASSOCIATED PURE RED CELL APLASIA WITH STAT3 MUTATION	Guangsheng He	Received

P-0838	THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE POST-MARKETING SETTING	Jens Panse	Received

P-0840	ELTROMBOPAG PROMOTES THE ENGRAFTMENT OF BONE MARROW FAILURE SYNDROME WITH ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Meng Zhou	Received

P-0841	IMPROVEMENT IN IRON OVERLOAD WITH PEGCETACOPLAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PREVIOUSLY TREATED WITH ECULIZUMAB	David Kuter	Received

P-0842	ADVANCING INSIGHTS INTO MONOCLONAL ANTIBODY MECHANISMS: A NOVEL EX VIVO ASSAY USING WHOLE BONE MARROW ENVIRONMENT TO INVESTIGATE THE EFFICACY OF DARATUMUMAB IN MULTIPLE MYELOMA.	Jenifer Sanchez	Received

P-0843	NONO IS REQUIRED FOR MULTIPLE MYELOMA CELL LINES GROWTH THROUGH STABILISATION OF LNCRNA NEAT1 AND PARASPECKLE INTEGRITY	Elisa Taiana	Received

P-0845	IRF2 REGULATES SPECIFIC SIGNALING PATHWAYS THAT PARTICIPATE IN THE DEVELOPMENT AND PATHOGENESIS OF MULTIPLE MYELOMA	Nahia Gomez-Echarte	Received

P-0846	INFLAMMATORY BONE MARROW MICROENVIRONMENT IMPAIRS RESPONSES TO DARATUMUMAB AND LENALIDOMIDE IN MULTIPLE MYELOMA. A CORRELATIVE STUDY OF THE IFM2017-03 TRIAL.	Silvia Gaggero	Received

P-0847	IBERDOMIDE IS IMMUNE STIMULATORY AND INDUCES DEEP ANTI-MYELOMA ACTIVITY ACROSS DOSES IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH TNE NDMM FROM THE CC-220-MM-001 STUDY	Michael Amatangelo	Received

P-0848	NON-CODING RNAS REGULATE NOVEL SIGNALING PATHWAYS IN AL AMYLOIDOSIS THAT ARE TARGETABLE BY FDA APPROVED DRUGS	Tal Zvida-Bloch	Received

P-0849	FUNCTIONAL DISSECTION AND CLINICAL RELEVANCE OF THE SINGLE CELL TRANSCRIPTOMIC LANDSCAPE OF GENOTYPICALLY-IDENTIFIED POLYCLONAL PLASMACELLS IN MULTIPLE MYELOMA MICROENVIRONMENT	matteo claudio da via´	Received

P-0850	EXPRESSION PATTERN OF P53 POST-TRANSLATIONAL MODIFICATIONS AND ITS CLINICAL IMPACT IN HOMOGENOUSLY TREATED MULTIPLE MYELOMA PATIENTS.	Elizabeta A. Rojas	Received

P-0851	ALTERATIONS IN CHROMATIN ACCESSIBILITY OF PLASMA CELLS ALLOW NUCLEAR RESPIRATORY FACTOR 1 (NRF1) TO PROMOTE THE DEVELOPMENT AND PROGRESSION OF MULTIPLE MYELOMA.	Giacomo Corleone	Received

P-0852	CD4+ CYTOTOXIC T LYMPHOCYTES CONTRIBUTE TO ANTITUMOR IMMUNITY IN MULTIPLE MYELOMA	Hyunsoo Cho	Received

P-0853	IMPACT OF PRIOR ANTIBIOTIC EXPOSURE BEFORE INITIATING BISPECIFIC MONOCLONAL ANTIBODY THERAPY IN MULTIPLE MYELOMA	Roberto Garcia-Vicente	Received

P-0854	IMPLICATION OF GLYCOLYTIC AND MITOCHONDRIAL METABOLISM IN MULTIPLE MYELOMA RESPONSE TO ANTI-CD38 DARATUMUMAB TREATMENT	Alizée Steer	Received

P-0855	DECIPHERING MULTIPLE MYELOMA COMPLEXITY: EXPLORING TUMOR MICROENVIRONMENT DYNAMICS THROUGH MULTI-OMICS INTEGRATION FOR PERSONALIZED THERAPEUTIC INSIGHTS	Elina Alaterre	Received

P-0856	HIGH-RESOLUTION SINGLE-CELL RNA SEQUENCING (SCRNA-SEQ) DEFINES DISTINCT NEUTROPHIL GENE SIGNATURES WITHIN FOCAL LESIONS LINKED TO MULTIPLE MYELOMA PROGRESSION FREE SIGNATURE	Philip Mccarthy	Received

P-0857	EXPLOITING APOBEC3B-INDUCED VULNERABILITIES FOR RISK-ADAPTED TREATMENT IN MM PATIENTS WITH DEL(17P)	Afsaneh Panahi	Received

P-0858	GENETIC DISRUPTION OF BLIMP-1 REMODELS THE TRANSCRIPTOME OF ARI0002H, AN ACADEMIC BCMA-TARGETING CAR-T CELL, TOWARDS A MORE FAVORABLE DIFFERENTIATION PROFILE AND IMPROVED ANTI-TUMOR EFFICACY	Anthony Battram	Received

P-0859	CHARACTERIZATION OF BONE MARROW NICHE AND IMMUNOPHENOTYPING IN A MULTIPLE MYELOMA MOUSE MODEL DRIVEN BY COMBINED EXPRESSION OF ACTIVE RANK AND TCL1	Lisa Pfeuffer	Received

P-0861	VALIDATION OF PROTOTYPE BIOMARKERS TO IDENTIFY RISK FACTORS OF INFLAMMATORY ADVERSE EVENTS FOLLOWING IDECABTAGENE VICLEUCEL INFUSION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN KARMMA-3	Salomon Manier	Received

P-0864	UNRAVELLING THE ROLE OF THE NON-IMMUNE BONE MARROW MICROENVIRONMENT IN THE PROGRESSION FROM MGUS TO SMOULDERING AND MULTIPLE MYELOMA	Miguel Cócera Fernández	Received

P-0865	GENETIC CHARACTERIZATION OF T(11;14) POSITIVE NEWLY DIAGNOSED MULTIPLE MYELOMA AND MANTLE CELL LYMPHOMA PATIENTS	Jana Wobst	Received

P-0866	ALTERATIONS IN EXPRESSION OF GENES CONTROLLING CELL SURFACE SIALYLATION IMPACT PROGNOSIS OF PATIENTS TREATED WITH CURRENT ANTI-MYELOMA THERAPIES	Michael O´Dwyer	Received

P-0867	CYCLOPHOSPHAMIDE-POMALIDOMIDE COMBINATION ALTERS THE TUMOUR CELL SECRETOME AND ENHANCES THE ANTI-MYELOMA ACTIVITY OF ELOTUZUMAB THROUGH NK MEDIATED CYTOTOXICITY	Michael O´Dwyer	Received

P-0868	OPTICAL GENOME MAPPING RESULTS IN 96 CASES OF MULTIPLE MYELOMA, A NEW OVERVIEW OF THE PLASMA CELL GENOME.	Adela Cisneros	Received

P-0869	TRANSCRIPTOMIC ANALYSIS OF METABOLISM-ASSOCIATED GENES AS BIOMARKERS AND POTENTIAL THERAPEUTIC TARGETS FOR MULTIPLE MYELOMA	Naroa Barrena	Received

P-0870	EXOSOME-DERIVED CIRCCOG5 PLAYS A ROLE IN REGULATING RANKL EXPRESSION IN MULTIPLE MYELOMA CELLS BY TARGETING MIR-625-3P	xing cui	Received

P-0871	JAK2 AS A POTENTIAL THERAPEUTIC TARGET TO ERADICATE CD34+ MYELOMA-INITIATING CELLS THAT PERSIST AS A MAJOR FRACTION OF MRD	Ko Fujimoto	Received

P-0872	ULTRA-SENSITIVE ASSESSMENT OF CFDNA FOR MINIMALLY INVASIVE DETECTION AND CHARACTERIZATION OF MEASURABLE RESIDUAL DISEASE IN MULTIPLE MYELOMA	Natalia Buenache Cuenda	Received

P-0873	DISTINCT IMMUNOPHENOTYPE AND GENE EXPRESSION PROFILES OF T CELLS IN PERIPHERAL BLOOD VERSUS BONE MARROW OF PATIENTS WITH MULTIPLE MYELOMA	Glykeria Gkoliou	Received

P-0874	BUD23-MEDIATED M7G MODIFICATION PROMOTES MULTIPLE MYELOMA IMMUNE EVASION BY REGULATING IGF2BP1/PD-L1 AXIS	Xing Cui	Received

P-0875	EPIGENETIC LIQUID BIOPSY FOR THE DIFFERENTIATION OF BENIGN AND MALIGNANT FORMS OF PLASMA CELL DISORDERS.	Ilana Fox-Fisher	Received

P-876	ASSOCIATION OF PATIENT FACTORS AND PHARMACODYNAMIC BIOMARKERS WITH PROGRESSION-FREE SURVIVAL AFTER IDECABTAGENE VICLEUCEL IN PATIENTS FROM KARMMA-3	Bertrand Arnulf	Received

P-0877	UNDERSTANDING THE ROLE OF CAR-NEGATIVE CELLS IN THE EFFICACY AND SAFETY OF CAR-T THERAPIES	Belén Sierro Martínez	Received

P-0878	BET INHIBITORS DOWNREGULATE THE EXPRESSION OF THE ESSENTIAL LNCRNA SMILO IN MULTIPLE MYELOMA THROUGH REGULATION OF THE TRANSCRIPTION FACTOR FLI1	Nahia Gomez-Echarte	Received

P-0879	CD200 IMMUNE CHECKPOINT EXPRESSION IS ASSOCIATED WITH TREATMENT RESISTANCE AND INFERIOR OUTCOME IN MM PATIENTS TREATED BY ANTI-CD38 MOAB	Charles Herbaux	Received

P-0880	WHOLE GENOME SEQUENCING REVEALS SPATIAL HETEROGENEITY OF EXTRAMEDULLARY DISEASE AT DIAGNOSIS AND RELAPSE IN MULTIPLE MYELOMA PATIENTS	sahin sarihan	Received

P-0881	LYMPHOCYTOSIS AFTER BCMA CAR-T AS A MARKER OF CAR-T EXPANSION, RESPONSE, AND PROGRESSION FREE SURVIVAL IN MULTIPLE MYELOMA.	Mark Bustoros	Received

P-0882	SOLUBLE BCMA IN LACRIMAL FLUID AS A MEDIATOR OF KERATOPATHY IN MULTIPLE MYELOMA	Umair Munawar	Received

P-0883	MULTIPLE MYELOMA INDUCES STRESS-MEDIATED MITOPHAGY, AND IMPAIRS MITOCHONDRIAL FITNESS AND IMMUNE FUNCTION IN NK CELLS	Katia Beider	Received

P-0884	B-CELL SUBCLONES CHARACTERIZATION REVEALS THE EVOLUTION OF MYD88 MUTATED IGM MONOCLONAL GAMMOPATHIES	David Moreno	Received

P-0885	THE M6A REGULATORY GENES, WITH THE SPECIAL IMPLICATION OF VIRMA, PLAY AN ESSENTIAL ROLE IN MULTIPLE MYELOMA	Estibaliz Urizar-Compains	Received

P-0886	MEK1/2 INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS INDUCES IRF1-MEDIATED INTERFERON/PD-L1 SIGNALING AXES IN THE BONE MARROW IMMUNE MICROENVIRONMENT	Chaitanya Acharya	Received

P-0888	KANSL2 IS AN ACTIONABLE ONCOGENIC DRIVER IN MULTIPLE MYELOMA	Kaiting Jiang	Received

P-0890	BELANTAMAB MAFODOTIN EXHIBITS NO EVIDENCE OF IMMUNE CELL IMPAIRMENT: POTENTIAL IMPLICATIONS FOR SEQUENCING THERAPIES IN MULTIPLE MYELOMA	Michal Mielnik	Received

P-0891	NEUTROPHIL-TO-PLATELET RATIO IDENTIFIES MGUS PATIENTS AT HIGH-RISK OF PROGRESSION: A RETROSPECTIVE SINGLE-CENTER STUDY	Alessandra Romano	Received

P-0892	THE DEVELOPMENTAL STAGE OF MULTIPLE MYELOMA DISCLOSES THE STEMNESS OF LILRB4+ MYELOMA CELLS	Zhen Cai	Received

P-0893	BONE MARROW MYELOID PRECURSORS PREDICT TUMOR EVOLUTION AND RESPONSE TO ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA PATIENTS	ANNA MARIA CORSALE	Received

P-0895	CHARACTERISING THE UNMET MEDICAL NEED IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE: INSIGHTS FROM THE PREAMBLE REGISTRY	Claudio Cerchione	Received

P-0896	REAL-WORLD TREATMENT TRENDS AND TRIPLE CLASS EXPOSED STATUS IN JAPANESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A RETROSPECTIVE CLAIMS DATABASE STUDY	linghua Xu	Received

P-0897	A PATIENT-REPORTED QUESTIONNAIRE MAY ELIMINATE THE NEED FOR AN OPHTHALMIC EXAM BEFORE BELANTAMAB MAFODOTIN DOSING IN NEWLY DIAGNOSED TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA	Evangelos Terpos	Received

P-0899	IBERDOMIDE COMBINED WITH LOW-DOSE CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IBERCD): FIRST RESULTS OF THE PHASE 2 ICON STUDY	Charlotte L.B.M. Korst	Received

P-0900	AN INDIRECT COMPARISON OF ELRANATAMAB´S PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FROM MAGNETISMM-3 VERSUS COUNTRY-SPECIFIC TREATMENT REGIMENS FROM REAL-WORLD DATA SOURCES	Luciano J. Costa	Received

P-0902	REAL-WORLD SCHEDULE DE-ESCALATION OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	Carlyn Tan	Received

P-0903	MEZIGDOMIDE (MEZI), TAZEMETOSTAT (TAZ), AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM THE CA057-003 TRIAL	Luciano J. Costa	Received

P-0904	CORRELATIVE BIOMARKER ANALYSES FOR OPTIMAL THERAPEUTIC DOSE DETERMINATION OF ABBV-383, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	Katja Weisel	Received

P-0905	VENOUS THROMBOEMBOLISM IN MULTIPLE MYELOMA. A POPULATION-BASED STUDY ON 8672 MULTIPLE MYELOMA PATIENTS DIAGNOSED 2008 -2021 FROM THE SWEDISH MYELOMA REGISTRY	Mariana Villegas-Scivetti	Received

P-906	EFFICACY AND SAFETY OF ELRANATAMAB MONOTHERAPY IN THE REAL-WORD SETTING IN RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE FRENCH COMPASSIONATE USE PROGRAM ON BEHALF OF THE IFM	Mohamad Mohty	Received

P-0907	KTD OR KRD INDUCTION FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT INELIGIBLE (TIE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM). FINAL ANALYSIS OF THE AGMT MM02 TRIAL	Heinz Ludwig	Received

P-0909	PATIENTS WITH MULTIPLE MYELOMA - WHAT HAPPENS IN SECOND LINE AFTER FIRST-LINE LENALIDOMIDE? DATA FROM THE GERMAN MYRIAM REGISTRY	Renate Grugel	Received

P-0910	LOW-DOSE VENETOCLAX-DEXAMETHASONE IN T(11;14)-POSITIVE RELAPSED AND REFRACTORY MULTIPLE MYELOMA; INTERIM RESULTS OF THE ONGOING, DANISH, INVESTIGATOR-INITIATED, PHASE 2 VICTORIA STUDY	Agoston Gyula Szabo	Received

P-912	EFFICACY OF VENETOCLAX-DEXAMETHASONE V POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA [T(11;14)+ RRMM]:PHASE 3 CANOVA BIOMARKER SUBGROUP ANALYSIS	Nizar J Bahlis	Received

P-0914	VACCINATING AGAINST MUTATED RAS IN MULTIPLE MYELOMA: THE PHASE I/II TG01 STUDY	Hanne Norseth	Received

P-0916	ALL-ORAL TRIPLET IBERDOMIDE IXAZOMIB AND DEXAMETHASONE IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA AT FIRST RELAPSE: RESULTS OF THE IFM PHASE 2 STUDY I2D	Cyrille Touzeau	Received

P-0917	LISAFTOCLAX (APG-2575) COMBINED WITH NOVEL THERAPEUTIC REGIMENS IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MULTIPLE MYELOMA (MM) OR IMMUNOGLOBULIN LIGHT-CHAIN (AL) AMYLOIDOSIS	Sikander Ailawadhi	Received

P-0918	REAL-WORLD CARFILZOMIB PRESCRIBING PATTERNS AND OUTCOMES FOR PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)	Sharlene Dong	Received

P-0919	FUNCTIONAL ASSESSMENTS INCLUDING SARCOPENIA BETTER DETECT FRAILTY THAN THE IMWG FRAILTY SCORE AND IMPROVE PREDICTION OF OUTCOME IN MULTIPLE MYELOMA	Febe Smits	Received

P-0921	CARDIAC RESPONSE DYNAMICS IN NEWLY DIAGNOSED LIGHT-CHAIN AMYLOIDOSIS PATIENTS WHO ACHIEVED A HIGH-QUALITY HEMATOLOGIC RESPONSE WITHIN THREE MONTHS	Chengyang Xu	Received

P-0924	IMPROVED ACCURACY OF MONOCLONAL IMMUNOGLOBULIN MEASUREMENT BY EXENT MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA AND KIDNEY FAILURE: ANALYSIS FROM THE EULITE TRIAL	Graham McIlroy	Received

P-0925	INCLUSION CRITERIA OF CLINICAL TRIALS SELECT PATIENTS WITH AL AMYLOIDOSIS WITH FAVORABLE OUTCOME AND EXCLUDE ALMOST ONE HALF OF THE REAL-LIFE POPULATION	Claudia Bellofiore	Received

P-928	CLINICAL PRESENTATION AND OUTCOMES OF PATIENTS WITH MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS): A MULTICENTRIC RETROSPECTIVE STUDY	Katia Mancuso	Received

P-0929	EFFECTIVENESS AND SAFETY OF BISPECIFIC ANTIBODIES TARGETING BCMA AND CD3 IN PATIENTS WITH CENTRAL NERVOUS SYSTEM MULTIPLE MYELOMA (CNS-MM): IFM 2023-06, A RETROSPECTIVE COHORT STUDY.	Florence Lachenal	Received

P-930	DISEASE CHARACTERISTICS AND SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA BY EXTRAMEDULLARY DISEASE STATUS: FINDINGS FROM THE CONNECT® MM DISEASE REGISTRY	Hans Lee	Received

P-0931	IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01	Arthur Bobin	Received

P-0933	EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT-CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK	Efstathios Kastritis	Received

P-0936	PREDICTORS OF LIVER RESPONSE KINETICS IN LIGHT CHAIN (AL) AMYLOIDOSIS	Matthew Rees	Received

P-0937	REAL WORLD OUTCOMES WITH ELOTUZUMAB-BASED THERAPIES FOR PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A MAYO CLINIC EXPERIENCE	Ricardo Parrondo	Received

P-0938	DREAMM-7 UPDATE: SUBGROUP ANALYSES FROM A PHASE 3 TRIAL OF BELANTAMAB MAFODOTIN + BORTEZOMIB AND DEXAMETHASONE VS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Maria-Victoria Mateos	Received

P-0939	IMPROVED DISEASE STATUS PRE-INFUSION LEADS TO BETTER OUTCOMES WITH STANDARD OF CARE IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)	Aimaz Afrough	Received

P-0940	RELAPSE FROM MEASURABLE DISEASE NEGATIVITY AS INDICATION FOR TREATMENT IN MULTIPLE MYELOMA: THE PHASE 3 REMNANT STUDY	Frida Bugge Askeland	Received

P-0941	FIRST-IN-HUMAN STUDY OF GPRC5D-TARGETED CAR T CELLS (CT071) WITH AN ACCELERATED MANUFACTURING PROCESS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)	Juan Du	Received

P-943	ORAL IXAZOMIB MAINTENANCE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FINAL OVERALL SURVIVAL (OS) ANALYSIS FROM THE TOURMALINE-MM3 STUDY	Meletios A. Dimopoulos	Received

P-0944	DIFFERENTIAL PROGNOSTIC OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH DISTINCT HIGH-RISK CYTOGENETIC ABNORMALITY COMBINATIONS	Lu Xiaowei	Received

P-0945	PATIENT-REPORTED OUTCOMES FROM DREAMM-7 A RANDOMIZED PHASE 3 STUDY OF BELANTAMAB MAFODOTIN, BORTEZOMIB + DEXAMETHASONE (DEX) VS DARATUMUMAB, BORTEZOMIB + DEX IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Vania Hungria	Received

P-0947	LONG-TERM FOLLOW UP DEFINES THE POPULATION THAT BENEFITS FROM EARLY INTERCEPTION IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA USING THE COMBINATION OF IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE	Omar Nadeem	Received

P-0948	SPECTRUM AND DURATION OF INFECTIOUS COMPLICATIONS IN PATIENTS TREATED WITH BCMA- AND GPRC5D-TARGETED IMMUNOTHERAPIES IN MULTIPLE MYELOMA	Julia Mersi	Received

P-0949	TIMING AND OUTCOMES OF SECOND LINE THERAPY IN THE ERA OF DARATUMUMAB-BASED FRONTLINE THERAPY IN AL AMYLOIDOSIS	Abdul-Hamid Bazarbachi	Received

P-0950	CHARACTERISICS AND OUTCOMES OF PATIENTS WITH FUNCTIONAL HIGH RISK MULTIPLE MYELOMA FROM THE HONEUR FEDERATED DATA NETWORK	Yael Cohen	Received

P-0952	LIGHT CHAIN SMOLDERING MULTIPLE MYELOMA – THE MISSING LINK: RESULTS FROM THE SCREENED ISTOPMM STUDY	Sigrún Thorsteinsdóttir	Received

P-953	EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT-CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK	Efstathios Kastritis	Received

P-0955	ADVANCING PERSONALIZED THERAPY IN MULTIPLE MYELOMA: MACHINE LEARNING-DRIVEN RISK STRATIFICATION FOR PREDICTING OUTCOMES WITH BELANTAMAB MAFODOTIN MONOTHERAPY	Adrian Mosquera-Orgueira	Received

P-0956	MULTIVARIABLE RISK STRATIFICATION REFINES THE CURRENT IMWG DIAGNOSTIC CRITERIA FOR PLASMA CELL LEUKEMIA	Jessica Peter	Received

P-957	A PHASE 2 STUDY OF ISATUXIMAB IN COMBINATION WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE, FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NDMM PATIENTS WITH SEVERE RENAL IMPAIRMENT	Evangelos Terpos	Received

P-0958	IBERDOMIDE MAINTENANCE AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: AN UPDATE FROM THE PHASE 2 EMN26 TRIAL	Francesca Gay	Received

P-0960	SHOULD WE ADOPT THE NEW ISTOPMM BASED CRITERIA FOR LC-MGUS?	Dor Shpitzer	Received

P-0961	A PHASE I MONOTHERAPY STUDY ASSESSING THE SAFETY AND EFFICACY OF GR1803, A BCMA×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	Jie Jin	Received

P-0962	CURRENT USE OF BCMA-TARGETED AGENTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AND KEY DRIVERS WHEN SELECTING CAR T-CELLS VERSUS BISPECIFICS. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES AND IN THE US	Nicolas Blin	Received

P-0963	OPTIMIZING THE ACADEMIC ANTI-BCMA CAR CARTEMIS-1: ASSESSING THE IMPACT OF MANUFACTURING PROCEDURE ON CAR-T CELL FEATURES	Belén Sierro Martínez	Received

P-0964	THE PROGNOSTIC IMPACT OF THE PRESENCE OF T(11;14) IN NEWLY DIAGNOSED MYELOMA PATIENTS IS TREATMENT DEPENDENT: AN ANALYSIS OF THE BALKAN MYELOMA STUDY GROUP	Efstathios Kastritis	Received

P-0965	SAFETY AND EFFICACY ANALYSIS OF GPRC5D-TARGETED CAR-T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS	Shiqi Li	Received

P-0966	SAFETY AND UTILITY OF BISPECIFIC MONOCLONAL ANTIBODIES AS SALVAGE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH CAR-T CELLS	Luis-Esteban Tamariz-Amador	Received

P-0969	LOW SOCIO-ECONOMIC STATUS IS ASSOCIATED WITH REDUCED ACCESS TO QUALITY HEALTHCARE IN MULTIPLE MYELOMA; A POPULATION-BASED STUDY	Flores Weverling	Received

P-0970	PRE-EMPTIVE DARATUMUMAB TREATMENT IN ASYMPTOMATIC BIOCHEMICAL RELAPSE CAN PROLONG SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA: RESULTS OF THE RANDOMIZED, MULTICENTER PREDATOR-BR CLINICAL TRIAL	Krzysztof Jamroziak	Received

P-0972	ASSESSING FRAILTY IN MYELOMA: THE PURSUIT OF SIMPLICITY MAY SACRIFICE PRECISION OF PREDICTING CLINICAL OUTCOMES	Kaz Groen	Received

P-0973	BRIDGING STRATEGIES FOR ANTI-BCMA CAR-T CELL THERAPIES IN MULTIPLE MYELOMA PATIENTS WITH PRIOR EXPOSURE TO BISPECIFIC ANTIBODIES	Johannes Waldschmidt	Received

P-0975	MONOCLONAL PROTEIN DETECTION BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY (LC-MS) FOR IDENTIFICATION OF EXCEPTIONAL RESPONDERS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)	Tadeusz Kubicki	Received

P-0976	METABOLIC SYNDROME AND THE RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A POPULATION-BASED SCREENING STUDY IN ICELAND	Kristján Berg Guðmundsson	Received

P-0977	IMPACT OF DARA-VTD INDUCTION THERAPY ON HEMATOPOIETIC STEM CELL COLLECTION AND ENGRAFTMENT IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR ASCT: RESULTS OF THE PRIMULA STUDY	Vanda Strafella	Received

P-0979	PROSPECTIVE EVALUATION OF 3T WHOLE-BODY MRI AND 18F-FDG PET/CT IN THE MANAGEMENT OF MULTIPLE MYELOMA AND SMOLDERING MYELOMA	Claudio Cerchione	Received

P-980	ISATUXIMAB CYCLOPHOSPHAMIDE BORTEZOMIB AND DEXAMETHASONE INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MYELOMA: REPORT OF THE PROSPECTIVE CANADIAN MYELOMA RESEARCH GROUP 008 TRIAL	Rami Kotb	Received

P-0983	BOTH SINGLE AND BIALLELIC TP53 ABERRATIONS PREDICT POOR PROGNOSIS IN MULTIPLE MYELOMA	Romana Nesnadná	Received

P-0984	RADIATION THERAPY IN THE MODERN ERA OF MULTIPLE MYELOMA MANAGEMENT: TRENDS OF RT INTEGRATION, PATTERNS OF UTILIZATION, AND RADIOLOGIC, BIOCHEMICAL, AND CYTOGENETIC CORRELATES OF OUTCOME AND RESPONSE	Alexandra Dreyfuss	Received

P-0985	COMBINED MASS SPECTROMETRY AND NEXT GENERATION FLOW AS EARLY PREDICTORS OF RESPONSE IN RELAPSED/REFRACTORY MYELOMA PATIENTS TREATED WITH CAR-T CELLS AND T-CELL ENGAGERS	Noemi Puig	Received

P-0987	A SINGLE-ARM PHASE 2 STUDY EVALUATING THE OPTIMIZED SCHEDULE OF BELANTAMAB MAFODOTIN 1.9 MG/KG Q8W PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA	Tereza Popková	Received

P-0990	REAL-WORLD SCHEDULE DE-ESCALATION OF TECLISTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA – A US NATIONAL HEALTHCARE CLAIMS ANALYSIS	Matthew J. Pianko	Received

P-0991	STEM CELL BOOST FOR PERSISTENT CYTOPENIAS AFTER BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY	Anupama Kumar	Received

P-0992	TECLISTAMAB (TEC) STEP-UP DOSING (SUD) AND TREATMENT DOSE SCHEDULE DE-ESCALATION IN THE REAL-WORLD (RW) SETTING – AN ANALYSIS OF MULTICENTER ELECTRONIC MEDICAL RECORDS	Rahul Banerjee	Received

P-0993	FINAL RESULTS OF A PHASE 1 STUDY OF DARATUMUMAB, IXAZOMIB, AND DEXAMETHASONE IN NEWLY DIAGNOSED AND PREVIOUSLY TREATED AL AMYLOIDOSIS	Hans Lee	Received

P-0995	SYNCHRONOUS AND SECOND PRIMARY CANCERS IN NEWLY DIAGNOSED MULTIPLE MYELOMA NON-TRANSPLANT-ELIGIBLE TREATED WITH LENALIDOMIDE.	Thomas Systchenko	Received

P-0996	LONG TERM OUTCOME OF A SEQUENTIAL RESPONSE-DRIVEN BORTEZOMIB-BASED THERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN AL AMYLOIDOSIS	Marco Basset	Received

P-0997	ADAPTIVE FREQUENTIST DESIGNS IN THE RANDOMIZED HOVON-87/NMSG18 CLINICAL TRIAL FOR PATIENTS WITH MULTIPLE MYELOMA	Maarten Seefat	Received

P-0998	REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS	Edvan Crusoe	Received

P-0999	NOVEL SELINEXOR TRIPLET AND QUADRUPLET REGIMENS (SND, SPED, SBD, SDPD): RESULTS FROM THE PHASE 1B/2 STOMP MULTIPLE MYELOMA TRIAL	Sumit Madan	Received

P-1000	TARGETING EXHAUSTED CYTOTOXIC T CELLS BY CTLA-4 BLOCKADE PROMOTES ELIMINATION OF NEOPLASTIC CELLS IN HUMAN MYELOFIBROSIS XENOGRAFTS	Lara Tavernari	Received

P-1001	THE EFFECT OF METHYLATION ON THE LET-7-BCL-XL-BCL2 AXIS AND THE POTENTIAL USE OF BH3 MIMETIC DRUGS IN HISTIOCYTIC NEOPLASMS	Oshrat Hershkovitz-Rokah	Received

P-1002	EFFICACY OF INCA033989 IN CHRONIC AND ADVANCED FORMS OF CALRDEL52 AND CALRINS5 MYELOPROLIFERATIVE NEOPLASMS (MPN) MODELS	Isabelle Plo	Received

P-1003	THE ATYPICAL CHEMOKINE RECEPTOR CCRL2 IS UPREGULATED AND PROMOTES INTERFERON-GAMMA SIGNALING IN ADVANCED MYELOPROLIFERATIVE NEOPLASMS.	Theodora Chatzilygeroudi	Received

P-1004	UMBILICAL CORD MESENCHYMAL STROMAL CELLS AMELIORATE MYELOFIBROSIS IN VIVO.	Chien-Chin Lin	Received

P-1005	TAGRAXOFUSP EXHIBITS ANTITUMORAL ACTIVITY IN PRECLINICAL MODELS OF MYELOFIBROSIS AND ENHANCES ANTILEUKEMIC ACTIVITY OF JAK INHIBITORS	Vittoria Nicolis di Robilant	Received

P-1006	ADVANCING EARLY DETECTION AND IMPROVED TARGETED THERAPY IN MYELOPROLIFERATIVE NEOPLASMS: INSIGHTS FROM MULTIMODAL IMAGING AND NANOPARTICLE-MEDIATED DRUG DELIVERY	Julian Baumeister	Received

P-1007	SINGLE CELL MULTIOMICS IDENTIFIES ABERRANT COMMUNICATION BETWEEN DENDRITIC CELLS AND LEUKAEMIA STEM CELLS AS A THERAPEUTICALLY TARGETABLE AXIS IN JUVENILE MYELOMONOCYTIC LEUKAEMIA	Eleni Louka	Received

P-1008	TARGETED T CELLS AGAINST HEMATOPOIETIC CELLS EXPRESSING ONCOGENIC CALRETICULIN MUTANTS	Robert Kralovics	Received

P-1009	TET2 ADDITIONAL MUTATIONS AT DIAGNOSIS IMPACT THE RESPONSE OF FIRST-LINE TREATMENT WITH HYDROXYUREA OR INTERFERON-? IN ESSENTIAL THROMBOCYTHEMIA	Carole Mosnier	Received

P-1010	ESTABLISHMENT OF A NOVEL PRECLINICAL MOUSE MODEL FOR ADVANCED SYSTEMIC MASTOCYTOSIS	Martina Konantz	Received

P-1011	IMPACT OF GENETIC BACKGROUND ON THE FIBROTIC TRANSFORMATION IN MURINE MPN-MODELS	Yu-An Lin	Received

P-1012	REAL WORLD PRACTICE REVEALS SERUM TNF? AS THE EARLY PROGNOSTIC PREDICTOR FOR MYELOFIBROSIS WITH RUXOLITINIB TREATMENT	Xinjie Chen	Received

P-1013	RKER-050, A MODIFIED ACTIVIN RECEPTOR TYPE IIA LIGAND TRAP, RESCUED ANEMIA AND INCREASED MUSCLE MASS AND STRENGTH IN A MOUSE MODEL OF MYELOFIBROSIS	Blake Moses	Received

P-1015	COMPLEX ALTERNATIVE SPLICING AND RELATED NEOANTIGEN PATTERNS IN MYELOPROLIFERATIVE NEOPLASMS	Jing Sun	Received

P-1016	IMMUNOPHENOTYPIC ANALYSIS OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS RECEIVING THERAPY WITH THE BET INHIBITOR PELABRESIB	Rosa Andres Ejarque	Received

P-1017	T-CELL PHENOTYPING SUPPORTS THE USE OF T-CELL ENGAGING ANTIBODIES FOR TREATMENT OF CALRETICULIN MUTATED MYELOPROLIFERATIVE NEOPLASMS	Anna Kuchnio	Received

P-1018	CDK8/19 INHIBITION: A PROMISING THERAPEUTIC STRATEGY IN MYELOPROLIFERATIVE NEOPLASMS	Zachary Zaroogian	Received

P-1019	ALK2 AND JAK2 INHIBITION FOR IMPROVED TREATMENT OF ANEMIA IN MYELOFIBROSIS PATIENTS: PRECLINICAL PROFILE OF AN ALK2 INHIBITOR ZILURGISERTIB IN COMBINATION WITH RUXOLITINIB	Ricardo Macarron	Received

P-1020	FEDRATINIB INHIBITS IMMUNE EVASION AND RESTORES B CELL MATURATION: BIOMARKER ANALYSIS FROM THE FREEDOM2 STUDY	Claire Harrison	Received

P-1021	EFFECT OF NOVEL AGENTS ON THE MECHANISM OF FIBROCYTE-MEDIATED INDUCTION OF MYELOFIBROSIS	Takaaki Maekawa	Received

P-1022	INFLAMMATION NOT HAEMATOPOIESIS CAUSES SPLENOMEGALY IN A MOUSE MODEL OF POLYCYTHAEMIA VERA.	Cavan Bennett	Received

P-1023	EXPRESSION OF GERMLINE JAK2 R1063H REPRESENTS INCREASED RISK OF THROMBOSIS AND IMPAIRS NORMAL HEMATOPOIETIC DEVELOPMENT IN MICE	Veronika Zimolova	Received

P-1024	MIR-93 ATTENUATES CALR MUTANT-DRIVEN ONCOGENIC ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS	Chih-Cheng Chen	Received

P-1025	HUMANIZED IMMUNOCOMPETENT MOUSE MODEL FOR THE PRECLINICAL THERAPEUTIC EVALUATION OF T CELL ENGAGING BISPECIFIC ANTIBODIES TARGETING CALRETICULIN MUTANT MPN	Shengen Xiong	Received

P-1026	DUPLICATION OF CHROMOSOME 9P INDUCES T CELL EXHAUSTION AND INCREASED CLONOGENICITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN JAK2-MUTANT MYELOPROLIFERATIVE NEOPLASMS	Ruggiero Norfo	Received

P-1027	MUTATIONAL LANDSCAPE OF PATIENTS ENROLLED IN THE LOW-PV TRIAL WITH ROPEGINTERFERON ALFA-2B	Paola Guglielmelli	Received

P-1028	PRECLINICAL EVALUATION OF INCB160058 - A NOVEL AND POTENTIALLY DISEASE-MODIFYING THERAPY FOR JAK2V617F MUTANT MYELOPROLIFERATIVE NEOPLASMS	Hamza Celik	Received

P-1029	CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS	Daniel Moreno-Andrés	Received

P-1030	PROGRESSION TO MYELOFIBROSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: AN ANALYSIS FROM THE PROSPECTIVE MOST STUDY	Ruben Mesa	Received

P-1031	UNVEILING THE EFFECTIVENESS AND PREDICTIVE FACTORS OF JAKTINIB TREATMENT IN MYELOFIBROSIS PATIENTS WITH ANEMIA	Yi Zhang	Received

P-1033	IMPACT OF TP53 MUTATION ALLELIC BURDEN ON OUTCOME OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: A STUDY FROM COMMAND CONSORTIUM.	Talha Badar	Received

P-1034	PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH OUTCOMES IN A REAL-WORLD POPULATION OF PATIENTS WITH MYELOFIBROSIS TREATED WITH FEDRATINIB	Francesco Passamonti	Received

P-1035	DECIPHERING THE PREDICTORS OF DEATH IN POLYCYTHEMIA VERA: FOCUS ON THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AND THE INCIDENCE OF ARTERIAL THROMBOSIS	Tiziano Barbui	Received

P-1036	AGE-DEPENDENT LINK BETWEEN ARTERIAL THROMBOSIS AND SECONDARY CANCER IN PH-NEG MPN: CASE-CONTROL STUDY INSIGHTS	Tiziano Barbui	Received

P-1037	EFFICACY OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS WHO HAVE OVERLAPPING THROMBOCYTOPENIA AND ANEMIA	Pankit Vachhani	Received

P-1038	REAL-WORLD DATA ON DIRECT ORAL ANTICOAGULANTS IN BCR::ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A MULTICENTER STUDY ON BEHALF OF SUBCOMMITTEE ON MPNS FOR TURKISH SOCIETY OF HEMATOLOGY	Mehmet Baysal	Received

P-1039	LONG TERM FOLLOW-UP RESULTS OF PHASE II CLINICAL TRIAL EVALUATING RUXOLITINIB (RUX) AND AZACITIDINE (AZA) COMBINATION THERAPY IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)	Sankalp Arora	Received

P-1040	CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB	Francesca Palandri	Received

P-1041	REVISED "IRR6" MODEL IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB	Francesca Palandri	Received

P-1042	A PHASE 2 STUDY OF PEMIGATINIB (FIGHT-203; INCB054828) IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE REARRANGEMENT	Alessandro Vannucchi	Received

P-1043	RUXOLITINIB STARTING DOSE REDUCTION AFFECT OVERALL SURVIVAL IN MYELOFIBROSIS: AIFA MONITORING REGISTRIES ANALYSIS	Massimo Breccia	Received

P-1044	THE IMPACT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN 2233 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: RESULTS FROM THE EXPANDED-ACCESS JUMP STUDY	Haifa Kathrin Al-Ali	Received

P-1045	ANALYSIS OF CARDIOVASCULAR RISK IN 920 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS USING NATURAL LANGUAGE PROCESSING	Andrea Duminuco	Received

P-1046	IMPACT OF CALR MUTATION TYPE AND NON-DRIVER MUTATIONS ON THE RESPONSE TO CYTOREDUCTIVE TREATMENT AND OUTCOMES IN PATIENTS INCLUDED IN THE SPANISH REGISTRY OF ESSENTIAL THROMBOCYTHEMIA (RETE)	Marta Santaliestra Tomas	Received

P-1047	A REAL-WORLD EVALUATION OF RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL	Michael Grunwald	Received

P-1048	THE TRIPLE A MODEL-AAA (AGE, ABSOLUTE NEUTROPHIL COUNT, ABSOLUTE LYMPHOCYTE COUNT) PREDICTS SURVIVAL AND THROMBOSIS IN POLYCYTHEMIA VERA	Ivan Krecak	Received

P-1049	RUXOLITINIB TREATMENT IN PATIENTS WITH POLYCYTHEMIA VERA REDUCES JAK2 ALLELE BURDEN AND IMPROVES HEMATOCRIT CONTROL AND SYMPTOM BURDEN	Claire Harrison	Received

P-1050	NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN POLYCYTHEMIA VERA (PV): CORRELATION WITH ROPEG-INTERFERON RESPONSE IN LOW PV TRIAL	Tiziano Barbui	Received

P-1051	FEDRATINIB IN PATIENTS WITH MYELOFIBROSIS EXPOSED TO RUXOLITINIB: AN INDIRECT TREATMENT COMPARISON WITH MOMELOTINIB AND PACRITINIB	Francesca Palandri	Received

P-1052	INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION	Francesca Palandri	Received

P-1053	HIGH RATE OF DISEASE PROGRESSION IN PATIENTS WITH LOW-RISK MYELOFIBROSIS (MF) ENROLLED IN THE PROSPECTIVE MOST STUDY	Michael Grunwald	Received

P-1054	COMPREHENSIVE EVALUATION OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS: FINAL ANALYSIS RESULTS FROM A RANDOMIZED PHASE 3 STUDY	Jie Jin	Received

P-1055	SYMPTOM-FOCUSED RESULTS FROM SUMMIT PART 1: AN ONGOING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL OF BEZUCLASTINIB IN ADULT PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS	Emily Plummer	Received

P-1056	HIGH RESOLUTION CHEST COMPUTED TOMOGRAPHY RESPONSES FOR A COHORT OF ADULT WITH PULMONARY LANGERHANS CELL HISTIOCYTOSIS	Long Chang	Received

P-1057	A NEW MACHINE LEARINING CLINICAL SCORE FOR THROMBOSIS RISK IN POLYCYTHEMIA VERA: THROMBOVERA CS	Isidora Arsenovic	Received

P-1058	´REAL WORLD ANALYSIS APPLYING INTERNATIONAL PROGNOSTIC SCORE (IPSM) IN NON-ADVANCED SYSTEMIC MASTOCYTOSIS PATIENTS IN UK SINGLE CENTRE OF EXCELLENCE´	Priya Sriskandarajah	Received

P-1059	A PHASE 1B TRIAL OF DISC-0974, AN ANTI-HEMOJUVELIN ANTIBODY, IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA	Naseema Gangat	Received

P-1060	THE ACTIVIN RECEPTOR-LIKE KINASE-2 INHIBITOR ZILURGISERTIB (INCB000928) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS: PHASE 1/2 STUDY RESULTS	Prithviraj Bose	Received

P-1061	RECOGNITION OF SYMPTOM BURDEN IN MPN: DISCREPANCIES BETWEEN PATIENT- AND PHYSICIAN-REPORTED ASSESSMENT – AN INTRA-INDIVIDUAL ANALYSIS BY THE GERMAN MPN STUDY GROUP (GSG-MPN)	Susanne Isfort	Received

P-1062	PROGNOSTIC IMPACT OF LEUKOCYTOSIS, MONOCYTOSIS AND EOSINOPHILIA IN ADVANCED SYSTEMIC MASTOCYTOSIS: A REGISTRY-BASED ANALYSIS OF THE GREM	Johannes Lübke	Received

P-1063	EVALUATING MYELODYSPLASIA RELATED MUTATIONS BY ELN 2022 CLASSIFICATION AND IT IMPACT ON ACCELERATED PHASE AND BLAST PHASE MYELOPROLIFERATIVE NEOPLASMS.	Verna Cheung	Received

P-1064	CLINICAL AND MOLECULAR CHARACTERISATION OF PATIENTS WITH LOW JAK2V617F ALLELE BURDEN: INSIGHTS FROM LONGITUDINAL FOLLOW-UP	Nieves Garcia-Gisbert	Received

P-1065	BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 IN PATIENTS WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY	Pankit Vachhani	Received

P-1066	IMPACT OF GENETIC FACTORS IN THE OVERALL SURVIVAL OF PATIENTS WITH CALR-MUTATED MYELOFIBROSIS	Ruth Stuckey	Received

P-1067	REAL-WORLD OUTCOMES OF MOMELOTINIB AS AN ALTERNATIVE THERAPY TO OTHER JAK INHIBITORS IN MYELOFIBROSIS PATIENTS WITH ANEMIA.	Valentin Garcia-Gutierrez	Received

P-1068	CPH DEEP NEURAL NETWORK AND CONTINUOUS-TIME MULTI-STATE MARKOV CHAIN MODELS CONFIRM HMA TO BE THE BEST FIRST LINE TREATMENT OPTION FOR CMML PATIENTS – AN INTERNATIONAL STUDY COORDINATED BY THE AGMT	Lisa Pleyer	Received

P-1069	SELINEXOR PLUS RUXOLITINIB IMPACT ON SYMPTOM BURDEN IN PATIENTS WITH MYELOFIBROSIS AND POTENTIAL MECHANISM OF ACTION VIA INHIBITION OF NF-?B AND ACTIVATION OF P53 PATHWAYS	Srinivas Tantravahi	Received

P-1070	LENALIDOMIDE AND DEXAMETHASONE FOR ROSAI-DORFMAN DISEASE: A SINGLE ARM, SINGLE CENTER, PROSPECTIVE PHASE 2 STUDY	Long Chang	Received

P-1072	REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MYELOFIBROSIS TREATED WITH PACRITINIB IN THE UNITED STATES	John Mascarenhas	Received

P-1073	PREVALENCE OF POLYCYTHEMIA VERA, CYTOREDUCTIVE TREATMENT, AND THROMBOEMBOLIC EVENTS IN AFFECTED PATIENTS: A STUDY BASED ON LONGITUDINAL GERMAN HEALTH CLAIMS DATA	Anja Mocek	Received

P-1075	GERMLINE INACTIVATING VARIANTS IN SH2B3 DEFINE A NOVEL DISORDER CHARACTERIZED BY A TRANSIENT NEONATAL/INFANCY MYELOPROLIFERATIVE DISORDER AND SUBSEQUENT DEVELOPMENT OF THROMBOCYTOSIS IN CHILDHOOD	Davide Leardini	Received

P-1076	DECIPHERING THROMBOTIC COMPLICATIONS AND INFLAMMATORY FACTORS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND ATRIAL FIBRILLATION: A MULTI-CENTRE RETROSPECTIVE STUDY	Olga Chyrko	Received

P-1077	ENHANCING ACCURACY AND SAFETY OF AI-BASED BONE MARROW ASSESSMENT IN MPNS WITH AN AUTOMATED QUALITY CONTROL PIPELINE	Xuezi Hu	Received

P-1078	ADVANCED-STAGE HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (A-HIPI) IN TURKISH CLASSICAL HODGKIN LYMPHOMA PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY	Oguzhan Koca	Received

P-1079	TREATMENT OF ADVANCED STAGE, HIGH RISK SCORE HODGKIN´S DISEASE PATIENTS WITH CONVENTIONAL CHEMOTHERAPY PLUS BRENTUXIMAB VEDOTIN AND NIVOLUMAB: A PHASE II TRIAL RESULTS	Maher Salamoon	Received

P-1080	BRENTUXIMAB VEDOTIN (BV)+AVD IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTRIC STUDY	Giovanni Manfredi Assanto	Received

P-1081	GERIATRIC FITNESS AND REAL-LIFE OUTCOMES IN ELDERLY PATIENTS WITH HODGKIN´S LYMPHOMA	Silvio Ligia	Received

P-1082	CONGESTIVE HEART FAILURE FOLLOWING ANTHRACYCLINE-CONTAINING TREATMENT FOR CLASSICAL HODGKIN LYMPHOMA: A SWEDISH MATCHED COHORT STUDY	Sissel Johanne Godtfredsen	Received

P-1083	PEMBROLIZUMAB PLUS THE ANTI–LAG-3 ANTIBODY FAVEZELIMAB FOR HEAVILY PRETREATED ANTI–PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): AN UPDATED ANALYSIS OF A PHASE 1/2 STUDY	Gareth Gregory	Received

P-1084	LONG-TERM CAUSE-SPECIFIC MORTALITY IN A COHORT OF 1,435 HODGKIN LYMPHOMAS TREATED AT THE NATIONAL ADULT PUBLIC CANCER PROGRAM IN CHILE OVER A 30-YEAR PERIOD	Massimo Federico	Received

P-1085	EVALUATION OF GONADAL FUNCTION IN YOUNG MEN AND WOMEN DIAGNOSED WITH HODGKIN LYMPHOMA	ANGELIKI GEORGOPOULOU	Received

P-1086	BENDAMUSTINE AND ADCETRIS IN UNTREATED HODGKIN LYMPHOMA OF THE ELDERLY: LONG-TERM RESULTS OF THE HALO TRIAL	Andrea Gallamini	Received

P-1087	PEMBROLIZUMAB PLUS THE ANTI–LAG-3 ANTIBODY FAVEZELIMAB FOR ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA: AN UPDATED ANALYSIS OF A PHASE 1/2 STUDY	Peter Borchmann	Received

P-1088	KEYNOTE-667: RESULTS FROM THE PHASE 2 STUDY OF PEMBROLIZUMAB (PEMBRO) IN CHILDREN AND YOUNG ADULTS WITH LOW-RISK CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE (SER) TO FRONT-LINE CHEMOTHERAPY	Lisa Giulino-Roth	Received

P-1090	INNOVATIVE EVA REGIMEN (ETOPOSIDE, VINBLASTINE, DOXORUBICIN) IN HODGKIN´S LYMPHOMA TREATMENT FOR PREGNANT WOMEN.	Joanna Romejko-Jarosinska	Received

P-1091	DATA REQUIREMENTS FOR DEVELOPMENT OF PREDICTION MODELS FOR SURVIVAL AMONG HODGKIN LYMPHOMA PATIENTS: HOW MANY PATIENTS ARE NEEDED?	Rasmus Rask Kragh Jørgensen	Received

P-1092	BASELINE PET-CT RADIOMICS PREDICT 5-YEAR PROGRESSION FREE SURVIVAL IN ADVANCED STAGE HODGKIN LYMPHOMA	Fer de Wit	Received

P-1094	EARLY DETECTION OF CLASSIC HODGKIN LYMPHOMA RELAPSE USING ROUTINE SERUM TARC MEASUREMENTS DURING FOLLOW-UP	Sophie Teesink	Received

P-1095	ANIMATE: A UK PHASE II PET RESPONSE-ADAPTED TRIAL OF NIVOLUMAB IN RELAPSED / REFRACTORY CLASSICAL HODGKIN LYMPHOMA	Graham Collins	Received

P-1096	BRENTUXIMAB-VEDOTIN PLUS AVD CHEMOTHERAPY AS FRONTLINE THERAPY IN PATIENTS WITH STAGE IV CLASSICAL HODGKIN LYMPHOMA: A REAL-WORLD REPORT ON FEASIBILITY, EFFICACY AND INTERIM-PET RESULTS	Chiara Rusconi	Received

P-1097	KEYNOTE-667: UPDATED RESULTS FROM THE PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH HIGH-RISK CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE (SER) TO FRONT-LINE CHEMOTHERAPY	Christine Mauz-Koerholz	Received

P-1098	THE ADDITIONAL PROGNOSTIC VALUE OF ?SUVMAX TO THE FIRST-LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA	Laszlo Pinczes	Received

P-1099	HISTOLOGICAL GRADING OF NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA (NSHL) RETAINS PROGNOSTIC SIGNIFICANCE WITHIN THE MODERN THERAPEUTIC LANDSCAPE	Alessandro Cellini	Received

P-1100	TREATMENT EFFECTS OF BRECADD ON HEALTH-RELATED QUALITY OF LIFE: AN ANALYSIS OF PATIENT REPORTED OUTCOMES IN THE RANDOMIZED INTERNATIONAL PHASE III GERMAN HODGKIN STUDY GROUP HD21 TRIAL	Justin Ferdinandus	Received

P-1101	FAVORABLE, CONTEMPORARY, REAL-WORLD OUTCOMES OF BRENTUXIMAB VEDOTIN AS POST-ASCT CONSOLIDATION IN RRHL: A SYSTEMATIC REVIEW AND META-ANALYSIS	Anna Sureda Balari	Received

P-1102	SAFETY AND EFFICACY OF SYK INHIBITOR SOVLEPLENIB IN HEAVILY PRE-TREATED HODGKIN LYMPHOMA PATIENTS	Paolo Strati	Received

P-1103	SAFETY AND EFFICACY RESULTS FROM AN OPEN-LABEL PHASE 1/2 TRIAL OF SABESTOMIG (AZD7789) IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PREVIOUSLY TREATED WITH ANTI-PD-(L)1 THERAPIES	Gaetano Corazzelli	Received

P-1104	A NATIONWIDE STUDY OF NEWLY DIAGNOSED NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA OVER TWO DECADES	Katrin Bamdeg-Hvolbek	Received

P-1105	COMBINATION OF BRENTUXIMAB VEDOTIN AND PEMBROLIZUMAB BEFORE INTENSIFICATION WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA.	Hanne Massa	Received

P-1106	BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: SEVEN-YEAR OVERALL SURVIVAL ANALYSIS FROM THE ECHELON-1 STUDY	John Radford	Received

P-1107	OUTCOME OF PATIENTS WITH LIMITED-STAGE HODGKIN LYMPHOMA (HL) ENROLLED IN THE EORTC/LYSA/FIL H10 AND PROGRESSED/RELAPSED AFTER INITIAL THERAPY	Manuel Gotti	Received

P-1108	TIMING MATTERS: IMPACT OF EARLY HISTOLOGICAL TRANSFORMATION ON SURVIVAL IN FOLLICULAR LYMPHOMA (FL) PATIENTS: A MULTICENTRE ANALYSIS	Andrea Franch	Received

P-1109	TUMOR ASSOCIATED MACROPHAGES´ CYTOKINES; CD163, CCL4 AND CCL2, AS POSSIBLE NEW BIOMARKERS IN WALDENSTROM´S MACROGLOBULINEMIA.	Alexandros Gkiokas	Received

P-1111	RELAPSE PATTERNS AND OUTCOMES OF PATIENTS WITH FOLLICULAR LYMPHOMA ACHIEVING COMPLETE METABOLIC RESPONSE AFTER INDUCTION THERAPY. A FIL FOLL12 SUB-STUDY.	Maria Elena Nizzoli	Received

P-1112	COMBINATION TREATMENT WITH NOVEL BCL-2 INHIBITOR SONROTOCLAX (BGB-11417) AND ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MCL	Constantine Tam	Received

P-1113	WAVE STUDY, A RETROSPECTIVE OF FILO TRIAL : PATIENTS WITH RELAPSE WALDENSTRÖM´S MACROGLOBULINEMIA TREATED BY VENETOCLAX IN REAL LIFE	Mathilde Vonfeld	Received

P-1114	PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA TREATED WITH EPCORITAMAB	Wojciech Jurczak	Received

P-1115	SPLENOMEGALY AT THE TIME OF LGLL DIAGNOSIS IS ASSOCIATED WITH POOR DISEASE OUTCOMES AND EXPANSION OF LGLL CLONES.	Ahmad Kiwan	Received

P-1116	CLINICAL FEATURES AND GENETIC ALTERATIONS ASSOCIATED WITH HISTOLOGIC GRADING OF FOLLICULAR LYMPHOMA	Huilai Zhang	Received

P-1117	BENEFIT OF RITUXIMAB MAINTENANCE AFTER FIRST-LINE BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH MANTLE CELL LYMPHOMA	Yucai Wang	Received

P-1120	ZR STUDY:A PROSPECTIVE PHASE II STUDY OF ZANUBRUTINIB-RITUXIMAB INDUCTION WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED MANTLE CELL LYMPHOMA	Chang-Ju Qu	Received

P-1125	TP53 AND CDKN2A DISRUPTIONS ARE INDEPENDENT PROGNOSTIC DRIVERS IN MANTLE CELL LYMPHOMA: LONG TERM OUTCOME OF THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 TRIAL	Riccardo Moia	Received

P-1126	SUBGROUP ANALYSES IN PATIENTS WITH R/R MCL TREATED WITH LISOCABTAGENE MARALEUCEL BY PRIOR LINES OF THERAPY AND RESPONSE TO BRUTON TYROSINE KINASE INHIBITOR FROM THE TRANSCEND NHL 001 MCL COHORT	Manali Kamdar	Received

P-1127	RESPONSE-ADAPTED TREATMENT WITH MOSUNETUZUMAB WITH OR WITHOUT OBINUTUZUMAB AND POLATUZUMAB VEDOTIN IN TREATMENT NAÏVE FOLLICULAR AND MARGINAL ZONE LYMPHOMA: INTERIM RESULTS AND PHASED-SEQ MRD ANALYSIS	Ryan Lynch	Received

P-1128	EFFICACY AND SAFETY OF IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) AND TP53 MUTATIONS IN THE SYMPATICO STUDY	Wojciech Jurczak	Received

P-1129	CLINICAL CHARACTERISTICS AND OUTCOMES OF MCL PATIENTS AGED 80 YEARS AND OLDER	Simon Pahnke	Received

P-1130	VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL OR ARI-0001) IN RELAPSED / REFRACTORY ADULT FOLLICULAR LYMPHOMA	Nuria Martinez-Cibrian	Received

P-1131	AZD0486, A NOVEL CD19XCD3 T-CELL ENGAGER, SHOWS DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATE ON EFFICACY AND SAFETY	Sumana Devata	Received

P-1133	COMPARATIVE EFFECTIVENESS OF EPCORITAMAB VERSUS REAL-WORLD USUAL CARE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA	Tycel Phillips	Received

P-1134	PATIENT CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL) IN THE UNITED STATES (US), CANADA, AND EUROPE: A PANEL-BASED CHART REVIEW STUDY	Craig Portell	Received

P-1135	SAFETY AND PRELIMINARY EFFICACY OF BI-1206, AN ANTIBODY TO CD32B (FCGRIIB), GIVEN IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA	Mariana Beatriz Bastos	Received

P-1136	EPIDEMIOLOGICAL FEATURES AND PROGNOSIS FOR PRIMARY GASTROINTESTINAL FOLLICULAR LYMPHOMA	Huilai Zhang	Received

P-1137	UNDETECTABLE MEASURABLE RESIDUAL DISEASE (MRD) IS ASSOCIATED WITH IMPROVED LONG-TERM OUTCOME IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) TREATED WITH CHEMO-IMMUNOTHERAPY: RESULTS FROM SWOG S0016	Alexey Danilov	Received

P-1138	PRELIMINARY SAFETY AND EFFICACY OF BOVEN (ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX) FOR FRONTLINE THERAPY FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA	Anita Kumar	Received

P-1140	THE EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS STANDARD OF CARE (SCHOLAR-5) IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER =2 SYSTEMIC THERAPIES: AN INDIRECT TREATMENT COMPARISON	Anna Sureda Balari	Received

P-1141	ORELABRUTINIB-LENALIDOMIDE-RITUXIMAB IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (MCL): UPDATED RESULTS OF THE MULTICENTER, PHASE II POLARIS STUDY	Huilai Zhang	Received

P-1142	CLINICAL FEATURES, TREATMENT PATTERNS, AND OUTCOMES OF DUODENAL-TYPE FOLLICULAR LYMPHOMA WITH A LONG-TERM FOLLOW-UP OBSERVATIONAL STUDY	Fuka Mima	Received

P-1144	INCIDENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH WALDENSTRÖM´S MACROGLOBULINEMIA: A SINGLE CENTRE REAL-WORLD EXPERIENCE	Nicole Japzon	Received

P-1145	ZANUBRUTINIB IN BING-NEEL SYNDROME: EFFICACY AND TOLERABILITY	Josephine Vos	Received

P-1146	EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) IN PREVIOUSLY UNTREATED (1L) FOLLICULAR LYMPHOMA (FL) AND EPCORITAMAB MAINTENANCE THERAPY IN FL: NOVEL RESULTS FROM EPCORE NHL-2 ARMS 6 AND 7	Lorenzo Falchi	Received

P-1147	CLINICAL EFFICACY OF RUXOLITINIB IN T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA VIA A NON-TUMOR CELL AUTONOMOUS MECHANISM	Amira Marouf	Received

P-1148	FRONTLINE TREATMENT WITH ZANUBRUTINIB PLUS RITUXIMAB (ZR) FOLLOWED BY SHORT COURSE R-DHAOX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) – RESULTS OF PHASE II CHESS TRIAL	Qingqing Cai	Received

P-1149	EZH2 ABERRATIONS IN ADVANCED FOLLICULAR LYMPHOMA: FIRST TRANSLATIONAL RESULTS OF FOLL-EZ, AN ANCILLARY STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL	Simone Ferrero	Received

P-1150	A COMPARISON OF TREATMENT OUTCOMES BETWEEN CYCLOSPORIN AND CHEMOTHERAPY IN SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA (SPTCL): REPORT FROM THE NATIONWIDE MULTI-CENTER THAI LYMPHOMA STUDY GROUP	Thitirat Tirachotikul	Received

P-1151	EXTENDED FOLLOW-UP BEYOND 2.5 YEARS SHOWS LONG-TERM EFFICACY IN COMPLETE RESPONDERS FOLLOWING EPCORITAMAB MONOTHERAPY IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA	Catherine Thieblemont	Received

P-1153	OUTCOMES IN PATIENTS WITH LARGE B-CELL LYMPHOMA TREATED WITH TAFASITAMAB PLUS LENALIDOMIDE POST-CD19-TARGETING CAR-T THERAPY: A LYSA STUDY FROM THE DESCAR-T REGISTRY	Vincent Camus	Received

P-1154	DEFINITION AND USE OF BULKY DISEASE IN LYMPHOMA CARE: A STUDY FROM THE AUSTRALASIAN LYMPHOMA AND RELATED DISEASES REGISTRY (LARDR)	Eliza Chung	Received

P-1155	PREVALENCE OF CARDIOVASCULAR RISK FACTORS AND LEFT VENTRICULAR DYSFUNCTION IN SURVIVORS OF DIFFUSE LARGE B-CELL LYMPHOMA COMPARED WITH SIBLING CONTROLS	Suzanne Neppelenbroek	Received

P-1156	SECONDARY PRIMARY MALIGNANCIES AFTER CD19-DIRECTED CAR-T CELL THERAPY IN LYMPHOMAS: A REPORT FROM THE ITALIAN CART-SIE STUDY	Angelica Barone	Received

P-1158	BRIGATINIB MONOTHERAPY IN CHILDREN WITH R/R ALK+ ALCL: PRELIMINARY RESULTS FROM THE BRIGAPED (ITCC-098) PHASE 1 DOSE-ESCALATION STUDY	Charlotte Rigaud	Received

P-1159	ZUMA-24 PRELIMINARY ANALYSIS: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL IN THE OUTPATIENT SETTING WITH PROPHYLACTIC CORTICOSTEROIDS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA	Lori Leslie	Received

P-1160	A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY WITH A PD-1 KNOCKOUT (CB-010) FOR RELAPSED/REFRACTORY B CELL NON-HODGKIN LYMPHOMA (R/R B-NHL): UPDATED PHASE 1 RESULTS FROM THE ANTLER TRIAL	Boyu Hu	Received

P-1161	EPCORITAMAB + R-DHAX/C ELICITS DEEP, DURABLE RESPONSES IN TRANSPLANT-ELIGIBLE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING HIGH-RISK DISEASE	Pau Abrisqueta	Received

P-1163	PLASMA CELL-FREE DNA AS AN ALTERNATIVE TO TISSUE DNA FOR DETECTING GENETIC ALTERATIONS OF IVLBCL	Chao Chen	Received

P-1164	SUPERIOR EFFECTS OF CD19/20 DUAL-TARGETING CAR-T IN PATIENTS WITH RELAPSED/REFRACTIVE B-CELL LYMPHOMA: A MULTICENTER PRELIMINARY INTERIM REPORT	Jiaqi Guo	Received

P-1166	REAL-WORLD ANALYSIS OF GLOFITAMAB FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN GERMANY, AUSTRIA AND SWITZERLAND	Rebecca Wurm-Kuczera	Received

P-1167	ORIENT STUDY: ORELABRUTINIB ADDITION TO R-CHOP-LIKE REGIMEN ADAPTED TO RESPONSE IN TREATMENT-NAÏVE NON-GCB DLBCL	Chang-Ju Qu	Received

P-1168	PHASE I-II STUDY COMBINING BRENTUXIMAB VEDOTIN WITH R-DHAP AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN CD30 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS OF THE HOVON 136 STUDY	Pieternella (Elly) Lugtenburg	Received

P-1169	GENOMIC PROFILING IN A SUBGROUP ANALYSIS OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND EXTRANODAL (EN) SITES OF INVOLVEMENT IN THE PHASE III POLA-R-CHP VERSUS R-CHOP (POLARIX) STUDY	Jennifer Lue	Received

P-1170	PHASE 2 STUDY OF ANTI-PD-L1 ANTIBODY ATEZOLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA: NCCH1903/ATTACK STUDY	Shinichi Makita	Received

P-1172	VALEMETOSTAT MONOTHERAPY IN RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS: A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL	Dai Maruyama	Received

P-1173	FEASABILITY AND SAFETY DATA OF THE CHEMOTHERAPY-LIGHT COMBINATION OF RITUXIMAB, POLATUZUMAB VEDOTIN AND GLOFITAMAB IN AGGRESSIVE B-CELL LYMPHOMA PATIENTS INELIGIBLE FOR FULLY DOSED R-CHOP	Rebecca Wurm-Kuczera	Received

P-1174	ANALYSIS OF CCND3 MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA	Jin-Hua Liang	Received

P-1175	ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PROOF-OF-CONCEPT PHASE II STUDY	Yan Zhang	Received

P-1176	POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) - FINNISH REAL-LIFE DATA WITH LONG-TERM FOLLOW-UP ON 215 SOLID ORGAN RECIPIENTS	Terhi Friman	Received

P-1177	THE PROGNOSTIC SIGNIFICANCE OF MYC/BCL2 DOUBLE EXPRESSION IN DIFFUSE LARGE B CELL LYMPHOMA IN THE GENETIC CLASSIFICATION ERA	Jin-Hua Liang	Received

P-1178	BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS– UPDATED ANALYSIS OF REAL-WORLD DATA	Magdalena Klanova	Received

P-1180	FRONTLINE TREATMENT CHOICES AND GENETIC CHARACTERISTICS OF PATIENTS WITH UNTREATED AGGRESSIVE B-CELL LYMPHOMA WITH SYNCHRONOUS CNS AND SYSTEMIC INVOLVEMENT.	Jacopo Calabrese De Feo	Received

P-1182	REAL-WORLD EXPERIENCE OF POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB AND BENDAMUSTINE IN RELAPSED AND REFRACTORY LARGE B-CELL LYMPHOMAS.	Michal Danecki	Received

P-1183	PREDICTING THE TRULY LOW-RISK PATIENTS WITH TNFRSF14 MUTATION USING MACHINE LEARNING ALGORITHMS IN DIFFUSE LARGE B CELL LYMPHOMA	Jin-Hua Liang	Received

P-1186	SIGNIFICANT OUTCOME IMPROVEMENT OF THE ENTIRE R/R DLBCL POPULATION RECEIVING THIRD LINE THERAPY IN THE CAR T-CELL ERA	Marek Trneny	Received

P-1188	BASELINE PET TOTAL METABOLIC TUMOR VOLUME HAS A PROGNOSTIC ROLE IN PTCLS – DATA FROM INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0	Tetiana Skrypets	Received

P-1189	CD22-TARGETED CAR T CELL SINGLE CELL MULTIOMIC FEATURES LINKED TO PATIENT OUTCOMES IN CD19-CAR RESISTANT LARGE B CELL LYMPHOMA	Anne Marijn Kramer	Received

P-1190	TUMOR MUTATIONS AND IMMUNOHISTOCHEMICAL TUMOR EXPRESSION IMPACTS SURVIVAL IN PATIENTS WITH B CELL LYMPHOMA TREATED WITH BISPECIFIC CD20XCD3 ANTIBODIES	Emil Kyvsgaard	Received

P-1191	UPDATED TRENDS IN REAL-WORLD OUTPATIENT (OP) ADMINISTRATION OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) IN RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)	Radhika Bansal	Received

P-1192	CAR-T CELL THERAPY SHOWS SIMILAR EFFICACY AND TOXICITY IN PATIENTS WITH DLBCL AGED 70 AND OLDER COMPARED TO YOUNGER PATIENTS: A MULTICENTER COHORT STUDY	Philipp Berning	Received

P-1193	THE PRIMARY RESULTS OF R-MTO REGIMEN (RITUXIMAB, METHOTREXATE, THIOTEPA, AND ORELABRUTINIB) AS THE FIRST-LINE INDUCTION THERAPY IN NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Zengjun Li	Received

P-1194	ORELABRUTINIB IN COMBINATION WITH PD-1 INHIBITOR IN REFRACTORY OR RELAPSED PRIMARY CNS LYMPHOMA	Yan Zhang	Received

P-1195	PHASE IB/II STUDY OF RITUXIMAB, LENALIDOMIDE, AND METHOTREXATE FOLLOWED BY LENALIDOMIDE MAINTENANCE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: THE REMLA TRIAL	Yan Zhang	Received

P-1196	IMPACT OF CD19 EXPRESSION BY IMMUNOHISTOCHEMISTRY IN LYMPHOMA PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL	Marcos Rivada	Received

P-1197	DECREASES IN LEFT VENTRICULAR FUNCTION IN ELDERLY PATIENTS WITH LARGE B-CELL LYMPHOMA RECEIVING CHOP REGIMENS IN THE RICOVER-60 TRIAL: RISK FACTORS AND OUTCOMES	Igor Age Kos	Received

P-1198	NIVOLUMAB CONSOLIDATION AFTER DA-EPOCH-R INDUCTION INDUCES HIGH RATES OF DISEASE-FREE AND OVERALL SURVIVAL IN PATIENTS WITH DOUBLE AND TRIPLE HIT HIGH-GRADE B-CELL LYMPHOMA	Martine Chamuleau	Received

P-1199	REAL-WORLD OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR TREATMENT OF RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA IN CANADA	Christopher Lemieux	Received

P-1200	ANATOMICAL PATTERN OF CNS RELAPSE IN AGGRESSIVE B-CELL LYMPHOMAS	Izel Okcu	Received

P-1201	CLINICAL CHARACTERISTICS, TREATMENTS, AND OUTCOMES OF LARGE B-CELL LYMPHOMA PATIENTS IN THIRD-LINE THERAPY INCLUDED BETWEEN 2018 AND 2023 IN THE FRENCH PROSPECTIVE MULTICENTRIC REALYSA COHORT	Caterina Cristinelli	Received

P-1202	EARLY PET EVALUATION AT DAY 14 POST AXICABTAGENE CILOLEUCEL INFUSION PREDICTS OUTCOME IN LARGE B-CELL LYMPHOMA: RESULTS FROM THE ALYCANTE PHASE II STUDY	Yassine Al Tabaa	Received

P-1203	TAFASITAMAB PLUS LENALIDOMIDE AS SALVAGE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: THE SPANISH GROUP OF LYMPHOMA (GELTAMO) REAL-WORLD EXPERIENCE.	Antonio Gutiérrez	Received

P-1204	REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH TREATMENT-NAÏVE AND RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES	Jennifer Lue	Received

P-1205	COFORMULATED VIBOSTOLIMAB/PEMBROLIZUMAB IN RELAPSED/REFRACTORY NHL AND MM: AN ANALYSIS OF COHORTS C TO F OF THE PHASE 2 KEYVIBE-004 STUDY	Sylvain Choquet	Received

P-1206	INITIAL RESULTS FROM THE PRIZM+ PHASE II PLATFORM STUDY FOR RELAPSED AND REFRACTORY PRIMARY CNS LYMPHOMA: COHORT 1 ZANUBRUTINIB MONOTHERAPY	Christopher Fox	Received

P-1207	ANALYSIS OF LARGE B-CELL LYMPHOMA PATIENTS FAILED AFTER CAR T-CELL THERAPY: SEVERAL FACTORS PREDICTING OUTCOME OF RELAPSED/PROGRESSED PATIENTS ARE ALREADY PRESENT BEFORE CELL INFUSION	Robert Pytlík	Received

P-1208	CLINICAL CHARACTERISTICS, TREATMENT OPTIONS AND OUTCOME OF REFRACTORY AND EARLY RELAPSE LARGE B CELL LYMPHOMA (LBCL) PATIENTS INCLUDED IN THE REALYSA COHORT BEFORE CAR T CELLS ERA.	Stephanie Guidez	Received

P-1209	SINTILIMAB PLUS GEMOX IS AN EFFECTIVE SALVAGE THERAPY IN PATIENTS WITH REFRACTORY/RELAPSING NODAL PERIPHERAL T CELL LYMPHOMAS	Xibin Xiao	Received

P-1211	DIAGNOSTIC AND PROGNOSTIC IMPACTS OF RHOA G17V MUTATION IN CELL-FREE DNA ASSESSED BY DROPLET DIGITAL POLYMERASE CHAIN REACTION IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA	Yi Miao	Received

P-1212	WAVELINE-004: UPDATED RESULTS FROM THE PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (ZV) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Muhit Ozcan	Received

P-1213	ENHANCED EFFICACY AND SAFETY FROM PHASE 2 STUDY OF IMC-001, ANTI-PD-L1 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA (R/R ENKTL), NASAL TYPE: DISTINKT STUDY	Won Seog Kim	Received

P-1214	EARLYMIND, A RETROSPECTIVE MULTICENTER STUDY IN REAL-WORLD SETTINGS TO CHARACTERIZE TAFASITAMAB-LENALIDOMIDE EFFICACY IN TRANSPLANT-INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA	Charles Herbaux	Received

P-1215	PROGNOSTICATION IN SECONDARY CNS LYMPHOMA PATIENTS TREATED WITH MATRIX OR AN ALTERNATIVE (KORFEL ET AL. NCT01148173) INDUCTION REGIMEN AND AUTOLOGOUS STEM CELL TRANSPLANTATION CONSOLIDATION	Fleur de Groot	Received

P-1216	OUTCOMES OF ANTHRACYCLINE-BASED CHEMOIMMUNOTHERAPY IN DE NOVO AND TRANSFORMED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Maximilian Seib	Received

P-1217	COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSES OF AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA IN SINGAPORE	Francesca Lim	Received

P-1218	THE PHASE II STUDY OF ZANUBRUTINIB COMBINED WITH R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS WITH SPECIFIC GENE-EXPRESSION	Qunling Zhang	Received

P-1219	POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER 5797 SOLID-ORGAN TRANSPLANTS OVER A 30-YEAR PERIOD IN A SINGLE HOSPITAL.	Ana Isabel Jimenez Ubieto	Received

P-1220	INTELLIGENT INTEGRATION: DEEP LEARNING ENSEMBLE CLASSIFIER FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, GLIOMA, AND BRAIN METASTASIS - A RETROSPECTIVE STUDY	Bihui Pan	Received

P-1221	MONOMORPHIC LYMPHOPROLIFERATIVE DISORDERS FOLLOWING HEART TRANSPLANTATION: A SINGLE CENTER EXPERIENCE ON 1055 TRANSPLANTS.	Anna Maria Barbui	Received

P-1222	A MULTI-CENTER, OPEN-LABEL, PHASE 1/2 STUDY OF ONCT-808, A ROR1-TARGETING CAR-T CELL THERAPY, IN ADULTS WITH RELAPSED/REFRACTORY (R/R) AGGRESSIVE B CELL LYMPHOMAS (BCL)	Michael Wang	Received

P-1223	POLATUZUMAB VEDOTIN-INDUCED INNATE IMMUNE CELL INFILTRATION CONTRIBUTES TO ITS ANTITUMOR EFFECT IN A HUMAN DLBCL XENOGRAFT MODEL	Mayu Tomita	Received

P-1224	IMPACT OF BCR-IGH DIVERSITY ON PROGNOSIS IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA	Takahiro Haeno	Received

P-1225	MUTANT STAT5B TRIGGERS NK-CELL NEOPLASMS	Dagmar GOTTHARDT	Received

P-1226	CD58 GENETIC ALTERATIONS GOVERN ANTITUMOR IMMUNE RESPONSES BY REGULATING PD-L1 AND IDO VIA THE LYN/CD22/SHP1 AXIS IN DLBCL	Xiyue Xu	Received

P-1227	INTEGRATION OF [18F]FDG-PET RADIOMICS WITH LIQUID BIOPSY IMPROVES OUTCOME PREDICTION IN NEWLY DIAGNOSED DLBCL PATIENTS	Riccardo Dondolin	Received

P-1228	SPECIFIC IMMUNE-MOLECULAR PROFILES DISTINGUISH TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA FROM NODAL-DLBCL-ABC	Ruben de Groen	Received

P-1229	PD-1 AND TIGIT IMMUNE-CHECKPOINT BLOCKADE IN NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA	Maher Gandhi	Received

P-1231	UNRAVELING THE MECHANISMS OF BCL7A-MEDIATED TUMOR SUPPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA: A MULTI-OMIC APPROACH	Fernando Montenegro Elvira	Received

P-1232	ALK INHIBITORS ENHANCE PHAGOCYTOSIS INDUCED BY CD47 BLOCKADE IN SENSITIVE AND RESISTANT ALK+ ALCL	Federica Malighetti	Received

P-1233	MICRORNA-1181, UPREGULATED IN BONE MARROW-DERIVED EXTRACELLULAR VESICLES, PROMOTES REDUCED PROLIFERATION CAPACITY AND INCREASED APOPTOSIS OF DLBCL CELLS	Inna Tzoran	Received

P-1235	APAF-1 DOWNREGULATION PROMOTES ANGIOIMMUNOBLASTIC T CELL LYMPHOMA.	Barbara Chalhoub	Received

P-1236	UNCOVERING A UNIQUE LEUKEMIC CLONE OF KLRG1-CD8+ EFFECTOR T CELLS IN T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA SENSITIVE TO PI3K INHIBITOR: A PILOT TRIAL	Ruonan Li	Received

P-1237	GENE EXPRESSION PROFILING OF RELAPSED AND REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA REVEALS ENRICHMENT OF IMMUNE SIGNALING PATHWAYS	Ya Hwee Tan	Received

P-1239	RESPONSE IN MOLECULAR SUBGROUPS AND CIRCULATING TUMOR (CT)DNA KINETICS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) TREATED WITH GLOFITAMAB MONOTHERAPY	Carmelo Carlo-Stella	Received

P-1240	HYPERSPECTRAL IMAGING FOR NON-INVASIVE DIAGNOSIS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A PILOT STUDY	Ji Ma	Received

P-1241	3D IN-VITRO RECREATED TUMOR MICROENVIRONMENT AFFECTS DLBCL DRUGS SENSITIVITY AND ALTERS THE CYTOKINE MILIEU	Jessica Ceccato	Received

P-1244	IMMUNE CORRELATES OF RESPONSE TO EPCORITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: DOSE EXPANSION IN A PHASE 1/2 TRIAL	Jimin Zhang	Received

P-1245	ROLE OF INFLAMMATION IN WALDENSTROM MACROGLOBULINEMIA: INSIGHTS FROM A MULTICENTER STUDY	Pierre-Edouard Debureaux	Received

P-1247	MYELOID CLONAL HEMATOPOIESIS AFFECTS OUTCOME IN YOUNGER MANTLE CELL LYMPHOMA PATIENTS: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI MCL0208 CLINICAL TRIAL	Simone Ragaini	Received

P-1248	GUT MICROBIAL SHORT-CHAIN FATTY ACIDS AS POTENTIAL CHEMICAL MODIFIER OF CAR-T CELLS FOR NON-HODGKIN LYMPHOMA	Roberto Garcia-Vicente	Received

P-1249	POPULATION MODELING OF AXICABTAGENE CILOLEUCEL PHARMACOKINETICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA	Sylvain Lamure	Received

P-1250	AMINO ACID INFLUX VIA LAT1 REGULATES IRON DEPENDENCY OF AGGRESSIVE NATURAL KILLER CELL LEUKEMIA	Ryo Yanagiya	Received

P-1251	PRECLINICAL ASSESSMENT OF IPH6501, A FIRST-IN-CLASS IL2V-ARMED TETRASPECIFIC NK CELL ENGAGER DIRECTED AGAINST CD20 FOR R/R B-NHL, IN COMPARISON WITH A CD20-TARGETING T CELL ENGAGER	Eric Vivier	Received

P-1253	ELUCIDATING THE MECHANISM OF HMGB2 IN AUGMENTING THE WARBURG EFFECT AND FACILITATING THE ONSET OF HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA THROUGH THE REGULATION OF U2AF2 STABILITY	Jun Li	Received

P-1254	COMBINATION OF SELINEXOR WITH BTK INHIBITOR FOR CENTRAL NERVOURS SYSTEM DIFFUSE LARGE B-CELL LYMPHOMA, POSSIBLE MECHANISMS AND THERAPEUTIC POTENTIAL EXPLORATION	Xiaobo Wang	Received

P-1255	PLEIOTROPIC RISK LOCI IN LYMPHOID NEOPLASMS: PHENOCLUSTERING REVEALS NOVEL INSIGHTS	Murat Güler	Received

P-1256	ORAL ARV-393 IS A BCL6 DEGRADING PROTAC EFFICACIOUS AS MONOTHERAPY IN B-CELL LYMPHOMA PRECLINICAL CDX AND PDX MODELS	Sheryl Gough	Received

P-1257	ANTIBIOTIC-ASSOCIATED DYSBIOSIS IMPACTS ON THE PROGRESSION OF NON-HODGKIN LYMPHOMA THROUGH T CELL DYSFUNCTION	María Hernández-Sánchez	Received

P-1259	RESISTANCE MECHANISMS AND CLONAL KINETICS IN MANTLE CELL LYMPHOMA TREATED WITH SEQUENTIAL BTKI AND VENETOCLAX THERAPY	Tamás László	Received

P-1260	TRANSLATIONAL RESEARCH TARGETING INTRACTABLE LYMPHOMAS WITH T FOLLICULAR HELPER CELL PHENOTYPE	Sakurako Suma	Received

P-1261	SERIAL MONITORING OF CIRCULATING TUMOR DNA WITH AN ULTRASENSITIVE ASSAY FACILITATES OUTCOME PREDICTION IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH MODERN AGENTS	Julia K. Schleifenbaum	Received

P-1263	EXPRESSION OF MUTATED MYD88 IN A FEW GERMINAL CENTER B CELLS DEMONSTRATES THE ROLE OF ANTIGENIC STIMULATION IN THE CLONAL EMERGENCE OF LYMPHOPLASMACYTIC LYMPHOMA IN A NEW DUAL COLOR MOUSE MODEL	Ophélie Téteau	Received

P-1264	XPO1 INHIBITOR TRIGGERS AUTOPHAGY OF TP53-MUTATED BURKITT LYMPHOMA CELLS	Mowang Wang	Received

P-1265	COLLABORATIVE ADVANCEMENTS IN DRUG DEVELOPMENT: LEVERAGING CEVI-PDX, THE ANNOTATED LYMPHOMA PDX COLLECTION FROM FRANCE	Carole Soussain	Received

P-1268	PROGNOSTIC IMPACT OF TP53 ABERRATIONS DETECTED IN TISSUE OR CFDNA IN SPLENIC MARGINAL ZONE LYMPHOMAS	Ramón Diez-Feijóo Varela	Received

P-1269	COMPETITION BETWEEN AID-IMPRINTED B-CELLS OVEREXPRESSING REL OR NOT INDICATES THAT REL HAS THE CHARACTERISTICS OF A PRIMARY GENETIC EVENT FOR GERMINAL CENTER B-CELL TRANSFORMATION.	Nathalie Faumont	Received

P-1270	A NOVEL STAT5B-DRIVEN MOUSE MODEL OF HEPATOSPLENIC T CELL LYMPHOMA REVEALS THERAPEUTIC EFFICACY OF JAK INHIBITORS	Myint Myat Khine Aung	Received

P-1271	CHARACTERIZING THE MUTATIONAL LANDSCAPE OF FOLLICULAR LYMPHOMA AT DIAGNOSIS AND RELAPSE: INSIGHTS FROM MSK-IMPACT NEXT GENERATION SEQUENCING PLATFORM	Alfredo Rivas-Delgado	Received

P-1272	THE MULTIKINASE CDK4/6 INHIBITOR NARAZACICLIB OVERCOMES BTK-I RESISTANCE IN MANTLE CELL LYMPHOMA BY TARGETING USP24-P53 SIGNALING AXIS	Gaël Roué	Received

P-1273	CELL-FREE DNA GENOMIC AND FRAGMENTOMIC FEATURES FOR EARLY OUTCOME PREDICTIONS IN DIFFUSE LARGE B-CELL LYMPHOMA	Steven Wang	Received

P-1275	HIGH MYELOID DERIVED SUPPRESSOR CELLS AND HYPERACTIVATED T CELLS SHOW IMPAIRED IMMUNE FUNCTION YEARS AFTER THERAPY IN DLBCL SURVIVORS	Giulia Benintende	Received

P-1276	ONE-THIRD OF MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA CASES ARE PRECEDED BY A PROLONGED MONOCLONAL B-CELL LYMPHOCYTOSIS-LIKE PRECURSOR PHASE	Pieter Martijn Kolijn	Received

P-1277	ACTIVATION-INDUCED CYTIDINE DEAMINASE CAUSES RECURRENT SPLICING MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA	Pedro Medina	Received

P-1278	DISSECTING THE SINGLE-CELL LANDSCAPE OF LEUKEMIC MANTLE CELL LYMPHOMA	Hosna Baniadam	Received

P-1285	TGF-?1 ACTIVATING ANTIBODIES AS A TREATMENT FOR GRAFT-VERSUS-HOST DISEASE	Séverine Wautier	Received

P-1287	QUIZARTINIB SENSITISES HEMATOPOIETIC PROGENITORS TO DNA DAMAGING THERAPIES VIA DOWNREGULATION OF DNA DAMAGE REPAIR GENES	Samuel Taylor	Received

P-1289	A MURINE NON-CONDITIONED BONE MARROW TRANSPLANTATION MODEL TO INVESTIGATE CLONAL HEMATOPOIESIS AND MYELOID MALIGNANCIES	Sofia Bentivegna	Received

P-1290	HEREDITARY ALLELIC VARIATION IN THE APOE GENE AND POST-TRANSPLANTATION OUTCOMES IN ACUTE MYELOID LEUKEMIA	Julian Ronnacker	Received

P-1291	STUDY OF HUANGQIN DECOCTION IN TREATING INTESTINAL AGVHD BY REGULATING INTESTINAL MICROFLORA FOR ANTI-INFLAMMATION AND INTERVENTION IN AUTOPHAGY	xing cui	Received

P-1293	ACCESS ALL AREAS: ACUTE GVHD UNLOCKS ACCESS TO THE TISSUES FOR INVADING OLIGOCLONAL T CELLS AND DONOR MYELOID CELLS	Callum Wright	Received

P-1294	C-KIT X CD16A X CD47 SWITCH-DARPIN WITH CONDITIONAL BLOCKADE OF CD47: A NEXT-GENERATION TARGETED CONDITIONING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION	Alexander Link	Received

P-1295	LACTATE INDUCES TH1 RESPONSE IN ACUTE GRAFT-VERSUS-HOST DISEASE	Hengwei Wu	Received

P-1297	NGS-MRD IMPROVES RELAPSE PREDICTION IN PATIENTS TRANSPLANTED FOR ACUTE LYMPHOBLASTIC LEUKEMIA WITH POSITIVE-NON-QUANTIFIABLE QPCR MRD RESULTS	Krystof Seferna	Received

P-1298	ASSOCIATION BETWEEN INFUSED CD34+ CELL DOSE AND OUTCOMES IN AUTOHCT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA	Oren Pasvolsky	Received

P-1300	EPSTEIN-BARR VIRUS REACTIVATION ACCELERATE IMMUNE RECONSTITUTION AFTER HAPLO-PERIPHERAL BLOOD STEM CELL TRANSPLANTATION	Wan Liping	Received

P-1301	BROADENING ELIGIBILITY FOR HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN LYMPHOMA; SINGLE CENTRE EXPERIENCE OF CONDITIONING WITH ETOPOSIDE AND MELPHALAN.	Harriet Ambrose	Received

P-1302	IMPACT OF INSUFFICIENT TOTAL NUCLEATED CELL COUNT ON BONE MARROW TRANSPLANTATION	Shinsuke Kusakabe	Received

P-1303	IMPACT OF CONDITIONING INTENSITY ON VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME SEVERITY AND OUTCOMES IN ADULT HEMATOPOIETIC CELL TRANSPLANT PATIENTS: RESULTS FROM THE DEFIFRANCE REGISTRY	Mohamad Mohty	Received

P-1305	DISTRIBUTION AND OUTCOMES ACCORDING TO WHO 2016, 2022 AND ICC IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Jacob Jendro	Received

P-1306	DELETIONS OF COMPLEMENT FACTOR H-RELATED GENES CFHR1 AND CFHR3 AND CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	Lars Klingen Gjærde	Received

P-1307	COMPARATIVE STUDY ON THE EFFECT OF DIFFERENT INFUSION FREQUENCIES OF UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS ON SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Tao Wang	Received

P-1308	NOVEL CONDITIONING REGIMEN IN UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T CELL LYMPHOMA	Jiexian Ma	Received

P-1309	CLINICAL UTILITY OF NGS HAPLOTYPE-BASED MIXED CHIMERISM DETECTION IN POST ALLOGENEIC STEM CELL TRANSPLANT PATIENTS WITH MYELOID NEOPLASMS	Constantine Logothetis	Received

P-1310	OUTCOMES OF MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT WITH SUBOPTIMAL PRE-TRANSPLANT RESPONSE	Oren Pasvolsky	Received

P-1312	EFFECT OF EARLY POST-HEMATOPOIETIC STEM CELL TRANSPLANT TACROLIMUS CONCENTRATION ON TRANSPLANT OUTCOMES IN PEDIATRIC RECIPIENTS: ONE FACILITY´S TEN-YEAR EXPERIENCE.	Natalia Maximova	Received

P-1313	DONOR-DERIVED DEL(20Q) CLONE POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY PROVIDE LONG-TERM SURVIVAL BENEFITS	Tong Wang	Received

P-1314	IMPACT OF DAY 11 METHOTREXATE DOSE ADJUSTMENTS ON OUTCOMES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT IN THE SETTING OF ANTI THYMOCYTE GLOBULIN (ATG) BASED GVHD PROPHYLAXIS	Vinita Dhir	Received

P-1315	ALLOGENEIC TRANSPLANT FOR CLL RICHTER´S TRANSFORMATION: SINGLE CENTER RETROSPECTIVE ANALYSIS	Alejandro Velarde	Received

P-1316	RECENT INFECTION WITH SARS-COV-2 IN DONORS WAS ASSOCIATED WITH A HIGHER INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE IN RECIPIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.	Fan Lin	Received

P-1317	LONG TERM OUTCOMES OF CONSOLIDATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)	Muzaffar H. Qazilbash	Received

P-1318	OPTIMIZING ALTERNATIVE DONOR SELECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE IMPACT OF HAPLOIDENTICAL DONOR AGE ON TRANSPLANTATION OUTCOMES COMPARED TO UMBILICAL CORD BLOOD	Takashi Nagayama	Received

P-1319	ONE-DAY CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH GRAFT FAILURE: A SINGLE-CENTER EXPERIENCE	Nihar Desai	Received

P-1321	AXATILIMAB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: RESPONSES IN FIBROSIS-DOMINANT ORGANS IN AGAVE-201	Tricia Fleming	Received

P-1322	FEMALE-TO-MALE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AFFECTS SURVIVAL OUTCOMES DIFFERENTLY ACCORDING TO THE TYPE OF HAPLO-IDENTICAL TRANSPLANTATION	Masaharu Tamaki	Received

P-1323	MESENCHYMAL STEM CELL TREATMENT FOR INTESTINAL ACUTE GVHD COEXISTING WITH MICROANGIOPATHY	Tomoki Naito	Received

P-1324	SALVAGE HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH UNRELATED CORD BLOOD ENHANCES SURVIVAL AND REDUCES THE INCIDENCE OF GRADE III-IV AGVHD FOR NON-REMISSION ACUTE MYELOID LEUKEMIA	Jing Long	Received

P-1325	LOW-INTENSITY VENETOCLAX-BASED PRECONDITIONING FOLLOWED BY SEQUENTIAL ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROMES	Andrius Žucenka	Received

P-1326	POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN PAEDIATRIC PATIENTS: THE IRISH PERSPECTIVE	Alanna Allen	Received

P-1327	OUTPATIENT NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A VIABLE APPROACH	Ana Margarida Rebelo	Received

P-1328	IMPACTS OF DONOR AGE AND HLA DISPARITY ON SURVIVAL OUTCOMES AFTER UNRELATED ALLO-HCT WERE SIGNIFICANTLY INFLUENCED BY DONOR CMV SEROSTATUS	Shunto Kawamura	Received

P-1329	PATIENT TELOMERE LENGTH AND PROGNOSTIC INSIGHTS IN ALLO-HSCT FOR MALIGNANT HEMATOLOGIC DISEASES	Hengwei Wu	Received

P-1330	EFFECTIVENESS OF ORAL RUXOLITINIB FOR ACUTE GVHD PROPHYLAXIS AFTER HAPLOIDENTICAL BONE MARROW TRANSPLANTATION IN PATIENTS WITH SEVERE APLASTIC ANEMIA: A PHASE ?,SINGLE-CENTER, SINGLE-COHORT, PROSPECTIVE CLINICAL TRIAL	Yan Yang	Received

P-1331	COMPARISON OF BUSULFAN-BASED MYELOABLATIVE CONDITIONING WITH CYCLOPHOSPHAMIDE VERSUS FLUDARABINE FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS.	Tetsuhiro Masaki	Received

P-1332	DUAL T-CELL DEPLETION WITH ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME	Dong Hyun Kim	Received

P-1333	IMPROVED OUTCOMES IN ADOLESCENTS AND ADULTS WITH THALASSAEMIA MAJOR USING MODERN TRANSPLANTATION TECHNIQUES COMBINED WITH IMPROVED PRE-TRANSPLANT CONDITION	Jianyun Liao	Received

P-1334	CURRENT USE OF DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENIC STEM CELL TRANSPLANTATION: A SURVEY ON BEHALF OF THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE EBMT	Christoph Schmid	Received

P-1335	THE PREDICTIVE VALUE OF T-CELL CHIMERISM FOR DISEASE RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Fang Zhou	Received

P-1338	COMPARABLE OUTCOMES AFTER HAPLOIDENTICAL AND HLA-MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOID SARCOMA	Jie Sun	Received

P-1341	IMPROVED SURVIVAL OF PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION WITH ATG AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE GVHD PROPHYLAXIS	Nihar Desai	Received

P-1342	REAL-WORLD EXPERIENCE OF BELUMOSUDIL TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER THE FAILURE OF MULTIPLE LINES OF THERAPY: A CANADIAN EXPERIENCE	Nihar Desai	Received

P-1343	DECODING THE IMPACT OF G-CSF ON MAIT CELLS IN BONE MARROW AND PERIPHERAL GRAFTS BY SINGLE-CELL RNA-SEQ	Mengge Gao	Received

P-1344	OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION AFTER GVHD PROPHYLAXIS WITH REDUCED ANTI-T LYMPHOCYTE GLOBULIN DOSES	Jakob Zillinger	Received

P-1346	CYTOKINE RELEASE SYNDROME IN HAPLOIDENTICAL PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANT. AN UNDERESTIMATED RISK FOR TRANSPLANT-RELATED MORTALITY?	Samih Salih	Received

P-1347	COUNTING ON RECOVERY: MONOCYTE RECOVERY AS A SURROGATE MARKER IN ALLOGENEIC STEM CELL TRANSPLANTS	Tommy Alfaro Moya	Received

P-1348	INTENSITY OF CONDITIONING BUT NOT MEASURABLE RESIDUAL DISEASE STATUS IMPACTS THE OUTCOMES OF UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH ACUTE LEUKAEMIA	Ka Lok Luke Chan	Received

P-1349	LYMPHOCYTE RECOVERY IS STILL A VITAL PROGNOSTIC TOOL IN POST-TRANSPLANT CYCLOPHOSPHAMIDE ERA	Tommy Alfaro Moya	Received

P-1350	COMPARISON OF INCIDENCE AND CLINICAL CHARACTERISTICS OF GRAFT VERSUS HOST DISEASE AMONG RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION FROM IDENTICAL VS HAPLOIDENTICAL DONORS IN COLOMBIA	Yirdley Gisella Sandoval Vargas	Received

P-1355	THE EFFICACY AND SAFETY OF AUTO FECAL MICROBIOTA TRANSPLANTATION FOR GVHD PROPHYLAXIS IN PATIENTS WITH HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION	Yin Liu	Received

P-1357	LOW-DOSE DEFIBROTIDE TREATMENT FOR HIGH-RISK TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE OBSERVATIONAL STUDY	Xiao-Hui Zhang	Received

P-1358	AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA. A REAL-WORLD EXPERIENCE FROM THE ARGENTINE GROUP FOR BONE MARROW TRANSPLANTATION AND CELL THERAPY (GATMO-TC)	Ana Romina Montivero	Received

P-1359	A SINGLE CENTER´S EXPERIENCE: THE IMPACT OF GRAFT IMMUNE COMPOSITION ON IMMUNE RECOVERY AND TRANSPLANT OUTCOME	angela carobene	Received

P-1360	THE EFFECT OF LYMPHOCYTE SUBSETS IN ALLOGENEIC BONE MARROW TRANSPLANTATION ON RELAPSE, GRAFT VERSUS HOST DISEASE AND SURVIVAL: A SINGLE-CENTER EXPERIENCE	Pelin Ozturk	Received

P-1361	IMPACT OF BASELINE RENAL FUNCTION ON HAPLOIDENTICAL STEM CELL TRANSPLANTATION OUTCOMES	Samer Srour	Received

P-1363	CYTOMEGALOVIRUS (CMV) REACTIVATION POST ALLOGENEIC STEM CELL TRANSPLANT (ALLO-SCT) IN THE LETERMOVIR ERA- THE GREEK TRANSPLANT EXPERIENCE: IS IT ADEQUATE AND UNTIL WHEN?	Sotirios Bristogiannis	Received

P-1364	MAINTENANCE THERAPY WITH ORAL DECITABINE PLUS CEDAZURIDINE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME	Portia Smallbone	Received

P-1367	BETTER PRE-TRANSPLANT TREATMENT OPTIONS FOR TP53-MUTATED MDS: CYTOREDUCTIVE OR NON-CYTOREDUCTIVE THERAPY?	Bingqian Jiang	Received

P-1369	ADMINISTRATION OF MELFALAN IN TWO DAYS (VS. ONE) ALONG WITH THE USE OF PROPHYLACTIC G-CSF AND ANTIBIOTICS IS ASOCIATED WITH A REDUCED RISK OF MUCOSITIS IN PATIENTS UNDERGOING ASCT FOR MULTIPLE MYELOMA	Irene Francés Alexandre	Received

P-1370	A PROSPECTIVE STUDY OF PTCY AS GVHD PROPHYLAXIS AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION USING LIPOSOME MITOXANTRONE IN COMBINATION WITH BUSULFAN AND FLUDARABINE CONDITIONING	Ruju Wang	Received

P-1371	PREDICTORS OF SURVIVAL AND SUCCESSFUL RESPONSE TO UPFRONT UC-MSC TREATMENT IN ACUTE GVHD PATIENTS: FINDINGS FROM A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED MULTICENTRE CLINICAL TRIAL	Nurul Natasha Mohd Anuar	Received

P-1372	EXPLORING THE PROGNOSTIC VALUE OF PROGNOSTIC NUTRITIONAL INDEX AND SYSTEMIC IMMUNE-INFLAMMATION INDEX IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	XiaoLi Chen	Received

P-1373	OLUTASIDENIB AS BRIDGE-TO-TRANSPLANT TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MIDH1 ACUTE MYELOID LEUKEMIA (AML)	Stéphane De Botton	Received

P-1374	PERIPHERAL BLOOD STEM CELL COLLECTION IN ALLOGENEIC DONORS: HOW TO PREDICT CD34+ COUNT IN PRODUCT.	Tigran Torosian	Received

P-1375	A SINGLE CENTER EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN AGED POPULATION.	Didier Blaise	Received

P-1378	CARDIAC TOXICITY AFTER ALLO-HCT IN PATIENTS WITH AML TREATED WITH PTCY-BASED PROPHYLAXIS. STUDY CONDUCTED ON BEHALF OF THE GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR (GETH-TC)	Maria Queralt Salas	Received

P-1380	DIFFERENTIATING ERYTHROBLASTS ADAPT TO TURBULENT FLOW BY ACCELERATING MATURATION AND ACTIVATING CHOLESTEROL BIOSYNTHESIS	Giulia Iacono	Received

P-1381	LOSS OF SFRP1 IN NICHE CELLS AND ITS IMPACT ON THE HEMATOPOIESIS	Emely Schönhals	Received

P-1383	THE SELECTIVE ADVANTAGE OF TET2-/- HSC IS ASSOCIATED WITH AN EPIGENETIC SWITCH AT TRANSPOSABLE ELEMENTS THAT PROTECTS THEM FROM CHRONIC INFLAMMATION.	Anne STOLZ	Received

P-1388	HETEROGENEOUS STROMAL POPULATIONS CHARACTERIZE THE BONE MARROW MICROENVIRONMENT IN B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA	Mauricio Ferrao Blanco	Received

P-1389	UNRAVELING THE IMPACT OF STAG2 MUTATIONS IN MDS AND AML.	Eve Dias	Received

P-1390	COMPREHENSIVE IDENTIFICATION OF PLEIOTROPIC ASSOCIATIONS FOR CLONAL HAEMATOPOIESIS OF INDETERMINATE POTENTIAL.	Esther Hazane Leroyer	Received

P-1391	BRIQUILIMAB POTENTLY INHIBITS SCF/C-KIT SIGNALING, WHICH DOES NOT INDUCE HEALTHY HUMAN HEMATOPOIETIC STEM CELL (HSC) APOPTOSIS, BUT SKEWS HSC DIFFERENTIATION POTENTIAL.	Hye-Sook Kwon	Received

P-1392	THE ROLE OF STATHMIN-1 IN MITOCHONDRIAL AND CELLULAR FUNCTION IN HEMATOPOIETIC STEM CELLS	Luana Chiquetto	Received

P-1393	CRACKING THE BIOELECTRICAL CODE OF LEUKEMIC MSCS TO REROUTE BONE MARROW MICROENVIRONMENT	Ambra Da Ros	Received

P-1394	ACTIVATION OF PPAR? IN BONE MARROW ENDOTHELIAL PROGENITOR CELLS REPAIRS THEIR HEMATOPOIESIS-SUPPORTING ABILITY AFTER MYELOSUPPRESSIVE INJURY	Mi Liang	Received

P-1395	BEMCENTINIB, AN AXL INHIBITOR, OVERCOMES MICROENVIRONMENT-MEDIATED RESISTANCE TO THE ANTI-LEUKEMIC ACTIVITY OF PIOGLITAZONE.	Valérie Bardet	Received

P-1397	NOVEL 3D CULTURE MODELS FOR STUDYING MYELOID NEOPLASIA	Sigrid Uxa	Received

P-1399	OPTIMIZATION AND APPLICATION OF MULTI-PRIME EDITING IN THE THERAPEUTIC APPROACH FOR GATA2 DEFICIENCY	ZHICHAO QIU	Received

P-1400	TARGETING THE ZAK?/P38/NLRP1 AXIS AS A NOVEL THERAPEUTIC STRATEGY FOR HEMATOPOIETIC DISORDERS ASSOCIATED WITH CHRONIC INFLAMMATION AND CONGENITAL ANEMIAS	Juan M Lozano-Gil	Received

P-1401	DECIPHERING THE EMERGENCE OF ERYTHRO-MYELOID PROGENITORS IN THE MOUSE YOLK SAC	Michaela Šímová	Received

P-1403	EVALUATION OF RED BLOOD CELL DISTRIBUTION WIDTH (RDW) AND MEAN CORPUSCULAR VOLUME (MCV) IN A CASE-COHORT STUDY OF HEALTHY SUBJECTS IN RELATION TO CANCER DIAGNOSIS.	Carmen Julia Tartari	Received

P-1404	MYELOID LINEAGE COMMITMENT INSTRUCTED BY LMO4-MEDIATED GATA FACTOR REDISTRIBUTION AT THE CHROMATIN	Alexandre Fagnan	Received

P-1405	MESENCHYMAL STROMAL CELLS FROM INDIVIDUALS WITH DNMT3AMUT CLONAL HEMATOPOIESIS ACTIVELY SIGNAL TOWARDS HEALTHY HEMATOPOIETIC STEM/PROGENITOR CELLS SUPPRESSING THEIR CYCLING CAPACITY	Anna Navarro Figueredo	Received

P-1406	IDENTIFICATION AND MAINTENANCE OF QUIESCENT HUMAN FETAL LIVER HEMATOPOIETIC STEM CELLS IN VITRO WITH FLT3-LIGAND	Margarita MacAldaz	Received

P-1408	SINGLE-CELL RESOLVED LONGITUDINAL CLONAL DYNAMICS IN HUMAN HEMATOPOIESIS AND REGENERATION	Lena Nitsch	Received

P-1410	LONG-TERM EX VIVO HAEMATOPOIETIC STEM CELL (HSC) EXPANSION USING BONE-DERIVED REINVIGORATING MESENCHYMAL STEM CELLS (RMSCS).	Sonia Fernández Torices	Received

P-1411	CD21 CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)	Nicola Maciocia	Received

P-1413	PRE-CLINICAL DEVELOPMENT OF AZD5492, A CD8-GUIDED T CELL ENGAGER, FOR B-NON HODGKIN LYMPHOMA INDICATIONS	Corinne Cayatte	Received

P-1414	GENETIC POLYMORPHISMS AND CLINICAL PARAMETERS ASSOCIATED WITH METHOTREXATE TOXICITY IN THAI ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCY RECEIVING HIGH-DOSE METHOTREXATE-CONTAINING REGIMENS	Palada Pitakkitnukun	Received

P-1416	PRECLINICAL DEVELOPMENT OF A CARLY3, A NEW CAR-T TREATMENT BASED ON CD79B FOR PATIENTS WITH NON-HODGKIN LYMPHOMA	Beatriz Martín-Antonio	Received

P-1417	AN ALLOGENIC, NON-VIRAL, DOUBLE SITE KNOCK-IN CAR-T TARGETING CD19 AND BCMA	Huan Shi	Received

P-1418	DEVELOPMENT OF ANTI-CD21 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR T CELL ACUTE LYMPHOBLASTIC LEUKEMIA – CAR ENGINEERING FOR TARGETING A COMPLEX ANTIGEN.	Nicola Maciocia	Received

P-1419	CAR T-CELL THERAPY TARGETING CD84 ALONE OR IN COMBINATION WITH CD19 FOR THE TREATMENT OF B-CELL MALIGNANCIES	Ane Altuna	Received

P-1420	CAR T CELLS RESIDE IN THE BONE MARROW AND INHIBIT HEMATOPOIESIS	Camille Bigenwald	Received

P-1421	LONGITUDINAL SINGLE CELL MULTIOMIC ANALYSIS ALLOW THE IDENTIFICATION OF MECHANISM OF PERSISTENCE AND RESISTANCE TO CAR-T CELLS IN MM	Lorea Jordana Urriza	Received

P-1422	WU-NK-101 IS AN OFF-THE-SHELF MEMORY NK CELL WITH A TME-RESILIENT, ANTI-TUMOR PHENOTYPE THAT CAN BE DETECTED IN R/R AML PATIENT PBMC AFTER INFUSION	Sergio Rutella	Received

P-1423	THE DIVERSITY AND COMPOSITION OF THE T CELL REARRANGEMENT REPERTOIRE IS ASSOCIATED WITH PROGNOSIS IN MULTIPLE MYELOMA PATIENTS TREATED WITH CAR-T CELL THERAPIES	Alejandro Medina-Herrera	Received

P-1424	A NOVEL NANOPARTICLE-BASED IMMUNOTHERAPY FOR ITTP. AUTOANTIGEN-LOADED LIPOSOMES TO RESTORE SELF-TOLERANCE	Daniela Greco	Received

P-1425	REAL-WORLD MANUFACTURING EXPERIENCE OF AXICABTAGENE CILOLEUCEL FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA TREATED IN SECOND LINE VERSUS THIRD LINE OF THERAPY AND BEYOND	Jason Westin	Received

P-1426	CORRELATIONS BETWEEN (CAR) T-CELL METABOLIC AND PHENOTYPICAL STATE AND CLINICAL OUTCOME OF CAR T-CELL THERAPY FOR LARGE B-CELL LYMPHOMA	Chaja F Jacobs	Received

P-1427	ACQUISITION OF AN IMMUNOSUPPRESSIVE MICROENVIRONMENT AFTER CD19 CAR T CELL TREATMENT IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA	Marianna Ponzo	Received

P-1429	SENESCENCE AND INFLAMMATION ARE ADVERSE UNCHARTED BARRIERS TO EFFICIENT CRISPR-CAS9 GENE-EDITING IN HEMATOPOIETIC STEM CELLS	Anastasia Conti	Received

P-1430	DIFFERENTIAL EXPRESSION OF COMPLEMENT-INTERFERON LOOP BEFORE CART THERAPY IN PATIENTS THAT DEVELOP CYTOKINE RELEASE SYNDROME	Maria georgia Koutra	Received

P-1431	TRANSCRIPTOMIC SIGNATURES IN T-CELLS COULD HELP TO PREDICT RESPONSE TO CAR T-CELLS IN PATIENTS WITH AGGRESSIVE B CELL LYMPHOMA	Ismael De La Iglesia San Sebastián	Received

P-1433	ADI-270: AN ARMORED ALLOGENEIC ANTI-CD70 CAR GAMMA-DELTA T CELL THERAPY DESIGNED FOR MULTIPLE SOLID AND HEMATOLOGICAL CANCER INDICATIONS	Shon Green	Received

P-1434	SPECIFIC AND PERSONALISED TARGETING OF ANTI-ADAMTS13 AUTOREACTIVE B CELLS IN IMMUNE-MEDIATED TTP USING SWITCHABLE REVCAR T CELLS.	Rutuja Gupte	Received

P-1435	PREVALENCE, ETIOLOGY, AND OUTCOME OF DELAYS BETWEEN INITIATION OF LYMPHODEPLETING CHEMOTHERAPY AND CAR T CELL INFUSION	Yannis Valtis	Received

P-1436	CIRCULATING T LYMPHOCYTE SUBSETS ON DAY +7 AFTER VARNIMCABTAGENE AUTOLEUCEL (ARI-0001) IN B-CELL NON-HODGKIN LYMPHOMA ARE ABLE TO PREDICT EFFICACY AND TOXICITY	Andrea Rivero Arango	Received

P-1437	LONG TERM SURVIVAL IN AML PATIENTS AFTER IMMUNOTHERAPY WITH VIDIDENCEL CORRELATES WITH FUNCTIONAL T AND B-CELL RESPONSES	Arjan van de Loosdrecht	Received

P-1438	INATICABTAGENE AUTOLEUCEL(CNCT19) IN RELAPSED OR REFRACTORY B-CELL LYMPHOMA: RESULTS OF A PHASE I CLINICAL TRIAL	Wei Liu	Received

P-1439	DENDRITIC CELL-BASED VACCINES (KSD-101) AGAINST EBV-ASSOCIATED HEMATOLOGIC NEOPLASMS: RESULTS FROM AN ONGOING PHASE I CLINICAL STUDY	Chunrui Li	Received

P-1440	IMPLICATIONS OF CAR T CELL REFERRAL AND APHERESIS DELAYS ON OUTCOMES AND TOXICITY IN LYMPHOMA PATIENTS	Alexander Boardman	Received

P-1441	IMMUNE RECONSTITUTION FOLLOWING CD19 CAR-T FOR R/R B-NHL IS ASSOCIATED WITH IMPROVED SURVIVAL OUTCOMES AND IS IMPAIRED AT TIME OF POST-CAR-T PROGRESSION	Sophia Stock	Received

P-1442	IMMUNOGENETIC PROFILING OF EX VIVO GENERATED PATHOGEN-SPECIFIC T CELLS FOR IMMUNOTHERAPY OF OPPORTUNISTIC INFECTIONS POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	Chrysa Pantazi	Received

P-1445	FREQUENCY OF CAR-T CELL MANUFACTURING FAILURES AND OUT-OF-SPECIFICATION PRODUCTS IN THE REAL-WORLD SETTING: A SURVEY FROM THE EBMT CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY (CTIWP)	Nina Worel	Received

P-1446	CAR-HEMATOTOX SCORE PREDICTS OVERALL SURVIVAL IN LARGE B-CELL LYMPHOMAS TREATED WITH ANTI-CD19 CAR T-CELLS: A SUBGROUP ANALYSIS OF CART-SIE	Federico Stella	Received

P-1448	LONG TERM FOLLOW-UP RESULTS OF BRL-201 PHASE I STUDY, A CRISPR-BASED NON-VIRAL PD-1 LOCUS SPECIFIC INTEGRATED ANTI-CD19 CAR-T CELLS IN TREATING RELAPSED OR REFRACTORY NON-HODGKIN´S LYMPHOMA	Biao Zheng	Received

P-1449	CAR T TREATMENT ACCESS AND OUTCOMES IN PATIENTS WITH LARGE B-CELL LYMPHOMA ACCORDING TO ETHNICITY AND SOCIOECONOMIC DEPRIVATION IN THE UK	Oana Diana Dragoi	Received

P-1450	CHANGING THE NATURAL HISTORY OF PYRUVATE KINASE DEFICIENCY WITH LENTIVIRAL-MEDIATED GENE THERAPY: RESULTS OF A GLOBAL PHASE 1 STUDY	Bhranti Shah	Received

P-1451	EARLY AND LATE INTRODUCTION OF CAR T-CELL THERAPY IN LARGE B-CELL LYMPHOMA HAVE COMPARABLE TOXICITY AND EFFICACY OUTCOMES	Magdalena Corona de Lapuerta	Received

P-1452	TWO-YEAR FOLLOW-UP RESULTS OF C-CAR066, A NOVEL ANTI-CD20 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA PATIENTS AFTER FAILURE OF CD19 CAR-T THERAPY	Dehui Zou	Received

P-1454	FIRST RESULTS OF A COMPREHENSIVE PROSPECTIVE PROTOCOL OF RADIOTHERAPY BRIDGING AND CONSOLIDATION FOR CAR T IN LARGE B-CELL LYMPHOMA (RESTART)	Christianne Bourlon	Received

P-1455	CLINICAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA TREATED WITH TISAGENLECLEUCEL: PHASE 2 ELARA 3-YEAR FOLLOW-UP	Martin Dreyling	Received

P-1456	ASSOCIATION BETWEEN BODY MASS INDEX AND OUTCOMES OF CAR-T THERAPY ACROSS HEMATOLOGIC MALIGNANCIES	Yannis Valtis	Received

P-1457	AFTER PROPENSITY SCORE WEIGHTING AXICABTAGENE CILOLEUCEL CONFER SUPERIOR PROGRESSION-FREE SURVIVAL COMPARED TO TISAGENLECLEUCEL IN LARGE B-CELL LYMPHOMAS: FINAL RESULTS OF THE ITALIAN CART-SIE STUDY	Federico Stella	Received

P-1458	LONG-TERM DURABLE RESPONSES IN PATIENTS WITH R/R ALL, DLBCL, AND FL TREATED WITH TISAGENLECLEUCEL AND ITS ASSOCIATION WITH PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS	Rakesh Awasthi	Received

P-1459	FIRST REAL-WORLD EXPERIENCE OF COMMERCIAL RELMACABTAGENE AUTOLEUCEL (RELMA-CEL) FOR RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA: A MULTICENTER RETROSPECTIVE ANALYSIS OF PATIENTS IN CHINA	Wenyan Yu	Received

P-1461	HIGH EFFICACY AND FAVORABLE SAFETY OF CD20-TARGETED CAR-T THERAPY FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL)	Brian Till	Received

P-1462	HEMATOPOIETIC STEM CELL GENE THERAPY FOR HURLER SYNDROME: INTERIM SKELETAL, NEUROLOGICAL AND SYSTEMIC OUTCOMES	Maria Ester Bernardo	Received

P-1463	CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IS FEASIBLE IN PATIENTS 80 YEARS OF AGE OR OLDER WITH B-CELL LYMPHOMA: A US MULTICENTER COLLABORATIVE STUDY	Julio C Chavez	Received

P-1466	ALLOGENIC STEM CELL TRANSPLANT (SCT) AFTER CAR-T CELL THERAPY FOR RELAPSE OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN PEDIATRIC PATIENTS. A SINGLE CENTER EXPERIENCE	Anna Alonso-Saladrigues	Received

P-1467	SINGLE CELL ANALYSIS REVEALS THAT T CELLS AND MONOCYTES CONTRIBUTE TO RESPONSE AND EARLY PROGRESSION RESPECTIVELY IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH PEMBROLIZUMAB	Zhi-Zhang Yang	Received

P-1468	COMPARABLE OUTCOMES OF CD19-TARGETING CAR-T THERAPY IN TRANSFORMED FOLLICULAR LYMPHOMA AND DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA	Alfredo Rivas-Delgado	Received

P-1470	EXPLORING PATIENT CHARACTERISTICS AND CLONAL EVOLUTION IN POST CAR-T MYELOID NEOPLASMS	Francesca Sillito	Received

P-1471	PHASE I STUDY OF AN ANTI-CD7 UNIVERSAL CAR-T THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY CD7 POSITIVE T-ALL/LBL	Bian Kangqi	Received

P-1472	CD7 CAR-T THERAPY FOR PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHO RELAPSED AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	Xingyu Cao	Received

P-1474	TARGETING OPPORTUNISTIC INFECTIONS POST ALTERNATIVE-DONOR HEMATOPOIETIC CELL TRANSPLANTATION WITH PATHOGEN-SPECIFIC T CELLS	Anastasia Papadopoulou	Received

P-1475	C-CAR039, A NOVEL ANTI-CD20/CD19 BI-SPECIFIC CAR T-CELL THERAPY SHOWS DEEP AND DURABLE CLINICAL BENEFITS IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA IN LONG TERM FOLLOW UP	Aibin Liang	Received

P-1477	CAR T-CELL THERAPY BRIDGING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA	Zhiyong Peng	Received

P-1479	ROBUST AUTOLOGOUS CD34+ HSPC MANUFACTURING WITH A CLOSED AND AUTOMATED PROCESS OPTIMIZED FOR PATIENTS WITH SICKLE CELL DISEASE	Paul Kopesky	Received

P-1480	A NOVEL ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE ENHANCES HUMAN AND MOUSE ENZYMATIC ACTIVITY AND LEADS TO HEMATOLOGICAL IMPROVEMENTS IN SICKLE CELL DISEASE MOUSE MODELS	Mira Pochron	Received

P-1481	GMI-1687-101, A PHASE 1A FIRST IN HUMAN TRIAL OF SECOND-GENERATION E-SELECTIN ANTAGONIST GMI-1687	Jay Lozier	Received

P-1482	FACTORS DRIVING PARTICIPATION IN CLINICAL TRIALS AMONG PEOPLE WITH SICKLE CELL DISEASE DIFFER IN IMPORTANCE ACROSS GEOGRAPHIC REGIONS: FINDINGS FROM THE GLOBAL LISTEN SURVEY	Raffaella Colombatti	Received

P-1483	ADHERENCE, TREATMENT USE, AND CLINICAL OUTCOMES IN PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES TREATED WITH L-GLUTAMINE, VOXELOTOR, OR CRIZANLIZUMAB IN THE UNITED STATES	Chuka Udeze	Received

P-1484	THE EFFECT OF RED BLOOD CELL EXCHANGE ON ECHOCARDIOGRAPHIC FINDINGS IN SCD	Jules M.Ross	Received

P-1485	CHANGES IN PHYSICAL, MENTAL, AND SOCIAL HEALTH OF ADULTS WITH SICKLE CELL DISEASE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: A MIXED-METHODS, PROSPECTIVE COHORT STUDY	Elisabeth Dovern	Received

P-1487	REAL-WORLD IMPLEMENTATION OF THE DAVID-CAROLL BUPRENORPHINE PROTOCOL FOR PAIN MANAGEMENT IN SICKLE CELL DISEASE	Najibah Galadanci	Received

P-1489	PHASE 1 STUDY OF SAFETY AND PHARMACOKINETICS OF CSL889 (HEMOPEXIN) IN ADULTS WITH SCD	Bart Biemond	Received

P-1490	ENHANCING SICKLE CELL CRISIS MANAGEMENT IN THE EMERGENCY DEPARTMENT: A MIXED-METHODS QUALITY IMPROVEMENT PROJECT	James Cai	Received

P-1491	IMPACT OF HYDROXYUREA ON CEREBRAL VASCULOPATHY IN CHILDREN WITH SICKLE CELL ANEMIA AFTER INITIATION FOR FREQUENT CRISES OR SEVERE ANEMIA IN ABSENCE OF ABNORMAL VELOCITIES AND ARTERIAL STENOSIS	Françoise Bernaudin	Received

P-1493	HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH SEVERE SICKLE CELL DISEASE	Haydar Frangoul	Received

P-1494	THE ROLE OF INDUCIBLE NITRIC OXIDE SYNTHASE IN HYDROXYUREA IMPAIRMENT OF ANGIOGENESIS	Teodora Dragojevic	Received

P-1495	PHYSICIANS´ PERCEPTIONS OF BARRIERS TO PRESCRIBING SICKLE CELL DISEASE TREATMENTS IN THE UNITED STATES	Aine Kyle	Received

P-1497	HEME-INDUCED NEUTROPHIL GASDERMIN-D ACTIVATION IS SUPPRESSED BY INTERLEUKIN-27 IN SICKLE CELL DISEASE	Adekunle Alagbe	Received

P-1498	VACUOLES OF RED CELLS IN ASPLENIA: MERE REMAINS OR ENCHANTED APPARITIONS (OR BOTH)?	Lucie Dumas	Received

P-1499	EFFECT OF VOXELOTOR ON CEREBRAL PERFUSION AND CEREBRAL OXYGENATION IN ADULT PATIENTS WITH SICKLE CELL DISEASE; 12 MONTH FOLLOW UP	Kadère Konté	Received

P-1501	CRYOPRESERVATION OF SICKLE RED BLOOD CELLS FOR COMPARISON OF OXYGENSCAN PARAMETERS BETWEEN LABORATORIES TO ENABLE DATA HARMONIZATION	Marissa Traets	Received

P-1502	EVALUATION OF LIVER IRON CONCENTRATION IN PATIENTS WITH SICKLE CELL DISEASE USING AUTOMATED DEEP-LEARNING ASSISTED ANALYSIS OF MAGNETIC RESONANCE IMAGES	Adlette Inati	Received

P-1503	RISK FACTORS FOR MULTIPLE ORGAN DAMAGES IN A COHORT OF INDIAN SICKLE CELL DISEASE PATIENTS	Nikhil Shinde	Received

P-1504	FACTORS LIMITING HYDROXYCARBAMIDE DOSING IN ADULTS WITH SCD. RESULTS FROM THE UK´S SICKLE NATURAL HISTORY STUDY	Michael Neale	Received

P-1505	DECIPHERING THE DIFFERENT MODELS OF VASO-OCCLUSIVE EVENTS: FIRST STEPS TOWARDS A PERSONALIZED APPROACH TO THE TREATMENT OF PAINFUL VASO-OCCLUSIVE CRISIS	Berengere Koehl	Received

P-1506	MORTALITY AND CLINICAL COMPLICATIONS AMONG PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VOCS IN CANADA	Lauren Lilly	Received

P-1507	TREATMENT UTILIZATION AND CLINICAL COMPLICATIONS IN PATIENTS WITH SICKLE CELL DISEASE RECEIVING FREQUENT RED BLOOD CELL TRANSFUSIONS IN THE UNITED STATES	Chuka Udeze	Received

P-1508	ALL-CAUSE ANAEMIA TRUMPS DEGREE OF HAEMOLYSIS AS A DETERMINANT OF QUALITY OF LIFE: THE UK MULTI-SITE SICKLE NATURAL HISTORY STUDY	Stella Jumoke Okikiolu	Received

P-1509	CO-INHERITANCE OF ?-THALASSEMIA IN HBSC DISEASE CORRELATES WITH INCREASED RED BLOOD CELL DEHYDRATION AND REDUCED CLINICAL COMPLICATIONS	Marissa Traets	Received

P-1510	INVESTIGATING INEFFECTIVE ERYTHROPOIESIS IN A PAEDIATRIC SICKLE CELL DISEASE COHORT	Margherita Di Mauro	Received

P-1512	MAPPING THE PRODROMAL STAGE OF VASO-OCCLUSIVE CRISES: A PATIENT EXPERIENCE AND WEARABLE BIOMETRICS-DRIVEN APPROACH	Kim Summers	Received

P-1513	THE EARLY MYELOID COMMITMENT OF HSPCS IN SICKLE CELL ANEMIA IS ASSOCIATED WITH ABERRANT DIFFERENTIATION TO THE MONOCYTIC LINEAGE	Berengere Koehl	Received

P-1514	EFFICACY AND SAFETY OF BRL-101, CRISPR-CAS9-MEDIATED GENE EDITING OF THE BCL11A ENHANCER IN TRANSFUSION-DEPENDENT ?ETA-THALASSEMIA	Biao Zheng	Received

P-1516	SAFETY DATA FROM THE DOSE-FINDING COHORTS: A PHASE 2A STUDY OF LUSPATERCEPT IN PEDIATRIC PATIENTS WITH ?ETA-THALASSEMIA	Antonis Kattamis	Received

P-1518	FREQUENCY, PATTERN, AND ASSOCIATIONS OF PANCREATIC IRON ACCUMULATION IN PEDIATRIC TRANSFUSION-DEPENDENT BETA-THALASSEMIA PATIENTS	Antonella Meloni	Received

P-1519	PHENOTYPIC CLUSTERING USING CARDIOVASCULAR MAGNETIC RESONANCE FOR RISK STRATIFICATION IN BETA-THALASSEMIA MAJOR	Antonella Meloni	Received

P-1520	EXPLORING THE REAL-LIFE EFFICACY AND SAFETY OF LUSPATERCEPT WITH A MIXED PATTERN STUDY	Yesim Aydinok	Received

P-1521	PROGNOSTIC ROLE OF MULTIPARAMETRIC CARDIAC MAGNETIC RESONANCE IN NEO TRANSFUSION-DEPENDENT THALASSEMIA	Antonella Meloni	Received

P-1522	CHARACTERIZING PATTERNS OF TRANSFUSION BURDEN (TB) REDUCTION IN PATIENTS (PTS) WITH TRANSFUSION-DEPENDENT (TD) ?ETA-THALASSEMIA TREATED WITH LUSPATERCEPT IN THE BELIEVE TRIAL	Kevin H.M. Kuo	Received

P-1523	ANALYSIS OF ERYTHROPOIESIS AND IRON METABOLISM IN A COHORT OF ?-THALASSEMIA PATIENTS TREATED WITH LUSPATERCEPT	Nicolò Tesio	Received

P-1524	UNRELATED DONOR TRANSPLANTATION OFFERS A REAL CURATIVE OPPORTUNITY FOR PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA. EXPERIENCE OF THE SPANISH GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN	Maribel Benítez Carabante	Received

P-1525	HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ?ETA-THALASSEMIA	Josu de la Fuente	Received

P-1526	IMMUNOPHENOTYPTIC ANALYSIS OF PBL FROM ??-THALASSEMIA/HEMOGLOBIN E PATIENTS FOLLOWING HYDROXYUREA THERAPY	Rattanawan Thubthed	Received

P-1527	TMPRSS6 INHIBITION RAPIDLY REVERSES LIVER IRON OVERLOAD AND SPLENOMEGALY IN THALASSEMIC MICE	Sarah Hatsell	Received

P-1528	AVAILABILITY AND USE OF IMAGING TECHNIQUES FOR MANAGEMENT OF HAEMOGLOBINOPATHIES IN ITALIAN NETWORK: PRELIMINARY RESULTS OF A SURVEY BY ITALIAN SOCIETY OF THALASSAEMIA AND HAEMOGLOBINOPATHIES (SITE)	Filomena Longo	Received

P-1530	PREDICTING AND EVALUATING RESPONSE TO LUSPATERCEPT IN TRANSFUSION-DEPENDENT ?-THALASSEMIA: NEW INSIGHT FROM A REAL-LIFE EXPERIENCE.	Daniele Lello Panzieri	Received

P-1531	IN VITRO MODELLING OF ?0-THALASSAEMIA: A CELLULAR PLATFORM ENABLING EXPERIMENTAL AND THERAPEUTIC INVESTIGATIONS	Jim Vadolas	Received

P-1532	TMPRSS6 INHIBITION IMPROVES BONE HEALTH IN B-THALASSEMIA MICE	Sarah Hatsell	Received

P-1533	GENOTYPE AND PHENOTYPE CORRELATION IN ?-THALASSEMIA IN GREECE: THE EXPERIENCE OF AN ADULT CENTER.	Maria Dimopoulou	Received

P-1534	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS BLOOD TRANSFUSION AND IRON CHELATION ON PATIENT QUALITY OF LIFE IN TRANSFUSION-DEPENDENT THALASSEMIA: A META-ANALYSIS OF OBSERVATIONAL STUDIES	Tsampika Vasileia Kalamara	Received

P-1536	REAL-WORLD EXPERIENCE OF IMMUNOCHEMOTHERAPY IN COLD AGGLUTININ DISEASE AND COLD AGGLUTININ SYNDROME	Femke Mulder	Received

P-1537	HEREDITARY STOMATOCYTOSIS (HST):EXPERIENCE IN A PEDIATRIC TERTIARY CARE CENTER IN ARGENTINA	Estefania Rossetti	Received

P-1539	DESCRIPTIVE ANALYSIS OF DRUG-INDUCED IMMUNE HEMOLYTIC ANEMIA REPORTED TO THE NATIONAL PHARMACOVIGILANCE DATABASE BETWEEN 2010 AND 2022.	Sylvain Audia	Received

P-1542	RILIPRUBART (SAR445088) IN COLD AGGLUTININ DISEASE: INTERIM ANALYSIS FROM PART 2 OF A LONG-TERM PHASE 1B TRIAL CONFIRMS ACCEPTABLE EFFICACY AND SAFETY WITH 12-WEEKLY IV ADMINISTRATION	Alexander Röth	Received

P-1543	BASELINE CHARACTERISTICS FROM THE FIRST INTERIM ANALYSIS OF CADENCE, THE COLD AGGLUTININ DISEASE (CAD) /COLD AGGLUTININ SYNDROME (CAS) REGISTRY	Marc MICHEL	Received

P-1544	EFFICACY OF SUTIMLIMAB STRATIFIED BY BASELINE HEMOGLOBIN IN PATIENTS WITH COLD AGGLUTININ DISEASE: A POST HOC ANALYSIS FROM CARDINAL AND CADENZA	Alexander Röth	Received

P-1545	OVERALL SURVIVAL OF PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA IN SWEDEN: A NATIONWIDE POPULATION-BASED STUDY	Honar Cherif	Received

P-1546	PROGNOSTIC AND THERANOSTIC RELEVANCE OF A SPLENOMIMETIC TOOL IN HEREDITARY SPHEROCYTOSIS	Alexis Lavergne	Received

P-1547	OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Moazzam Shahzad	Received

P-1548	EX VIVO GLYCOLYTIC FLUX MEASUREMENTS IN RED BLOOD CELLS FROM HEALTHY DONORS AND PATIENTS WITH ENZYMOPATHIES	Titine Ruiter	Received

P-1549	WHOLE EXOME SEQUENCING AND EX VIVO TWO-PHASE CULTURE SYSTEM REVEALED A NOVEL CNAN1 COMPOUND HETEROZYGOUS MUTATIONS IN PATIENTS WITH ALPHA-THALASSEMIA MINOR AND CONGENITAL DYSERYTHROPOIETIC ANEMIA	Yu-Hsuan Fu	Received

P-1550	EMBRYONIC ECTODERM DEVELOPMENT (EED) INHIBITOR APG-5918 IMPROVES CHRONIC KIDNEY DISEASE- (CKD)-INDUCED HEMOGLOBIN (HB) INSUFFICIENCY IN PRECLINICAL MODELS OF ANEMIA	Eric Liang	Received

P-1553	AUTOIMMUNE HEMOLYTIC ANEMIA ANTI-RBC IGM, BUT NOT IGG, ANTIBODIES DRIVE IN VITRO COMPLEMENT ACTIVATION IN FLOW INDIRECT ANTIGLOBULIN TEST (FLOW IAT)	Esther de Boer	Received

P-1554	DOES IRON OVERLOAD IN PATIENTS WITH THALASSEMIA AFFECT BONE MINERAL DENSITY ACQUISITION BY DUAL-ENERGY X-RAY ABSORPTIOMETRY AND ITS PRECISION?	Ali T. Taher	Received

P-1555	PEDIATRIC INTRAVENOUS IRON THERAPY: EVALUATING SAFETY AND EFFICACY OF IRON ISOMALTOSIDE	Sonata Saulyte Trakymiene	Received

P-1556	HYPOPHOSPHATEMIA AFTER INTRAVENOUS IRON: REAL-WORLD RESULTS IN 8,340 PATIENTS.	Khaled Atieh	Received

P-1559	COMBINATION THERAPY WITH LUSPATERCEPT AND THE FERROPORTIN INHIBITOR VAMIFEPORT IS SUPERIOR TO EITHER DRUG ALONE IN IMPROVING MDS PATHOPHYSIOLOGY	Francesca Vinchi	Received

P-1560	INCREASED RISK OF OSTEOARTHRITIS IN HFE C282Y HOMOZYGOUS INDIVIDUALS WITH NORMAL LEVELS OF IRON, TRANSFERRIN SATURATION, OR FERRITIN: A PROSPECTIVE STUDY OF 132,529 GENERAL POPULATION INDIVIDUALS	Jens Helby	Received

P-1561	LONGITUDINAL ASSESSMENT OF HUMAN APOTRANSFERRIN EFFICACY IN CONGENITAL HYPOTRANSFERRINEMIA: RESOLVING SYMPTOMS WITH SUBNORMAL TRANSFERRIN LEVELS	Ilona Kleine Budde	Received

P-1563	PHASE 1 HEALTHY VOLUNTEER STUDY OF DISC-3405, A RECOMBINANT HUMANIZED ANTIBODY TARGETING TMPRSS6	Guowen Liu	Received

P-1565	PREVALENCE OF IRON DEFICIENCY AND CARDIOVASCULAR PROGNOSTIC IMPACT IN ESSENTIAL THROMBOCYTHEMIA: A RETROSPECTIVE STUDY	Etienne Paubelle	Received

P-1567	VADADUSTAT VS. DARBEPOETIN IN ANEMIC CHRONIC KIDNEY DISEASE: ANALYZING EFFICACY, SAFETY, AND TOLERABILITY VIA META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	Ahmet Sarici	Received

P-1568	SINGLE ASCENDING DOSES OF 9MW3011, A MONOCLONAL ANTIBODY TARGETING TMPRSS6, RESULT IN SUSTAINED ELEVATION OF SERUM HEPCIDIN AND REDUCTION OF IRON LEVELS IN HEALTHY VOLUNTEERS	Jie Hou	Received

P-1569	RESULTS FROM THE BEACON TRIAL: A PHASE 2, RANDOMIZED, OPEN-LABEL TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA	Gayle Ross	Received

P-1570	NOVEL GNOMAD MISSENSE MUTATIONS IN THE CERULOPLASMIN GENE RESULT IN FERROXIDASE IMPAIRMENT AND ARE CONSISTENT WITH SIGNIFICANT UNDERDIAGNOSIS OF ACERULOPLASMINEMIA	Nicole Ziliotto	Received

P-1571	SINGLE ASCENDING DOSES OF REGN7999, A MONOCLONAL ANTIBODY INHIBITOR OF TMPRSS6, INCREASED SERUM HEPCIDIN AND CAUSED DEEP, SUSTAINED REDUCTIONS IN SERUM IRON IN HEALTHY HUMAN VOLUNTEERS	Nikhil Singh	Received

P-1572	COMPARING FERRIC CARBOXYMALTOSE AND IRON SUCROSE FOR TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT WOMEN WITH MENORRHAGIA	Varada Salimath	Received

P-1573	EVALUATION OF HEPCIDIN ASSAY AND UTILITY FOLLOWING INTRAVENOUS IRON INFUSION	Blanca De Felipe Noguerales	Received

P-1575	TOPLINE RESULTS OF THE AURORA TRIAL: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA	Amy Dickey	Received

P-1576	RETROSPECTIVE COHORT STUDY OF THE BURDEN OF INFECTION IN PATIENTS WITH NON-HODGKIN´S LYMPHOMA, WITH AND WITHOUT SECONDARY IMMUNODEFICIENCY DISEASE	Matthew Davids	Received

P-1578	TREATMENT PATTERN AND SURVIVAL OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION-RELATED LYMPHOMA IN CHINA 2011-2021	Chaoyu Wang	Received

P-1579	HIGH INCIDENCE OF INVASIVE FUNGAL INFECTIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF A MULTICENTRIC PROSPECTIVE SEIFEM STUDY (ALL-IFI)	Chiara Cattaneo	Received

P-1581	INFECTION BURDEN UPON TREATMENT OF PATIENTS WITH LYMPHOID-LINEAGE CANCERS	Thomas Lacoppidan	Received

P-1582	INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND SECONDARY IMMUNODEFICIENCY IN THE UNITED STATES: A REAL-WORLD ANALYSIS	Bharat Ramakrishna	Received

P-1583	COSTS OF HERPES ZOSTER IN HEMATOLOGICAL PATIENTS	Hannah Söderholm	Received

P-1584	DIAGNOSTIC ACCURACY AND CLINICAL USEFULNESS OF LUNG ULTRASOUND IN ONCO-HAEMATOLOGICAL PATIENTS WITH NEUTROPENIC FEVER: THE HAEMATO-LUS STUDY	Carolina Secreto	Received

P-1585	EFFICACY IN INFECTION PROPHYLAXIS AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS IN PATIENTS WITH HYPOGAMMAGLOBULINEMIA DUE TO HEMATOLOGICAL MALIGNANCIES: RESULTS FROM A NON-INTERVENTIONAL STUDY	Theresa Zekoll	Received

P-1586	MUCOSITIS-ASSOCIATED BLOODSTREAM INFECTIONS IN HAEMATOLOGY PATIENTSWITH FEVER DURING NEUTROPENIA	Nick De Jonge	Received

P-1587	HIGH INCIDENCE AND DISMAL PROGNOSIS OF INVASIVE FUNGAL INFECTIONS IN T-CELL NON-HODGKIN LYMPHOMA PATIENTS: RESULTS OF A LARGE RETROSPECTIVE SERIES	Chiara Cattaneo	Received

P-1588	CURRENT STATUS OF THERAPEUTIC DRUG MONITORING IN HEMATOLOGY	Francesco MARCHESI	Received

P-1590	THE CARV CHALLENGE: HOW DO HEMATOLOGICAL MALIGNANCY PATIENTS STRUGGLE WITH DIVERSE CARV PATHOGENS	Jon Salmanton-García	Received

P-1591	TREATMENT PATTERNS OF IMMUNOGLOBULIN REPLACEMENT THERAPY AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND SECONDARY IMMUNODEFICIENCY IN THE UNITED STATES: A REAL-WORLD ANALYSIS	Bharat Ramakrishna	Received

P-1592	THE INCIDENCE, RISK FACTORS AND SEVERITY OF COVID-19 PNEUMONIA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: DATA FROM A MULTI-CENTER REGISTRY IN CHINA	Jun Li	Received

P-1593	REVACCINATION WITH PNEUMOCOCCAL CONJUGATE VACCINE FIVE YEARS AFTER PRIMARY IMMUNIZATION WITH CONJUGATE OR POLYSACCHARIDE VACCINES INCREASES IMMUNITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Magdalena Kättström	Received

P-1594	OUTCOMES OF CAR T PATIENTS WHO DEVELOP HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	Nelson Leung	Received

P-1595	SARS-COV-2 REINFECTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES :A PROSPECTIVE, MULTICENTER REGISTRY FROM CHINA	Jun Li	Received

P-1596	LETERMOVIR IS EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AND IS ASSOCIATED WITH BETTER TRANSPLANT OUTCOME IN CORD BLOOD TRANSPLANTATION	Takahide Ara	Received

P-1597	INFECTIOUS COMPLICATIONS AFTER HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION: RESULTS OF A RETROSPECTIVE COHORT STUDY	Marcus Hentrich	Received

P-1598	RECURRENT CYTOMEGALOVIRUS REACTIVATIONS: FREQUENCY, VIRAL DYNAMIC AND RISK FACTORS IN ALLOGENEIC STEM CELL TRANSPLANTATION	Sylvia Dalcolmo	Received

P-1599	INFECTION PREVENTION MEASURES TAKEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS DURING THE COVID-19 PANDEMIC AND THEIR IMPACT ON CLINICAL OUTCOMES	Sarah Noetzlin	Received

P-1602	EPIDEMIOLOGY AND TREATMENT APPROACHES IN MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN HEMATOLOGICAL MALIGNANCIES: UPDATED RESULTS FROM A SINGLE-CENTER STUDY	Mariarita Sciume´	Received

P-1603	SHOT-REPORTABLE ACUTE TRANSFUSION REACTIONS - SINGLE TERTIARY-CENTRE IN LONDON 5-YEAR EXPERIENCE (2019-2023)	Zin Aung Soe	Received

P-1604	STRATEGIES TO DECREASE THE OVERUTILIZATION OF RED BLOOD CELL TRANSFUSION IN A TERTIARY CENTER: A QUALITY IMPROVEMENT STUDY	Cilomar Martins de Oliveira Filho	Received

P-1605	PROTHROMBIN COMPLEX CONCENTRATE USAGE IN UNIVERSITY COLLEGE LONDON HOSPITALS, A RETROSPECTIVE AUDIT	Athanasia Sinti Papadaki	Received

P-1606	AUTO (ALLO) IMMUNE HEMOLYTIC ANEMIA AND IMMUNE TROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS–DATA FROM A SINGLE INSTITUTION	Yonka Lazarova	Received

P-1608	IMPACT OF ABO INCOMPATIBILITY ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOID PATHOLOGIES	Juan Miguel Barbero Sánchez	Received

P-1610	IMPLEMENTATION OF A PATIENT BLOOD MANAGEMENT PROGRAM IN A MEDIUM SIZED HOSPITAL	Miguel Angel Sanz Caballer	Received

P-1612	GLYCOPROTEIN VI IS INVOLVED IN THE HEMOSTATIC FUNCTION OF PLATELETS IN WHOLE BLOOD PRODUCTS	Noriaki Tachi	Received

P-1613	MASS SPECTROMETRY-BASED PLASMA PROFILING: A POWERFUL TOOL TO DELINEATE SYSTEM-WIDE RESPONSES IN HEMATO-ONCOLOGICAL PATIENTS DURING TRANSFUSIONS	Diana Muñoz Sandoval	Received

P-1614	EXTRACORPORAL PHOTOPHERESIS (ECP) – IMPACT ON EX-VIVO APOPTOSIS AND PROLIFERATION	Sabine Seiffert	Received

P-1615	THROMBOELASTOGRAM (TEG) TO GUIDE TRANSFUSION OF FFP, FIBRINOGEN AND CRYOPRECIPITATE IN CARDIAC SURGERY	Silvia Lovato	Received

P-1616	GRANULOCYTE TRANSFUSION ACCELERATES RECOVERY FROM NEUTROPENIA IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES	Ali Unal	Received

P-1617	EFFECT OF PREMEDICATION PRIOR TO PLATELET TRANSFUSION ON PLATELET INCREMENT AMONG HEMATO-ONCOLOGICAL PATIENTS	Tamar Berger	Received

P-1620	DARATUMUMAB TREATMENT IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA	Júlia Weisinger	Received

P-1621	IMMATURE B CELL-SPECIFIC RECEPTOR EDITING DEFECTS DRIVE ANTI-PLATELET ANTIBODY PRODUCTION IN IMMUNE THROMBOCYTOPENIA	Zi Sheng	Received

P-1623	SYMPATHETIC NERVES REGULATE MEGAKARYOCYTE FUNCTION THROUGH CALCIUM SIGNALING IN IMMUNE THROMBOCYTOPENIA	Menglin Li	Received

P-1624	THROMBOPOIETIN-R AGONISTS EFFICACY AND SAFETY IN PREGNANT ITP PATIENTS AND THEIR BABIES: A MULTICENTER RETROSPECTIVE ITP-NET ITALIAN STUDY ON BEHALF OF GIMEMA WORKING GROUP "ANEMIA & THROMBOCYTOPENIA"	Monica Carpenedo	Received

P-1626	THE OUTCOME OF SPLENECTOMY IN REFRACTORY ITP IS POOR: AN ANALYSIS OF REAL WORLD UKITP REGISTRY DATA	Frederick Chen	Received

P-1627	DISFUNCTION OF BONE MARROW NEUTROPHILS AND STUDY OF THE THERAPEUTIC MECHANISMS OF JAK1 INHIBITORS IN ITP	Qingyuan Qu	Received

P-1628	PROLONGED RESPONSE AFTER TPO-RA DISCONTINUATION IN PRIMARY ITP: LONG TERM FOLLOW-UP OF THE STOPAGO STUDY, A PROSPECTIVE MULTICENTER STUDY	Adrien Cottu	Received

P-1629	SOVLEPLENIB IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS BY PRIOR LINES OF THERAPY: SUBGROUP ANALYSIS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (ESLIM-01)	Xiaofan Liu	Received

P-1630	INCIDENCE, DESCRIPTION, AND MANAGEMENT OF VENOUS THROMBOSES IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA. RESULTS FROM THE MULTICENTER PROSPECTIVE REGISTRY CARMEN-FRANCE.	François THERME	Received

P-1631	SOVLEPLENIB IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) PTS WITH PRIOR TPO/TPO-RA TREATMENT: SUBGROUP ANALYSIS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (ESLIM-01)	Heng Mei	Received

P-1633	EFFICACY AND SAFETY OF AVATROMBOPAG IN THE TREATMENT OF THROMBOCYTOPENIA AFTER UMBILICAL CORD BLOOD TRANSPLANTATION	Aijie Huang	Received

P-1634	THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH INHERITED PLATELET DISORDERS PREVENT THE BLEEDING RISK OF SURGERY.	Miguel Oliveira	Received

P-1636	IMMUNE TTP REFRACTORINESS AND EXACERBATIONS IN CAPLACIZUMAB-TREATED PATIENTS - AN INTERIM ANALYSIS OF THE REACT-2020 TTP REGISTRY	Lucas Kühne	Received

P-1637	THE DIAGNOSTIC VALUE AND DETERMINANTS OF THROMBIN GENERATION IN PATIENTS WITH BLEEDING DISORDERS.	Floor Heubel-Moenen	Received

P-1638	ASSOCIATION BETWEEN HEMOPHILIA AND FRACTURE RISK: SYSTEMATIC REVIEW AND META-ANALYSIS	Eleni Gavriilaki	Received

P-1639	BLEEDING EVENTS IN PATIENTS WITH HAEMOPHILIA A PRE AND POST EMICIZUMAB PROPHYLAXIS	Fiona O´Flynn	Received

P-1640	PREVALENCE AND CLINICAL CHARACTERISTICS OF PATIENTS WITH ACQUIRED VON WILLEBRAND SYNDROME AND ESSENTIAL THROMBOCYTHEMIA: RETROSPECTIVE ANALYSIS OF 40 PATIENTS.	Bolivar Luis Diaz Jordan	Received

P-1641	EPIDEMIOLOGICAL TRENDS AND CLINICAL SPECTRUM OF GLANZMANN THROMBASTHENIA IN SOUTHERN TUNISIA	Hanen Charfi	Received

P-1642	ASSOCIATION OF PSYCHOTROPIC DRUG USE WITH BLEEDING SEVERITY IN PATIENTS MILD TO MODERATE BLEEDING DISORDERS AND BLEEDING DISORDER OF UNKNOWN CAUSE	Tim Dreier	Received

P-1643	UNIVERSITY HOSPITAL BRNO EXPERIENCE: A COMPARISON OF TREATMENT EFFECTS ON STANDARD RECOMBINANT PRODUCTS IN ADULTS FOR 12 MONTHS, FOLLOWED SUBSEQUENTLY FOR 12 MONTHS ON EXTENDED HALF-LIFE PRODUCTS.	Gabriela Romanová	Received

P-1644	EXPLORING RED BLOOD CELLS AS A NOVEL TOLEROGENIC APPROACH FOR FACTOR VIII INHIBITORS EMPLOYING IMMUNO-DOMINANT FVIII DERIVED PEPTIDES PRESENTED ON MHC CLASS II	Mariarosaria Miranda	Received

P-1645	INDIVIDUAL PHARMACOKINETIC EVALUATION OF FIXED-SEQUENCE SINGLE-DOSE OCTOCOG ALFA, RURIOCTOCOG ALFA PEGOL, AND EFANESOCTOCOG ALFA IN ADULTS WITH SEVERE HEMOPHILIA A	Víctor Jiménez-Yuste	Received

P-1646	FIBRINOLYSIS ASSESSMENT WITH TPA-ROTEM IN PATIENTS WITH BLEEDING DISORDERS OF UNKNOWN CAUSE (BDUC)	Floor Heubel-Moenen	Received

P-1647	THE COMPLEMENT SYSTEM AND ITS ASSOCIATION WITH THE CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME: THE ROLE OF COMPLEMENT INHIBITION	Hugo Lara-Martinez	Received

P-1648	UNVEILING THROMBIN GENERATION DYNAMICS: INSIGHTS FROM VKA ANTICOAGULATION REVERSAL WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE	Thomas Bodewes	Received

P-1649	THE RISK OF VENOUS THROMBOEMBOLISM AND ABO BLOOD GROUP IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS	Vladimir Otasevic	Received

P-1650	COMPARATIVE ANALYSIS OF BLEEDING COMPLICATIONS IN DUAL ANTIPLATELET THERAPY COMBINED WITH WARFARIN VERSUS DIRECT ORAL ANTICOAGULANTS: A SYSTEMATIC REVIEW AND META-ANALYSIS	Moazzam Shahzad	Received

P-1651	INFLAMMATION AND COAGULATION RISK FACTORS FOR VENOUS THROMBOSIS IN PATIENTS WITH GRAFT VERSUS HOST DISEASE	Olivera Mitrovic Ajtic	Received

P-1652	A SYSTEMATIC REVIEW AND META-ANALYSIS OF ASPARAGINASE-ASSOCIATED THROMBOSIS AND RISK FACTORS IN PEDIATRICS AND ADULTS TREATED ALL	Jack Seki	Received

P-1653	THROLY SCORE AND P-SELECTIN PREDICT VENOUS THROMBOEMBOLISM DEVELOPMENT IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	Olivera Mitrovic Ajtic	Received

P-1654	THROMBOPHILIA SCREENING IN AUTOIMMUNE HEMOLYTIC ANEMIA: A SINGLE-CENTER CROSS-SECTIONAL STUDY	Nicola Cecchi	Received

P-1655	CONTRIBUTION OF HYPERCOAGULATION AND INFLAMMATORY BIOMARKERS IN THE PROGRESSION AND MORTALITY OF NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS	Patricia Gomez Rosas	Received

P-1656	CLINICAL AND MOLECULAR DIFFERENCES AMONG PATIENTS WITH MPN AND ASSOCIATED VENOUS THROMBOSIS IN USUAL AND UNUSUAL SITES.	Erika Morsia	Received

P-1657	STUDY OF THE EVOLUTION OF ADAMTS13 ACTIVITY DURING THE INITIAL RESPONSE IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA	Gonzalo del Campo Balguerías	Received

P-1658	EVALUATION OF TWO VENOUS THROMBOEMBOLISM RISK ASSESSMENT MODELS FOR LYMPHOMA ASSOCIATED THROMBOSIS IN CLINICAL PATIENT CARE.	SERGIO RAMOS	Received

P-1659	ELEVATED LEVELS OF (ACTIVE) VON WILLEBRAND FACTOR DURING ANTICOAGULATION ARE ASSOCIATED WITH EARLY RECURRENCE OF VENOUS THROMBOEMBOLISM IN MEN	Geke Poolen	Received

P-1660	ERN-EUROBLOODNET EUROPEAN MAPPING FOR MANAGEMENT OF VENOUS THROMBOSIS AND ARTERIAL THROMBOSIS IN PEDIATRIC PATIENTS: THE FIRST EUROPEAN PEDIATRIC THROMBOSIS WORKING GROUP	Victoria Gutierrez Valle	Received

P-1662	BEMIPARIN IN ONCOLOGICAL PATIENTS. A SYSTEMATIC REVIEW AND META-ANALYSIS	Hamlet Ghukasyan	Received

P-1665	COMPARING DOACS WITH WARFARIN IN AF PATIENTS WITH CHRONIC KIDNEY DISEASE OR VALVULAR DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	Wei Cen Wang	Received

P-1666	TREATMENT PREFERENCES AND QUALITY OF LIFE IN PATIENTS WITH RELAPSED / REFRACTORY FOLLICULAR LYMPHOMA	John Gribben	Received

P-1667	RETURN TO WORK AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS OF THE SOCIO-DEMOGRAPHIC PREDICTIVE FACTORS (PRELIMINARY ANALYSIS OF SOPRALLO PROJECT)	Yana Stepanishyna	Received

P-1668	AN EXAMINATION OF THE EFFECT OF AGE, SEX AND RELAPSE ON THE PSYCHOSOCIAL WELLBEING OF PATIENTS WITH LYMPHOMA - AN ANALYSIS OF THE LYMPHOMA COALITION´S 2022 GLOBAL PATIENT SURVEY	Natacha Bolanos	Received

P-1669	DISEASE AND TREATMENT BURDEN IN PATIENTS WITH LEUKEMIA: FAMILY MEMBERS/PARTNER PERSPECTIVE	Esther Oliva	Received

P-1671	ABILITY TO WORK IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA: A DANISH NATIONWIDE COHORT STUDY	Eva Maksten	Received

P-1672	PATIENT-REPORTED OUTCOMES IN NON-HODGKIN LYMPHOMA TRIALS: A SYSTEMATIC REVIEW	Julia Schroer	Received

P-1673	UNDERSTANDING THE PATIENT EXPERIENCE DURING CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY JOURNEY; A REVIEW OF QUALITATIVE RESEARCH	Sophie Van Tomme	Received

P-1674	VULNERABLE ELDERS SURVEY-13 (VES-13) AND ITS ASSOCIATION WITH SURVIVAL AND HEALTHCARE UTILIZATION IN OLDER ADULTS WITH AGGRESSIVE NON-HODGKIN LYMPHOMA	P. Connor Johnson	Received

P-1675	QUALITY OF LIFE OF PORTUGUESE MULTIPLE MYELOMA PATIENTS AND ITS RELATIONSHIP WITH CAREGIVERS – A NATIONAL STUDY	Adriana Roque	Received

P-1676	THE BURDEN OF SYSTEMIC MASTOCYTOSIS IN EUROPE: RESULTS FROM THE PRISM PATIENT SURVEY	Deepti Radia	Received

P-1677	THE BURDEN OF SYSTEMIC MASTOCYTOSIS: IMPACT OF SYMPTOMS ON WORK ABILITY AND QUALITY OF LIFE.	Emily Hansen	Received

P-1678	COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) AND ITS ASSOCIATION WITH SURVIVAL AND QUALITY OF LIFE IN OLDER ADULTS WITH AGGRESSIVE NON-HODGKIN LYMPHOMA	P. Connor Johnson	Received

P-1679	THE HAEMATOLOGY OUTREACH SERVICE. THINKING OUTSIDE THE DAY UNIT.	Rebecca Lloyd	Received

P-1680	LONGITUDINAL COGNITIVE OUTCOMES IN PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY	Anna Barata	Received

P-1681	QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY ANALYSIS OF HAPLOIDENTICAL RELATED DONOR VERSUS IDENTICAL SIBLING DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA	Yuewen Wang	Received

P-1682	PATIENT-REPORTED EXPERIENCE OF BEING DIAGNOSED WITH LEUKEMIA: A GLOBAL STUDY	Samantha Nier	Received

P-1683	PATIENT-REPORTED OUTCOMES OF CAR T-CELL THERAPY: AN INTERNATIONAL EUROPEAN STUDY EVALUATING PATIENTS´ EXPERIENCES, QUALITY OF LIFE AND UNMET CARE NEEDS	Elise R.A. Pennings	Received

P-1684	A NEW E-HEALTH TOOL TO PERSONALIZE CANCER CARE, BASED ON PROACTIVE PATIENTS´ NEEDS ASSESSMENT DURING AND AFTER TREATMENT: A DEVELOPMENTAL STUDY IN A HEMATOLOGICAL CARE PATHWAY, THE PROZORG-STUDY	Asiong Jie	Received

P-1685	HEALTH-RELATED QUALITY OF LIFE AMONG NON-HODGKIN LYMPHOMA PATIENTS IN FRANCE: A POPULATION-BASED STUDY	Stephane WASSE	Received

P-1686	PATIENT EXPERIENCE WITH AND PERCEPTIONS OF TRANSFUSION-DEPENDENT AND TRANSFUSION-INDEPENDENT MYELOFIBROSIS: A QUALITATIVE INTERVIEW STUDY	Melissa Ross	Received

P-1687	END OF LIFE CARE OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES COMPARED TO OTHER MALIGNANCIES – A STUDY ON THE SWEDISH PALLIATIVE CARE REGISTRY	Ellen Skåreby	Received

P-1688	PATIENT-REPORTED OUTCOME DOMAINS AND THEIR CONCORDANCE WITH PROGRESSION-FREE AND OVERALL SURVIVAL IN MULTIPLE MYELOMA RANDOMIZED CONTROLLED TRIALS	Darshi Shah	Received

P-1689	QUALITY OF LIFE (QOL) IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES RECEIVING RITUXIMAB BIOSIMILARS: RESULTS FROM A REAL-WORLD SETTING	Lorenzo Junior Masnata	Received

P-1690	PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA INITIATING A NEW LINE OF THERAPY IN REAL-WORLD CLINICAL PRACTICE: A PROSPECTIVE, MULTI-SITE OBSERVATIONAL STUDY	Cristina Koontz	Received

P-1691	THE OPIOID DILEMMA: PROLONGED HOSPITALIZATION AND INCREASED READMISSIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT CARE	Tommy Alfaro Moya	Received

P-1692	BASELINE QUALITY OF LIFE DATA MAY PREDICT ACHIEVEMENT OF EMR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TKIS: RESULTS FROM THE GIMEMA-SUSTRENIM TRIAL	Fabio Efficace	Received

P-1694	EXPLORING THE CURRENT STATUS OF LYMPHOMA CLINICAL TRIALS: WHERE WE STAND, WHAT WE LEARN, AND FUTURE PERSPECTIVES	Abdulrahman Alhajahjeh	Received

P-1695	PATIENT PREFERENCES FOR TREATMENT IN RELAPSED/REFRACTORY ACUTE LEUKEMIA IN THE UNITED KINGDOM	Samantha Nier	Received

P-1696	ANALYZING DETERMINANTS OF PREMATURE TRIAL DISCONTINUATION IN LEUKEMIA CLINICAL TRIALS	Abdulrahman Alhajahjeh	Received

P-1697	CURRENT USE OF SALVAGE 2ND LINE TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMA AND KEY DRIVERS FOR SELECTING THERAPY WITH CAR T CELLS. DATA FROM REAL-WORLD STUDY IN EU5	Nicolas Blin	Received

P-1698	GLOBAL DISPARITIES IN HEMATOLOGY, EVALUATING THE CHARACTERISTICS AND IMPACT OF LEUKEMIA CLINICAL TRIALS: A SYSTEMATIC REVIEW.	Abdulrahman Alhajahjeh	Received

P-1699	COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA + R-CHP) IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA IN DENMARK.	Christian Beck	Received

P-1700	INDIRECT TREATMENT COMPARISON OF IPTACOPAN VERSUS PEGCETACOPLAN FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND PERSISTENT ANEMIA DESPITE ANTI-C5 TREATMENT	Austin Kulasekararaj	Received

P-1701	ECONOMIC EVALUATION OF PROPHYLACTIC IMMUNOGLOBULIN VERSUS PROPHYLACTIC ANTIBIOTICS IN HEMATOLOGICAL MALIGNANCIES: RESULTS FROM THE RATIONAL FEASIBILITY TRIAL	Sara Carrillo De Albornoz	Received

P-1702	JUNCTIONAL ADHESION MOLECULE A: JAM-MING THE BRAKE ON MULTIPLE MYELOMA!	Niamh Mcauley	Received

P-1704	EXPERT-INDEPENDENT CLASSIFICATION OF ACUTE MYELOID LEUKEMIA WITH NEUTROPHIL LINEAGE DIFFERENTIATION USING STANDARDIZED FLOW CYTOMETRY: A EUROFLOW STUDY	Pilar Leoz Allegretti	Received

P-1705	CLINICAL RELEVANCE OF LOW-LEVEL VARIANTS DETECTED BY DEEP SEQUENCING	Manja Meggendorfer	Received

P-1706	DETECTION OF MEASURABLE RESIDUAL DISEASE IN AML BY NEXT-GENERATION SEQUENCING: INITIAL EXPERIENCES AND BENCHMARKING OF THE SURESEQ MYELOID MRD PANEL	Simon M. Krauß	Received

P-1707	WEARABLE TECHNOLOGY AND SUBJECTIVE HEALTH OUTCOMES IN WALDENSTROM MACROGLOBULINEMIA: A REMOTE LONGITUDINAL APPROACH TO ACTIVE MONITORING	Kim Summers	Received

P-1708	LEUKOCYTE COUNTS FOR CHILDREN FROM DRIED BLOOD SPOTS BY DNA METHYLATION ANALYSIS	Wouter Hubens	Received

P-1709	OPTICAL GENOME MAPPING IMPROVES CLASSIFICATION, RISK STRATIFICATION AND PERSONALIZED TREATMENT STRATEGIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA	Sanam Loghavi	Received

P-1710	HEMONITOR STUDY: MACHINE LEARNING-DRIVEN, NON-INVASIVE ASSESSMENT OF HEMOGLOBIN LEVELS IN HEMATOLOGICAL MALIGNANCIES	Anne Sophie Kubasch	Received

P-1711	MULTI-CENTER CLINICAL VALIDATION OF THE AUTOMATED EXENT® SOLUTION FOR THE DIAGNOSIS AND MONITORING OF MONOCLONAL GAMMOPATHIES	Oscar Berlanga	Received

P-1712	INTRINSIC ACTIVATED THROMBIN GENERATION FOR EFFICACY AND MONITORING OF FACTOR VIII REPLACEMENTS AND MIMETICS	Henri Spronk	Received

P-1713	DEEP LEARNING MODELS FOR PREDICTING OVERALL SURVIVAL OF ACUTE MYELOID LEUKEMIA PATIENTS USING SHORT-TERM LONGITUDINAL BLOOD MEASUREMENTS AND THE OMOP COMMON DATA MODEL	Eric Fey	Received

P-1714	CO-EVOLUTION OF MITOCHONDRIAL AND SOMATIC NUCLEAR DNA MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA.	Livius Penter	Received

P-1715	OPTICAL GENOME MAPPING AS A NEW TOOL TO IDENTIFY CHROMOANAGENESIS PHENOMENA IN HEMATOLOGICAL MALIGNANCIES	Blanca Espinet	Received

P-1716	TUMOR-INFORMED CIRCULATING TUMOR DNA ANALYSIS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING OF DIFFUSE LARGE B-CELL LYMPHOMA	Li Wang	Received

P-1717	IMPLEMENTATION AND EXTERNAL VALIDATION OF AN ARTIFICIAL INTELLIGENCE BASED PREDICTION MODEL USING 1132 DLBCL FDG PET/CT STUDIES.	Maria Ferrandez	Received

P-1718	OPTIMIZED SHRNAMIR SCREENS UNVEIL LEUKEMIA VULNERABILITIES IN THE ESSENTIAL GENE SPACE.	Jakub Zmajkovic	Received

P-1719	RADIOMICS BASED SUBTYPE DISCRIMINATION IN CLASSIC HODGKIN LYMPHOMA USING 18-FDG PET/CT IMAGING: A PROOF-OF-CONCEPT STUDY	Roeland Vas Nunes	Received

P-1720	THE ROLE OF ARTIFICIAL INTELLIGENCE IN PERIPHERAL BLOOD SMEAR EVALUATION: AUTOMATED ANALYZER VERSUS HEMATOLOGIST	ISIL ERDOGAN ÖZÜNAL	Received

P-1723	A NOVEL BIOINFORMATICS PIPELINE FOR NEOANTIGEN IDENTIFICATION FROM RNA-SEQ DATA	Carlos Perez Miguez	Received

P-1724	DEEP GENERATIVE MODELLING OF PERIPHERAL BLOOD FILM CYTOLOGY	Simon Deltadahl	Received

P-1725	MACHINE LEARNING ANALYSIS FOR EVALUATING GENOTYPE/PHENOTYPE DISCREPANCIES IN TYPE 1 GAUCHER DISEASE	Irene Serrano-Gonzalo	Received

P-1726	ARTIFICIAL INTELLIGENCE-BASED EVALUATION OF TERMINAL ERYTHROID DIFFERENTIATION: PROGNOSTIC IMPLICATIONS IN MYELODYSPLASTIC SYNDROMES	David Bermejo-Peláez	Received

P-1727	ARTIFICIAL INTELLIGENCE METHODOLOGIES FOR RISK STRATIFICATION AND PROGNOSIS OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS	Alvaro Lopez-Caro	Received

P-1728	THE PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN COHORT OF PATIENTS WITH MULTIPLE MYELOMA IN KAZAKHSTAN	Azaliya Turgunova	Received

P-1729	USING MACHINE LEARNING TO PREDICT CD34+ YIELDS IN GCSF-MOBILIZED STEM CELL COLLECTION FROM REGISTRY DONORS AT THE TIME OF PRE-ASSESSMENT.	Thomas Erblich	Received

P-1730	DEEP LEARNING-BASED PREDICTION OF T(11;14) IN MULTIPLE MYELOMA H&E-STAINED SAMPLES	Nadav Kerner	Received

EHA2024 Hybrid Congress

June, 13-16 Madrid

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 12/06/2024 TO 12/06/2024

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access